U.S. patent application number 13/157893 was filed with the patent office on 2011-09-29 for treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives.
This patent application is currently assigned to Novartis AG. Invention is credited to Gurpid Bhalay, Graham Charles Bloomfield, Emma Budd, Stephen Paul Collingwood, Andrew Dunstan, Lee Edwards, Peter Gedeck, Catherine Howsham, Peter Hunt, Thomas Anthony Hunt, Paul Oakley, Nichola Smith.
Application Number | 20110237572 13/157893 |
Document ID | / |
Family ID | 39322745 |
Filed Date | 2011-09-29 |
United States Patent
Application |
20110237572 |
Kind Code |
A1 |
Bhalay; Gurpid ; et
al. |
September 29, 2011 |
Treating diseases mediated by blockade of the epithelial sodium
channel with pyrazine-2-carboxamide derivatives
Abstract
A compound of Formula I ##STR00001## in free or salt or solvate
form, where R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6,
R.sup.7, R.sup.8, R.sup.9, R.sup.10 and R.sup.11 have the meanings
as indicated in the specification, is useful for treating diseases
which respond to the blockade of the epithelial sodium channel.
Pharmaceutical compositions that contain the compounds and
processes for preparing the compounds are also described.
Inventors: |
Bhalay; Gurpid; (Horsham,
GB) ; Budd; Emma; (Horsham, GB) ; Bloomfield;
Graham Charles; (Horsham, GB) ; Collingwood; Stephen
Paul; (Horsham, GB) ; Dunstan; Andrew;
(Horsham, GB) ; Edwards; Lee; (Horsham, GB)
; Gedeck; Peter; (Basel, CH) ; Howsham;
Catherine; (Horsham, GB) ; Hunt; Peter;
(Horsham, GB) ; Hunt; Thomas Anthony; (Horsham,
GB) ; Oakley; Paul; (Horsham, GB) ; Smith;
Nichola; (Horsham, GB) |
Assignee: |
Novartis AG
Basel
CH
|
Family ID: |
39322745 |
Appl. No.: |
13/157893 |
Filed: |
June 10, 2011 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12332086 |
Dec 10, 2008 |
|
|
|
13157893 |
|
|
|
|
Current U.S.
Class: |
514/218 ;
514/234.2; 514/252.11; 514/255.05 |
Current CPC
Class: |
A61P 27/02 20180101;
C07D 487/10 20130101; A61K 31/497 20130101; A61P 29/00 20180101;
A61P 11/00 20180101; C07D 471/20 20130101; A61P 11/06 20180101;
C07D 471/04 20130101; C07D 487/04 20130101; C07D 471/10 20130101;
A61P 1/02 20180101; A61P 37/00 20180101; A61P 11/08 20180101; A61P
35/00 20180101; A61P 31/00 20180101; C07D 519/00 20130101; A61P
37/08 20180101; C07D 473/34 20130101; A61P 43/00 20180101; C07D
403/12 20130101 |
Class at
Publication: |
514/218 ;
514/255.05; 514/234.2; 514/252.11 |
International
Class: |
A61K 31/551 20060101
A61K031/551; A61K 31/497 20060101 A61K031/497; A61K 31/506 20060101
A61K031/506; A61K 31/5377 20060101 A61K031/5377; A61P 29/00
20060101 A61P029/00; A61P 37/08 20060101 A61P037/08; A61P 11/00
20060101 A61P011/00; A61P 11/08 20060101 A61P011/08; A61P 11/06
20060101 A61P011/06; A61P 35/00 20060101 A61P035/00 |
Foreign Application Data
Date |
Code |
Application Number |
Dec 10, 2007 |
EP |
07122739.1 |
Claims
1-21. (canceled)
22. A method of treating a disease mediated by the blockade of an
epithelial sodium channel in a patient in need thereof, said method
comprising: administering to said patient a therapeutically
effective amount of a compound selected from the group consisting
of ##STR00312## ##STR00313## ##STR00314## ##STR00315## ##STR00316##
##STR00317## ##STR00318## ##STR00319## ##STR00320## ##STR00321##
##STR00322## ##STR00323## ##STR00324## ##STR00325## ##STR00326##
and the pharmaceutically acceptable salts thereof.
23. The method according to claim 22, wherein the compound is
selected from the group consisting of ##STR00327## ##STR00328##
##STR00329## and the pharmaceutically acceptable salts thereof.
24. The method according to claim 22, wherein the compound is
selected from the group consisting of ##STR00330## and the
pharmaceutically acceptable salts thereof.
25. The method according to claim 22, wherein the compound is
##STR00331## or a pharmaceutically acceptable salt thereof.
26. The method according to claim 22, wherein the compound is
##STR00332## or a pharmaceutically acceptable salt thereof.
27. The method according to claim 22, wherein the compound is
##STR00333## or a pharmaceutically acceptable salt thereof.
28. The method according to claim 22, wherein the compound is
##STR00334## or a pharmaceutically acceptable salt thereof.
29. The method according to claim 22, wherein the compound is
##STR00335## or a pharmaceutically acceptable salt thereof.
30. The method according to claim 22, wherein the compound is
##STR00336## or a pharmaceutically acceptable salt thereof.
31. The method according to claim 22, wherein the disease mediated
by the blockade of an epithelial sodium channel is an inflammatory
or allergic condition.
32. The method according to claim 31, wherein the inflammatory or
allergic condition is cystic fibrosis, primary ciliary dyskinesia,
chronic bronchitis, chronic obstructive pulmonary disease, asthma,
respiratory tract infections, lung carcinoma, xerostomia, or
keratoconjunctivitis sire.
33. The method according to claim 32, wherein the inflammatory or
allergic condition is cystic fibrosis, chronic obstructive
pulmonary disease, or asthma.
34. The method according to claim 32, wherein the inflammatory or
allergic condition is cystic fibrosis, or chronic obstructive
pulmonary disease.
35. The method according to claim 32, wherein the inflammatory or
allergic condition is cystic fibrosis.
Description
[0001] This application claims priority to E.P. Application Serial
No. 07122739.1 filed 10 Dec. 2007, the contents of which are
incorporated herein by reference in their entirety.
[0002] This invention relates to organic compounds, their
preparation and use as pharmaceuticals.
[0003] In one aspect, the invention provides compounds according to
Formula I:
##STR00002##
[0004] or solvates, hydrates or pharmaceutically acceptable salts
thereof, wherein
[0005] R.sup.1 is H, halogen, C.sub.1-C.sub.8-alkyl,
C.sub.1-C.sub.8-haloalkyl, C.sub.1-C.sub.8-haloalkoxy,
C.sub.3-C.sub.15-carbocyclic group, nitro, cyano, a
C.sub.6-C.sub.15-membered aromatic carbocyclic group, or a
C.sub.1-C.sub.8-alkyl substituted by a C.sub.6-C.sub.15-membered
aromatic carbocyclic group;
[0006] R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are each independently
selected from H and C.sub.1-C.sub.6 alkyl;
[0007] R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10 and R.sup.11
are each independently selected from H; SO.sub.2R.sup.16; aryl
optionally substituted by one or more Z groups; a C.sub.3-C.sub.10
carbocyclic group optionally substituted by one or more Z groups;
C.sub.3-C.sub.14 heterocyclic group optionally substituted by one
or more Z groups; C.sub.1-C.sub.8 alkyl optionally substituted by
an aryl group which is optionally substituted by one or more Z
groups, a C.sub.3-C.sub.10 carbocyclic group optionally substituted
by one or more Z groups or a C.sub.3-C.sub.14 heterocyclic group
optionally substituted by one or more Z groups; or is represented
by the formula 2:
[0008] --(C.sub.0-C.sub.6 alkylene)-A-(C.sub.0-C.sub.6
alkylene)-B-(X--R.sup.12).sub.q--R.sup.22, wherein the alkylene
groups are optionally substituted by one or more Z groups;
[0009] or R.sup.6 and R.sup.7 together with the atoms to which they
are attached form a 3- to 10-membered heterocyclic group, the
heterocyclic group including one or more further heteroatoms
selected from N, O and S, and the heterocyclic group being
optionally substituted by one or more Z groups; SO.sub.2R.sup.16;
C.sub.6-C.sub.15-aromatic carbocyclic group optionally substituted
by one or more Z groups; a C.sub.3-C.sub.10 carbocyclic group; a
C.sub.3-C.sub.14 heterocyclic group optionally substituted by one
or more Z groups; or a group represented by the formula 2;
[0010] or R.sup.7 and R.sup.8 together with the carbon atom to
which they are attached form a 3- to 10-membered carbocyclic or a
3- to 10-membered heterocyclic group, the heterocyclic group
including one or more heteroatoms selected from N, O and S, and the
carbocyclic and heterocyclic groups being optionally substituted by
one or more Z groups; SO.sub.2R.sup.16; C.sub.6-C.sub.15-aromatic
carbocyclic group optionally substituted by one or more Z groups; a
C.sub.3-C.sub.10 carbocyclic group; a C.sub.3-C.sub.14 heterocyclic
group optionally substituted by one or more Z groups; or a group
represented by the formula 2;
[0011] or R.sup.9 and R.sup.10 together with the carbon atom to
which they are attached form a 3- to 10-membered carbocyclic or a
3- to 10-membered heterocyclic group, the heterocyclic group
including one or more heteroatoms selected from N, O and S, and the
carbocyclic and heterocyclic groups being optionally substituted by
one or more Z groups; SO.sub.2R.sup.16; C.sub.6-C.sub.15-aromatic
carbocyclic group optionally substituted by one or more Z groups; a
C.sub.3-C.sub.10 carbocyclic group; a C.sub.3-C.sub.14 heterocyclic
group optionally substituted by one or more Z groups; or a group
represented by the formula 2;
[0012] or R.sup.8 and R.sup.9 together with the carbon atoms to
which they are attached form a 3- to 10-membered cycloalkyl or a 3-
to 10-membered heterocyclic group, the heterocyclic group including
one or more heteroatoms selected from N, O and S, and the
carbocyclic and heterocyclic groups being optionally substituted by
one or more Z groups; SO.sub.2R.sup.16; C.sub.6-C.sub.15-aromatic
carbocyclic group optionally substituted by one or more Z groups; a
C.sub.3-C.sub.10 carbocyclic group; a C.sub.3-C.sub.14 heterocyclic
group optionally substituted by one or more Z groups; or a group
represented by the formula 2;
[0013] or R.sup.10 and R.sup.11 together with the atoms to which
they are attached form a 3- to 10-membered heterocyclic group, the
heterocyclic group including one or more further heteroatoms
selected from N, O and S, and the heterocyclic group being
optionally substituted by one or more Z groups; SO.sub.2R.sup.16;
C.sub.6-C.sub.15-aromatic carbocyclic group optionally substituted
by one or more Z groups; a C.sub.3-C.sub.10 carbocyclic group; a
C.sub.3-C.sub.14 heterocyclic group optionally substituted by one
or more Z groups; or a group represented by the formula 2;
[0014] A is selected from a bond, --NR.sup.13(SO.sub.2)--,
--(SO.sub.2)NR.sup.13--, --(SO.sub.2)--, --NR.sup.13C(O)--,
--C(O)NR.sup.13--, --NR.sup.13C(O)NR.sup.14--, --NR.sup.13C(O)O--,
--NR.sup.13--, C(O)O, OC(O), C(O), O and S;
[0015] B is selected from a bond, --(C.sub.2-C.sub.4 alkenyl
group)-, --(C.sub.2-C.sub.4 alkynyl group)-, --NH--, aryl, O-aryl,
NH-aryl, a C.sub.3-C.sub.14 carbocyclic group and a 3- to
14-membered heterocyclic group, the heterocyclic group including
one or more heteroatoms selected from N, O and S, wherein the aryl,
carbocyclic and heterocyclic groups are each optionally substituted
by one or more Z groups;
[0016] X is selected from a bond, --NR.sup.15(SO.sub.2)--,
--(SO.sub.2)NR.sup.15--, --(SO.sub.2)--, --NR.sup.15C(O)--,
--C(O)NR.sup.15--, --NR.sup.15C(O)NR.sup.17--, --NR.sup.15C(O)O--,
--NR.sup.15--, C(O)O, OC(O), C(O), O and S;
[0017] R.sup.12 is selected from C.sub.1-C.sub.8 alkylene,
C.sub.1-C.sub.8 alkenylene, --C.sub.3-C.sub.8 cycloalkyl-,
--C.sub.1-C.sub.8 alkylene-C.sub.3-C.sub.8 cycloalkyl-, and -aryl-,
wherein the alkylene, cycloalkyl and aryl groups are optionally
substituted by one or more Z groups;
[0018] R.sup.13, R.sup.14, R.sup.15 and R.sup.17 are each
independently selected from H and C.sub.1-C.sub.6 alkyl;
[0019] R.sup.16 is selected from C.sub.1-C.sub.8 alkyl, aryl and a
3- to 14-membered heterocyclic group, the heterocyclic group
including one or more heteroatoms selected from N, O and S;
[0020] Z is independently selected from OH, aryl, O-aryl,
C.sub.7-C.sub.14 aralkyl, O--C.sub.7-C.sub.14 aralkyl,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy,
NR.sup.19(SO.sub.2)R.sup.21, (SO.sub.2)NR.sup.19R.sup.21,
(SO.sub.2)R.sup.20, NR.sup.19C(O)R.sup.20, C(O)NR.sup.19R.sup.20,
NR.sup.19C(O)NR.sup.20R.sup.18, NR.sup.19C(O)OR.sup.20,
NR.sup.19R.sup.21, C(O)OR.sup.19, C(O)R.sup.19, SR.sup.19,
OR.sup.19, oxo, CN, NO.sub.2, and halogen, wherein the alkyl,
alkoxy, aralkyl and aryl groups are each optionally substituted by
one or more substituents selected from OH, halogen, C.sub.1-C.sub.4
haloalkyl and C.sub.1-C.sub.4 alkoxy;
[0021] R.sup.18 and R.sup.20 are each independently selected from H
and C.sub.1-C.sub.6 alkyl;
[0022] R.sup.19 and R.sup.21 are each independently selected from
H; C.sub.1-C.sub.8 alkyl; C.sub.3-C.sub.8 cycloalkyl;
C.sub.1-C.sub.4 alkoxy-C.sub.1-C.sub.4 alkyl; (C.sub.0-C.sub.4
alkyl)-aryl optionally substituted by one or more groups selected
from C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy and halogen;
(C.sub.0-C.sub.4 alkyl)-3- to 14-membered heterocyclic group, the
heterocyclic group including one or more heteroatoms selected from
N, O and S, optionally substituted by one or more groups selected
from halogen, oxo, C.sub.1-C.sub.6 alkyl and C(O)C.sub.1-C.sub.6
alkyl; (C.sub.0-C.sub.4 alkyl)-O-aryl optionally substituted by one
or more groups selected from C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6
alkoxy and halogen; and (C.sub.0-C.sub.4 alkyl)-O-3- to 14-membered
heterocyclic group, the heterocyclic group including one or more
heteroatoms selected from N, O and S, optionally substituted by one
or more groups selected from halogen, C.sub.1-C.sub.6 alkyl and
C(O)C.sub.1-C.sub.6 alkyl; wherein the alkyl groups are optionally
substituted by one or more halogen atoms, C.sub.1-C.sub.4 alkoxy,
C(O)NH.sub.2, C(O)NHC.sub.1-C.sub.6 alkyl or C(O)N(C.sub.1-C.sub.6
alkyl).sub.2; or
[0023] R.sup.19 and R.sup.20 together with the nitrogen atom to
which they attached form a 5- to 10-membered heterocyclic group,
the heterocyclic group including one or more further heteroatoms
selected from N, O and S, the heterocyclic group being optionally
substituted by one or more substituents selected from OH; halogen;
aryl; 5- to 10-membered heterocyclic group including one or more
heteroatoms selected from N, O and S; S(O).sub.2-aryl;
S(O).sub.2--C.sub.1-C.sub.6 alkyl; C.sub.1-C.sub.6 alkyl optionally
substituted by one or more halogen atoms; C.sub.1-C.sub.6 alkoxy
optionally substituted by one or more OH groups or C.sub.1-C.sub.4
alkoxy; and C(O)OC.sub.1-C.sub.6 alkyl, wherein the aryl and
heterocyclic substituent groups are themselves optionally
substituted by C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl or
C.sub.1-C.sub.6 alkoxy;
[0024] R.sup.22 is selected from H, halogen, C.sub.1-C.sub.8 alkyl,
C.sub.1-C.sub.8 alkoxy, aryl, O-aryl, S(O).sub.2-aryl,
S(O).sub.2--C.sub.1-C.sub.6 alkyl, S(O).sub.2NR.sup.23R.sup.24,
NHS(O).sub.2NR.sup.23R.sup.24, a C.sub.1-4 carbocyclic group, a 3-
to 14-membered heterocyclic group, the heterocyclic group including
one or more heteroatoms selected from N, O and S, and O-(3- to
14-membered heterocyclic group, the heterocyclic group including
one or more heteroatoms selected from N, O and S), wherein the
alkyl, aryl, carbocyclic and heterocyclic groups are each
optionally substituted by one or more Z groups;
[0025] R.sup.23 and R.sup.24 are each independently selected from
H, C.sub.1-C.sub.8 alkyl and C.sub.3-C.sub.8 cycloalkyl; or
[0026] R.sup.23 and R.sup.24 together with the nitrogen atom to
which they are attached form a 5- to 10-membered heterocyclic
group, optionally including one or more further heteroatoms
selected from N, O and S, wherein the heterocyclic group is
optionally substituted by one or more Z groups;
[0027] n is 0, 1 or 2;
[0028] o and p are each independently an integer from 0 to 6;
and
[0029] q is 0, 1, 2 or 3;
[0030] with the proviso that when n is 0, at least one of R.sup.6,
R.sup.7, R.sup.8, R.sup.9, R.sup.10 and R.sup.11 is other than
H.
[0031] In an embodiment of the invention, there is provided a
compound according to the Formula Ia:
##STR00003##
[0032] wherein
[0033] R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10 and R.sup.11
are each independently selected from H; SO.sub.2R.sup.16; aryl
optionally substituted by one or more Z groups; a C.sub.3-C.sub.10
carbocyclic group optionally substituted by one or more Z groups;
C.sub.3-C.sub.14 heterocyclic group optionally substituted by one
or more Z groups; C.sub.1-C.sub.8 alkyl optionally substituted by
an aryl group, a C.sub.3-C.sub.10 carbocyclic group optionally
substituted by one or more Z groups or a C.sub.3-C.sub.14
heterocyclic group optionally substituted by one or more Z groups;
or is represented by the formula 2a:
--(CH.sub.2).sub.o-A-(CH.sub.2).sub.p-B-(X--R.sup.12).sub.q--R.sup.22;
[0034] or R.sup.7 and R.sup.8 together with the carbon atom to
which they are attached form a 3- to 7-membered carbocyclic or a 3-
to 7-membered heterocyclic group, the heterocyclic group including
one or more heteroatoms selected from N, O and S, and the
carbocyclic and heterocyclic groups being optionally substituted by
one or more Z groups; SO.sub.2R.sup.16; C.sub.6-C.sub.15-aromatic
carbocyclic group optionally substituted by one or more Z groups; a
C.sub.3-C.sub.10 carbocyclic group; a C.sub.3-C.sub.14 heterocyclic
group optionally substituted by one or more Z groups; or a group
represented by the formula 2a;
[0035] or R.sup.9 and R.sup.10 together with the carbon atom to
which they are attached form a 3- to 7-membered carbocyclic or a 3-
to 7-membered heterocyclic group, the heterocyclic group including
one or more heteroatoms selected from N, O and S, and the
carbocyclic and heterocyclic groups being optionally substituted by
one or more Z groups; SO.sub.2R.sup.16; C.sub.6-C.sub.15-aromatic
carbocyclic group optionally substituted by one or more Z groups; a
C.sub.3-C.sub.10 carbocyclic group; a C.sub.3-C.sub.14 heterocyclic
group optionally substituted by one or more Z groups; or a group
represented by the formula 2a;
[0036] or R.sup.8 and R.sup.9 together with the carbon atoms to
which they are attached form a 3- to 7-membered cycloalkyl or a 3-
to 7-membered heterocyclic group, the heterocyclic group including
one or more heteroatoms selected from N, O and S, and the
carbocyclic and heterocyclic groups being optionally substituted by
one or more Z groups; SO.sub.2R.sup.16; C.sub.6-C.sub.15-aromatic
carbocyclic group optionally substituted by one or more Z groups; a
C.sub.3-C.sub.10 carbocyclic group; a C.sub.3-C.sub.14 heterocyclic
group optionally substituted by one or more Z groups; or a group
represented by the formula 2a;
[0037] A is selected from a bond, --NR.sup.13(SO.sub.2)--,
--(SO.sub.2)NR.sup.13--, --(SO.sub.2)--, --NR.sup.13C(O)--,
--C(O)NR.sup.13--, --NR.sup.13C(O)NR.sup.14--, --NR.sup.13C(O)O--,
--NR.sup.13--, C(O)O, OC(O), C(O), O and S;
[0038] B is selected from a bond, aryl, a C.sub.3-C.sub.14
carbocyclic group and a C.sub.3-C.sub.14 heterocyclic group,
wherein the ring systems are optionally substituted by one or more
Z groups;
[0039] X is selected from a bond, --NR.sup.15(SO.sub.2)--,
--(SO.sub.2)NR.sup.15--, --(SO.sub.2)--, --NR.sup.15C(O)--,
--C(O)NR.sup.15--, --NR.sup.15C(O)NR.sup.17--, --NR.sup.15C(O)O--,
--NR.sup.15--, C(O)O, OC(O), C(O), O and S;
[0040] R.sup.12 is selected from H, C.sub.1-C.sub.8 alkyl,
C.sub.3-C.sub.8 cycloalkyl, C.sub.1-C.sub.8 alkyl-C.sub.3-C.sub.8
cycloalkyl, C.sub.1-C.sub.8 alkyl-aryl and aryl, wherein the alkyl,
cycloalkyl and aryl groups are optionally substituted by one or
more Z groups;
[0041] R.sup.13, R.sup.14, R.sup.15 and R.sup.17 are each
independently selected from H and C.sub.1-C.sub.6 alkyl;
[0042] R.sup.16 is selected from C.sub.1-C.sub.8 alkyl, aryl and a
3- to 14-membered heterocyclic group;
[0043] Z is independently selected from OH, aryl, O-aryl,
C.sub.7-C.sub.14 aralkyl, O--C.sub.7-C.sub.14 aralkyl,
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy,
NR.sup.19(SO.sub.2)R.sup.21, (SO.sub.2)NR.sup.19R.sup.21,
(SO.sub.2)R.sup.20, NR.sup.19C(O)R.sup.20, C(O)NR.sup.19R.sup.20,
NR.sup.19C(O)NR.sup.20R.sup.18, NR.sup.19C(O)OR.sup.20,
NR.sup.19R.sup.21, C(O)OR.sup.19, C(O)R.sup.19, SR.sup.19,
OR.sup.19, oxo, CN, NO.sub.2, and halogen, wherein the alkyl,
alkoxy, aralkyl and aryl groups are each optionally substituted by
one or more substituents selected from OH, halogen, C.sub.1-C.sub.4
haloalkyl and C.sub.1-C.sub.4 alkoxy;
[0044] R.sup.18, R.sup.19 and R.sup.20 are each independently
selected from H and C.sub.1-C.sub.6 alkyl;
[0045] R.sup.21 is selected from C.sub.1-C.sub.8 alkyl, aryl and a
3- to 14-membered heterocyclic group;
[0046] R.sup.22 is selected from H and C.sub.1-C.sub.8 alkyl;
[0047] n is 0, 1 or 2;
[0048] o and p are each independently an integer from 0 to 6;
and
[0049] q is 0, 1, 2 or 3;
[0050] with the proviso that when n is 0, at least one of R.sup.6,
R.sup.7, R.sup.8, R.sup.9, R.sup.10 and R.sup.11 is other than
H.
[0051] In a further embodiment of the invention as defined anywhere
above, R.sup.6 is selected from H, C.sub.1-C.sub.3 alkyl and
(CH.sub.2).sub.d-phenyl, where the phenyl group is optionally
substituted by OR.sup.23;
[0052] R.sup.23 is H or C.sub.1-C.sub.6 alkyl; and
[0053] d is an integer from 1 to 5 (optionally 2 to 4).
[0054] In a still further embodiment of the invention as defined
anywhere above, R.sup.7 is H or C.sub.1-C.sub.6; and
[0055] R.sup.8 is selected from H, C.sub.1-C.sub.6 alkyl;
(CH.sub.2).sub.ephenyl, where the phenyl group is optionally
substituted by one or more groups selected from halo and OR.sup.24;
(CH.sub.2).sub.fCOOR.sup.25; (CH.sub.2).sub.gOC.sub.1-C.sub.6
alkyl, where the alkyl group is optionally substituted by 1 to 3
groups selected from OH, C.sub.1-C.sub.3 alkyl and phenyl; and
(CH.sub.2).sub.hNHCO.sub.2(CH.sub.2).sub.iphenyl;
[0056] R.sup.24 is H or C.sub.1-C.sub.6 alkyl, where the alkyl
group is optionally substituted by 1 to 3 groups selected from OH
and OC.sub.1-C.sub.3 alkyl;
[0057] R.sup.25 is H or C.sub.1-C.sub.3 alkyl;
[0058] e is 0, 1, 2, 3, 4 or 5 (optionally 0, 1, 2, 3 or 4);
[0059] f, g and h are each independently an integer from 1 to 4;
and
[0060] i is 1 or 2;
[0061] or R.sup.7 and R.sup.8 together with the carbon atom to
which they attached form a 5- or 6-membered non-aromatic
carbocyclic ring system or a 5- or 6-membered non-aromatic
heterocyclic ring system containing one or more heteroatoms
selected from N, O and S, the ring systems being optionally
substituted by one or more Z groups; SO.sub.2R.sup.16;
C.sub.6-C.sub.15-aromatic carbocyclic group optionally substituted
by one or more Z groups; a C.sub.3-C.sub.10 carbocyclic group; a
C.sub.3-C.sub.14 heterocyclic group optionally substituted by one
or more Z groups; or a group represented by the formula 2 or 2a.
Suitably, the ring system defined by R.sup.7, R.sup.8 and the
carbon to which they are attached is optionally substituted by
C.sub.1-C.sub.3 alkyl, halo or benzyl.
[0062] Optionally, f is 2 or 3. Additionally or alternatively, g
may be 2 or 3. Additionally or alternatively, h may be 2, 3 or 4.
Additionally or alternatively, i may be 1. In the immediately
preceding sub-definitions off, g, h and i, each sub-definition may
be combined with more other sub-definitions or they may be combined
with the definitions for the relevant variables given above.
[0063] In a yet further embodiment of the invention as defined
anywhere above, R.sup.9 is H, C.sub.1-C.sub.6 alkyl or phenyl; or
R.sup.8 and R.sup.9 together with the carbon atoms to which they
attached form a 5-, 6- or 7-membered non-aromatic carbocyclic ring
system or a 5-, 6- or 7-membered non-aromatic heterocyclic ring
system containing one or more heteroatoms selected from N, O and S,
the ring systems being optionally substituted by C.sub.1-C.sub.3
alkyl, halo or benzyl.
[0064] In a further embodiment of the invention as defined anywhere
above, R.sup.11 is H, SO.sub.2C.sub.1-C.sub.6 alkyl or
SO.sub.2phenyl.
[0065] In a further embodiment of the invention as defined anywhere
above, R.sup.6 and R.sup.11 are both H.
[0066] A further embodiment of the invention provides a compound
according to the formula 1b
##STR00004##
[0067] or the formula 1c
##STR00005##
[0068] wherein R.sup.30 is -A-(C.sub.0-C.sub.6
alkylene)-B-(X--R.sup.12).sub.q--R.sup.22 and A, B, X, R.sup.12, q
and R.sup.22 are as defined anywhere herein.
[0069] A further aspect of the invention provides a compound of
Formula 2
##STR00006##
[0070] wherein [LINKER] is selected from C.sub.1-C.sub.6 alkylene,
C.sub.2-C.sub.6 alkenylene, C.sub.2-C.sub.6 alkynylene, a 5- to
10-membered carbocyclic group, aryl, and a 5- to 10-membered
heterocyclic group containing one or more heteroatoms selected from
N, O and S, the ring systems being optionally substituted by one or
more Z.sup.1 groups; and
[0071] Z.sup.1 is independently selected from OH, aryl, O-aryl,
benzyl, O-benzyl, C.sub.1-C.sub.6 alkyl optionally substituted by
one or more OH groups, C.sub.1-C.sub.6 alkyl optionally substituted
by one or more halogen atoms, C.sub.1-C.sub.6 alkoxy optionally
substituted by one or more OH groups or C.sub.1-C.sub.4 alkoxy,
NR.sup.19(SO.sub.2)R.sup.21, (SO.sub.2)NR.sup.19R.sup.20,
(SO.sub.2)R.sup.20, NR.sup.19C(O)R.sup.20, C(O)NR.sup.19R.sup.20,
NR.sup.19C(O)NR.sup.20R.sup.18, NR.sup.19C(O)OR.sup.20,
NR.sup.19R.sup.21, C(O)OR.sup.19, C(O)R.sup.19, SR.sup.19,
OR.sup.19, oxo, CN, NO.sub.2, and halogen, wherein R.sup.18,
R.sup.19, R.sup.20 and R.sup.21 are all as defined anywhere
herein.
[0072] The skilled person will appreciate that the compounds of
Formula 2 are dimeric forms of the compounds of formula 1b or
1c.
[0073] In a yet further embodiment of the invention as defined
anywhere above, there is provided a compound according to Formula I
selected from:
##STR00007## ##STR00008## ##STR00009## ##STR00010## ##STR00011##
##STR00012## ##STR00013## ##STR00014## ##STR00015## ##STR00016##
##STR00017## ##STR00018## ##STR00019## ##STR00020## ##STR00021##
##STR00022## ##STR00023## ##STR00024## ##STR00025## ##STR00026##
##STR00027## ##STR00028## ##STR00029## ##STR00030## ##STR00031##
##STR00032## ##STR00033## ##STR00034## ##STR00035## ##STR00036##
##STR00037## ##STR00038## ##STR00039## ##STR00040## ##STR00041##
##STR00042## ##STR00043## ##STR00044## ##STR00045## ##STR00046##
##STR00047## ##STR00048##
DEFINITIONS
[0074] Terms used in the specification have the following
meanings:
[0075] "Optionally substituted" means the group referred to can be
substituted at one or more positions by any one or any combination
of the radicals listed thereafter.
[0076] "optionally substituted by one or more Z groups" denotes
that the relevant group may include one or more substituents, each
independently selected from the groups included within the
definition of Z. Thus, where there are two or more Z group
substituents, these may be the same or different.
[0077] "Halo" or "halogen", as used herein, may be fluorine,
chlorine, bromine or iodine.
[0078] "C.sub.1-C.sub.8-Alkyl", as used herein, denotes straight
chain or branched alkyl having 1-8 carbon atoms. If a different
number of carbon atoms is specified, such as C.sub.6 or C.sub.3,
then the definition is to be amended accordingly.
[0079] "C.sub.1-C.sub.8-Alkoxy", as used herein, denotes straight
chain or branched alkoxy having 1-8 carbon atoms. If a different
number of carbon atoms is specified, such as C.sub.6 or C.sub.3,
then the definition is to be amended accordingly.
[0080] The term "alkylene" denotes a straight chain or branched
saturated hydrocarbon chain containing between 1 and 8 carbon
atoms. If a different number of carbon atoms is specified, such as
C.sub.6 or C.sub.3, then the definition is to be amended
accordingly.
[0081] "Amino-C.sub.1-C.sub.8-alkyl" and
"amino-C.sub.1-C.sub.8-alkoxy" denote amino attached by a nitrogen
atom to C.sub.1-C.sub.8-alkyl, e.g., NH.sub.2--(C.sub.1-C.sub.8)--,
or to C.sub.1-C.sub.8-alkoxy, e.g.,
NH.sub.2--(C.sub.1-C.sub.8)--O--. If a different number of carbon
atoms is specified, such as C.sub.6 or C.sub.3, then the definition
is to be amended accordingly.
[0082] "C.sub.1-C.sub.8-Alkylamino" and
"di(C.sub.1-C.sub.8-alkyl)amino" denote C.sub.1-C.sub.8-alkyl, as
hereinbefore defined, attached by a carbon atom to an amino group.
The C.sub.1-C.sub.8-alkyl groups in di(C.sub.1-C.sub.8-alkyl)amino
may be the same or different. If a different number of carbon atoms
is specified, such as C.sub.6 or C.sub.3, then the definition is to
be amended accordingly.
[0083] "Amino-(hydroxy)-C.sub.1-C.sub.8-alkyl" denotes amino
attached by a nitrogen atom to C.sub.1-C.sub.8-alkyl and hydroxy
attached by an oxygen atom to the same C.sub.1-C.sub.8-alkyl. If a
different number of carbon atoms is specified, such as C.sub.6 or
C.sub.3, then the definition is to be amended accordingly.
[0084] "C.sub.1-C.sub.8-Alkylcarbonyl" and
"C.sub.1-C.sub.8-alkoxycarbonyl", as used herein, denote
C.sub.1-C.sub.8-alkyl or C.sub.1-C.sub.8-alkoxy, respectively, as
hereinbefore defined, attached by a carbon atom to a carbonyl
group. If a different number of carbon atoms is specified, such as
C.sub.6 or C.sub.3, then the definition is to be amended
accordingly.
[0085] "C.sub.3-C.sub.8-Cycloalkylcarbonyl", as used herein,
denotes C.sub.3-C.sub.8-cycloalkyl, as hereinbefore defined,
attached by a carbon atom to a carbonyl group. If a different
number of carbon atoms is specified, such as C.sub.6 or C.sub.3,
then the definition is to be amended accordingly.
[0086] "C.sub.7-C.sub.14-Aralkyl", as used herein, denotes alkyl,
e.g., C.sub.1-C.sub.4-alkyl, as hereinbefore defined, substituted
by a C.sub.6-C.sub.10-aromatic carbocyclic group, as herein
defined. If a different number of carbon atoms is specified, such
as C.sub.6 or C.sub.3, then the definition is to be amended
accordingly.
[0087] "C.sub.3-C.sub.15-Carbocyclic group", as used herein,
denotes a carbocyclic group having 3- to 15-ring carbon atoms that
is saturated or partially saturated, such as a
C.sub.3-C.sub.8-cycloalkyl. Examples of
C.sub.3-C.sub.15-carbocyclic groups include but are not limited to
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or
cyclooctyl or a bicyclic group, such as bicyclooctyl, bicyclononyl
including indanyl and indenyl and bicyclodecyl. If a different
number of carbon atoms is specified, such as C.sub.6, then the
definition is to be amended accordingly.
[0088] "aryl" or "C.sub.6-C.sub.15-Aromatic carbocyclic group", as
used herein, denotes an aromatic group having 6- to 15-ring carbon
atoms. Examples of C.sub.6-C.sub.15-aromatic carbocyclic groups
include, but are not limited to, phenyl, phenylene, benzenetriyl,
naphthyl, naphthylene, naphthalenetriyl or anthrylene. If a
different number of carbon atoms is specified, such as C.sub.m,
then the definition is to be amended accordingly.
[0089] "4- to 8-Membered heterocyclic group", "5- to 6-membered
heterocyclic group", "3- to 10-membered heterocyclic group", "3- to
14-membered heterocyclic group", "4- to 14-membered heterocyclic
group" and "5- to 14-membered heterocyclic group", refers,
respectively, to 4- to 8-membered, 5- to 6-membered, 3- to
10-membered, 3- to 14-membered, 4- to 14-membered and 5- to
14-membered heterocyclic rings containing at least one ring
heteroatom selected from the group consisting of nitrogen, oxygen
and sulphur, which may be saturated, partially saturated or
unsaturated (aromatic). The heterocyclic group includes single ring
groups, fused ring groups and bridged groups. Examples of such
heterocyclic groups include, but are not limited to, furan,
pyrrole, pyrrolidine, pyrazole, imidazole, triazole, isotriazole,
tetrazole, thiadiazole, isothiazole, oxadiazole, pyridine,
piperidine, pyrazine, oxazole, isoxazole, pyrazine, pyridazine,
pyrimidine, piperazine, pyrrolidine, pyrrolidinone, morpholine,
triazine, oxazine, tetrahydrofuran, tetrahydrothiophene,
tetrahydrothiopyran, tetrahydropyran, 1,4-dioxane, 1,4-oxathiane,
indazole, quinoline, indazole, indole, 8-aza-bicyclo[3.2.1]octane
or thiazole.
[0090] A second aspect of the present invention provides for the
use of a compound of formula (I) in any of the aforementioned
embodiments, in free or pharmaceutically acceptable salt form, for
the manufacture of a medicament for the treatment of an
inflammatory or allergic condition, particularly an inflammatory or
obstructive airways disease or mucosal hydration.
[0091] An embodiment of the present invention provides for the use
of a compound of formula (I) in any of the aforementioned
embodiments, in free or pharmaceutically acceptable salt form, for
the manufacture of a medicament for the treatment of an
inflammatory or allergic condition selected from cystic fibrosis,
primary ciliary dyskinesia, chronic bronchitis, chronic obstructive
pulmonary disease, asthma, respiratory tract infections, lung
carcinoma, xerostomia and keratoconjunctivitis sire.
[0092] It is understood that any and all embodiments of the present
invention may be taken in conjunction with any other embodiment to
describe additional embodiments of the present invention.
Furthermore, any elements of an embodiment are meant to be combined
with any and all other elements from any of the embodiments to
describe additional embodiments. It is understood by those skilled
in the art that combinations of substituents where not possible are
not an aspect of the present invention.
[0093] Throughout this specification and in the claims that follow,
unless the context requires otherwise, the word "comprise", or
variations, such as "comprises" or "comprising", will be understood
to imply the inclusion of a stated integer or step or group of
integers or steps but not the exclusion of any other integer or
step or group of integers or steps.
[0094] Especially preferred specific compounds of formula (I) are
those described hereinafter in the Examples.
[0095] The compounds represented by formula (I) may be capable of
forming acid addition salts, particularly pharmaceutically
acceptable acid addition salts. Pharmaceutically acceptable acid
addition salts of the compound of formula (I) include those of
inorganic acids, e.g., hydrohalic acids, such as hydrofluoric acid,
hydrochloric acid, hydrobromic acid or hydroiodic acid, nitric
acid, sulfuric acid, phosphoric acid; and organic acids, e.g.,
aliphatic monocarboxylic acids, such as formic acid, acetic acid,
trifluoroacetic acid, propionic acid and butyric acid; aliphatic
hydroxy acids, such as lactic acid, citric acid, tartaric acid or
malic acid; dicarboxylic acids, such as maleic acid or succinic
acid; aromatic carboxylic acids, such as benzoic acid,
p-chlorobenzoic acid, diphenylacetic acid, para-biphenyl benzoic
acid or triphenylacetic acid; aromatic hydroxy acids, such as
o-hydroxybenzoic acid, p-hydroxybenzoic acid,
1-hydroxynaphthalene-2-carboxylic acid or
3-hydroxynaphthalene-2-carboxylic acid; cinnamic acids, such as
3-(2-naphthalenyl)propenoic acid, para-methoxy cinnamic acid or
para-methyl cinnamic acid; and sulfonic acids, such as
methanesulfonic acid or benzenesulfonic acid. These salts may be
prepared from compounds of formula (I) by known salt-forming
procedures.
[0096] Compounds of formula (I) which may contain acidic, e.g.,
carboxyl, groups, are also capable of forming salts with bases, in
particular, pharmaceutically acceptable bases, such as those
well-known in the art; suitable such salts include metal salts,
particularly alkali metal or alkaline earth metal salts, such as
sodium, potassium, magnesium or calcium salts; or salts with
ammonia or pharmaceutically acceptable organic amines or
heterocyclic bases, such as ethanolamines, benzylamines or
pyridine. These salts may be prepared from compounds of formula (I)
by known salt-forming procedures.
[0097] Stereoisomers are those compounds where there is an
asymmetric carbon atom. The compounds exist in individual optically
active isomeric forms or as mixtures thereof, e.g., as
diastereomeric mixtures. The present invention embraces both
individual optically active R and S isomers, as well as mixtures
thereof. Individual isomers can be separated by methods well-known
to those skilled in the art, e.g., chiral high performance liquid
chromatography (HPLC).
[0098] Tautomers are one of two or more structural isomers that
exist in equilibrium and are readily converted from one isomeric
form to another.
[0099] More specifically, for example, compounds of Formula Ia
where R.sup.6 and/or R.sup.11 are hydrogen may exist in one or both
of the following tautomeric forms:
##STR00049##
[0100] Compounds according to Formula I may exist in corresponding
tautomeric forms.
[0101] Examples of tautomers include but are not limited to those
compounds defined in the claims.
[0102] The compounds of the invention may exist in both unsolvated
and solvated forms. The term "solvate" is used herein to describe a
molecular complex comprising the compound of the invention and one
or more pharmaceutically acceptable solvent molecules, e.g.,
ethanol. The term "hydrate" is employed when said solvent is
water.
Synthesis
[0103] Generally, compounds according to Formula I can be
synthesized by the routes described in Scheme 1 and the
Examples.
[0104] For instance, intermediate 1 can be reacted with
intermediate 2 in an organic solvent to provide compound 3 which
can be isolated as the free base. The free base can then be
converted to a salt form by treatment with an appropriate acid.
[0105] Intermediates can be prepared from methods known by those
skilled in the art or are commercially available.
##STR00050##
[0106] In Scheme 1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5,
R.sup.6 and R.sup.11 are as defined above; Y is CR.sup.7R.sup.8; X
is CR.sup.9R.sup.10; n is 0; and R.sup.7, R.sup.8, R.sup.9 and
R.sup.10 are also as defined above. For compounds where n is 1 or
2, then the appropriate methylene or ethylene linking groups are
inserted between X and Y in the diamine reactant 2.
[0107] The compounds of Formula 1 and Formula 2 above can be
prepared according to conventional routes described in the
literature.
[0108] Compounds of formula (I), in free form, may be converted
into salt form, and vice versa, in a conventional manners
understood by those skilled in the art. The compounds in free or
salt form can be obtained in the form of hydrates or solvates
containing a solvent used for crystallisation. Compounds of formula
(I) can be recovered from reaction mixtures and purified in a
conventional manner. Isomers, such as stereoisomers, may be
obtained in a conventional manner, e.g., by fractional
crystallisation or asymmetric synthesis from correspondingly
asymmetrically substituted, e.g., optically active, starting
materials.
[0109] The compounds of formula (I) can be prepared, e.g., using
the reactions and techniques described below and in the Examples.
The reactions may be performed in a solvent appropriate to the
reagents and materials employed and suitable for the
transformations being effected. It will be understood by those
skilled in the art of organic synthesis that the functionality
present on the molecule should be consistent with the
transformations proposed. This will sometimes require a judgment to
modify the order of the synthetic steps or to select one particular
process scheme over another in order to obtain a desired compound
of the invention.
[0110] The various substituents on the synthetic intermediates and
final products shown in the following reaction schemes can be
present in their fully elaborated forms, with suitable protecting
groups where required as understood by one skilled in the art, or
in precursor forms which can later be elaborated into their final
forms by methods familiar to one skilled in the art. The
substituents can also be added at various stages throughout the
synthetic sequence or after completion of the synthetic sequence.
In many cases, commonly used functional group manipulations can be
used to transform one intermediate into another intermediate, or
one compound of formula (I) into another compound of formula (I).
Examples of such manipulations are conversion of an ester or a
ketone to an alcohol; conversion of an ester to a ketone;
interconversions of esters, acids and amides; alkylation, acylation
and sulfonylation of alcohols and amines; and many others.
Substituents can also be added using common reactions, such as
alkylation, acylation, halogenation or oxidation. Such
manipulations are well-known in the art, and many reference works
summarize procedures and methods for such manipulations. Some
reference works which gives examples and references to the primary
literature of organic synthesis for many functional group
manipulations, as well as other transformations commonly used in
the art of organic synthesis are March's Organic Chemistry,
5.sup.th Edition, Wiley and Chichester, Eds. (2001); Comprehensive
Organic Transformations, Larock, Ed., VCH (1989); Comprehensive
Organic Functional Group Transformations, Katritzky et al. (series
editors), Pergamon (1995); and Comprehensive Organic Synthesis,
Trost and Fleming (series editors), Pergamon (1991). It will also
be recognized that another major consideration in the planning of
any synthetic route in this field is the judicious choice of the
protecting group used for protection of the reactive functional
groups present in the compounds described in this invention.
Multiple protecting groups within the same molecule can be chosen
such that each of these protecting groups can either be removed
without removal of other protecting groups in the same molecule, or
several protecting groups can be removed using the same reaction
step, depending upon the outcome desired. An authoritative account
describing many alternatives to the trained practitioner is Greene
and Wuts, Protective Groups in Organic Synthesis, Wiley and Sons
(1999).
Pharmacological Activity
[0111] Having regard to their blockade of the epithelial sodium
channel (ENaC), compounds of formula (I), in free or
pharmaceutically acceptable salt form, hereinafter alternately
referred to as "agents of the invention", are useful in the
treatment of conditions which respond to the blockade of the
epithelial sodium channel, particularly conditions benefiting from
mucosal hydration.
[0112] Diseases mediated by blockade of the epithelial sodium
channel, include diseases associated with the regulation of fluid
volumes across epithelial membranes. For example, the volume of
airway surface liquid is a key regulator of mucociliary clearance
and the maintenance of lung health. The blockade of the epithelial
sodium channel will promote fluid accumulation on the mucosal side
of the airway epithelium thereby promoting mucus clearance and
preventing the accumulation of mucus and sputum in respiratory
tissues (including lung airways). Such diseases include respiratory
diseases, such as cystic fibrosis, primary ciliary dyskinesia,
chronic bronchitis, chronic obstructive pulmonary disease (COPD),
asthma, respiratory tract infections (acute and chronic; viral and
bacterial) and lung carcinoma. Diseases mediated by blockade of the
epithelial sodium channel also include diseases other than
respiratory diseases that are associated with abnormal fluid
regulation across an epithelium, perhaps involving abnormal
physiology of the protective surface liquids on their surface,
e.g., xerostomia (dry mouth) or keratoconjunctivitis sire (dry
eye). Furthermore, blockade of the epithelial sodium channel in the
kidney could be used to promote diuresis and thereby induce a
hypotensive effect.
[0113] Treatment in accordance with the invention may be
symptomatic or prophylactic.
[0114] Asthma includes both intrinsic (non-allergic) asthma and
extrinsic (allergic) asthma, mild asthma, moderate asthma, severe
asthma, bronchitic asthma, exercise-induced asthma, occupational
asthma and asthma induced following bacterial infection. Treatment
of asthma is also to be understood as embracing treatment of
subjects, e.g., of less than 4 or 5 years of age, exhibiting
wheezing symptoms and diagnosed or diagnosable as "wheezy infants",
an established patient category of major medical concern and now
often identified as incipient or early-phase asthmatics. (For
convenience this particular asthmatic condition is referred to as
"wheezy-infant syndrome".)
[0115] Prophylactic efficacy in the treatment of asthma will be
evidenced by reduced frequency or severity of symptomatic attack,
e.g., of acute asthmatic or bronchoconstrictor attack, improvement
in lung function or improved airways hyperreactivity. It may
further be evidenced by reduced requirement for other, symptomatic
therapy, i.e., therapy for or intended to restrict or abort
symptomatic attack when it occurs, e.g., anti-inflammatory (e.g.,
cortico-steroid) or bronchodilatory. Prophylactic benefit in asthma
may, in particular, be apparent in subjects prone to "morning
dipping". "Morning dipping" is a recognized asthmatic syndrome,
common to a substantial percentage of asthmatics and characterized
by asthma attack, e.g., between the hours of about 4-6 am, i.e., at
a time normally substantially distant from any previously
administered symptomatic asthma therapy.
[0116] Chronic obstructive pulmonary disease includes chronic
bronchitis or dyspnea associated therewith, emphysema, as well as
exacerbation of airways hyperreactivity consequent to other drug
therapy, in particular, other inhaled drug therapy. The invention
is also applicable to the treatment of bronchitis of whatever type
or genesis including, e.g., acute, arachidic, catarrhal, croupus,
chronic or phthinoid bronchitis.
[0117] The agents of the invention may also be useful as
acid-sensing ion channel (ASIC) blockers. Thus they may be useful
in the treatment of conditions which respond to the blockade of the
acid-sensing ion channel.
[0118] The suitability of epithelial sodium channel blocker as a
treatment of a disease benefiting from mucosal hydration, may be
tested by determining the inhibitory effect of the channel blocker
on ENaC in a suitable cell-based assay. For example single cells or
confluent epithelia, endogenously expressing or engineered to
overexpress ENaC can be used to assess channel function using
electrophysiological techniques or ion flux studies. See methods
described in: Hirsh et al., J Pharm Exp Ther (2004); Moody et al.,
Am J Physiol Cell Physiol (2005).
[0119] Epithelial sodium channel blockers, including the compounds
of formula (I), are also useful as co-therapeutic agents for use in
combination with other drug substances, such as anti-inflammatory,
bronchodilatory, antihistamine or anti-tussive drug substances,
particularly in the treatment of cystic fibrosis or obstructive or
inflammatory airways diseases such as those mentioned hereinbefore,
e.g., as potentiators of therapeutic activity of such drugs or as a
means of reducing required dosaging or potential side effects of
such drugs.
[0120] The epithelial sodium channel blocker may be mixed with the
other drug substance in a fixed pharmaceutical composition or it
may be administered separately, before, simultaneously with or
after the other drug substance.
[0121] Accordingly, the invention includes as a further aspect a
combination of epithelial sodium channel blocker with osmotic
agents (hypertonic saline, dextran, mannitol, Xylitol)+modifiers of
CFTR function, both wild-type and mutant (correctors+potentiators),
e.g., those described in WO 2007/021982, WO 2006/099256, WO
2006/127588, WO 2004/080972, WO 2005/026137, WO 2005/035514, WO
2005/075435, WO 2004/111014, WO 2006/101740, WO 2004/110352, WO
2005/120497 and US 2005/0176761, an anti-inflammatory,
bronchodilatory, antihistamine, anti-tussive, antibiotic or DNase
drug substance, said epithelial sodium channel blocker and said
drug substance being in the same or different pharmaceutical
composition.
[0122] Suitable antibiotics include macrolide antibiotics, e.g.,
tobramycin (TOBI.TM.).
[0123] Suitable DNase drug substances include dornase alfa
(Pulmozyme.TM.), a highly-purified solution of recombinant human
deoxyribonuclease I (rhDNase), which selectively cleaves DNA.
Dornase alfa is used to treat cystic fibrosis.
[0124] Other useful combinations of epithelial sodium channel
blockers with anti-inflammatory drugs are those with antagonists of
chemokine receptors, e.g., CCR-1, CCR-2, CCR-3, CCR-4, CCR-5,
CCR-6, CCR-7, CCR-8, CCR-9 and CCR10, CXCR1, CXCR2, CXCR3, CXCR4,
CXCR5, particularly CCR-5 antagonists, such as Schering-Plough
antagonists SC-351125, SCH-55700 and SCH-D; Takeda antagonists,
such as
N-[[4-[[[6,7-dihydro-2-(4-methyl-phenyl)-5H-benzo-cyclohepten-8-yl]carbon-
yl]amino]phenyl]-methyl]tetrahydro-N,N-dimethyl-2H-pyran-4-amin-ium
chloride (TAK-770); and CCR-5 antagonists described in U.S. Pat.
No. 6,166,037 (particularly claims 18 and 19), WO 00/66558
(particularly claim 8), WO 00/66559 (particularly claim 9), WO
04/018425 and WO 04/026873.
[0125] Suitable anti-inflammatory drugs include steroids, in
particular, glucocorticosteroids, such as budesonide,
beclamethasone dipropionate, fluticasone propionate, ciclesonide or
mometasone furoate, or steroids described in WO 02/88167, WO
02/12266, WO 02/100879, WO 02/00679 (especially those of Examples
3, 11, 14, 17, 19, 26, 34, 37, 39, 51, 60, 67, 72, 73, 90, 99 and
101), WO 03/35668, WO 03/48181, WO 03/62259, WO 03/64445, WO
03/72592, WO 04/39827 and WO 04/66920; non-steroidal glucocorticoid
receptor agonists, such as those described in DE 10261874, WO
00/00531, WO 02/10143, WO 03/82280, WO 03/82787, WO 03/86294, WO
03/104195, WO 03/101932, WO 04/05229, WO 04/18429, WO 04/19935 and
WO 04/26248; LTD4 antagonists, such as montelukast and zafirlukast;
PDE4 inhibitors, such as cilomilast (Ariflo.RTM. GlaxoSmithKline),
Roflumilast (Byk Gulden), V-11294A (Napp), BAY19-8004 (Bayer),
SCH-351591 (Schering-Plough), Arofylline (Almirall Prodesfarma),
PD189659/PD168787 (Parke-Davis), AWD-12-281 (Asta Medica), CDC-801
(Celgene), SelCID.TM. CC-10004 (Celgene), VM554/UM565 (Vernalis),
T-440 (Tanabe), KW-4490 (Kyowa Hakko Kogyo), and those disclosed in
WO 92/19594, WO 93/19749, WO 93/19750, WO 93/19751, WO 98/18796, WO
99/16766, WO 01/13953, WO 03/104204, WO 03/104205, WO 03/39544, WO
04/000814, WO 04/000839, WO 04/005258, WO 04/018450, WO 04/018451,
WO 04/018457, WO 04/018465, WO 04/018431, WO 04/018449, WO
04/018450, WO 04/018451, WO 04/018457, WO 04/018465, WO 04/019944,
WO 04/019945, WO 04/045607 and WO 04/037805; adenosine A2B receptor
antagonists such as those described in WO 02/42298; and beta-2
adrenoceptor agonists, such as albuterol (salbutamol),
metaproterenol, terbutaline, salmeterol fenoterol, procaterol, and
especially, formoterol, carmoterol and pharmaceutically acceptable
salts thereof, and compounds (in free or salt or solvate form) of
formula (I) of WO 0075114, which document is incorporated herein by
reference, preferably compounds of the Examples thereof, especially
a compound of formula:
##STR00051##
[0126] corresponding to indacaterol and pharmaceutically acceptable
salts thereof, as well as compounds (in free or salt or solvate
form) of formula (I) of WO 04/16601, and also compounds of EP
1440966, JP 05025045, WO 93/18007, WO 99/64035, USP 2002/0055651,
WO 01/42193, WO 01/83462, WO 02/66422, WO 02/70490, WO 02/76933, WO
03/24439, WO 03/42160, WO 03/42164, WO 03/72539, WO 03/91204, WO
03/99764, WO 04/16578, WO 04/22547, WO 04/32921, WO 04/33412, WO
04/37768, WO 04/37773, WO 04/37807, WO 04/39762, WO 04/39766, WO
04/45618, WO 04/46083, WO 04/80964, WO 04/108765 and WO
04/108676.
[0127] Suitable bronchodilatory drugs include anticholinergic or
antimuscarinic agents, in particular, ipratropium bromide,
oxitropium bromide, tiotropium salts and CHF 4226 (Chiesi), and
glycopyrrolate, but also those described in EP 424021, U.S. Pat.
No. 3,714,357, U.S. Pat. No. 5,171,744, WO 01/04118, WO 02/00652,
WO 02/51841, WO 02/53564, WO 03/00840, WO 03/33495, WO 03/53966, WO
03/87094, WO 04/018422 and WO 04/05285.
[0128] Suitable dual anti-inflammatory and bronchodilatory drugs
include dual beta-2 adrenoceptor agonist/muscarinic antagonists
such as those disclosed in USP 2004/0167167, WO 04/74246 and WO
04/74812.
[0129] Suitable antihistamine drug substances include cetirizine
hydrochloride, acetaminophen, clemastine fumarate, promethazine,
loratidine, desloratidine, diphenhydramine and fexofenadine
hydrochloride, activastine, astemizole, azelastine, ebastine,
epinastine, mizolastine and tefenadine, as well as those disclosed
in JP 2004107299, WO 03/099807 and WO 04/026841.
[0130] In accordance with the foregoing, the invention also
provides as a further aspect a method for the treatment of a
condition responsive to blockade of the epithelial sodium channel,
e.g., diseases associated with the regulation of fluid volumes
across epithelial membranes, particularly an obstructive airways
disease, which comprises administering to a subject, particularly a
human subject, in need thereof a compound of formula (I), in free
form or in the form of a pharmaceutically acceptable salt.
[0131] In another aspect the invention provides a compound of
formula (I), in free form or in the form of a pharmaceutically
acceptable salt, for use in the manufacture of a medicament for the
treatment of a condition responsive to blockade of the epithelial
sodium channel, particularly an obstructive airways disease, e.g.,
cystic fibrosis and COPD.
[0132] The agents of the invention may be administered by any
appropriate route, e.g. orally, e.g., in the form of a tablet or
capsule; parenterally, e.g., intravenously; by inhalation, e.g., in
the treatment of an obstructive airways disease; intranasally,
e.g., in the treatment of allergic rhinitis; topically to the skin;
or rectally. In a further aspect, the invention also provides a
pharmaceutical composition comprising a compound of formula (I), in
free form or in the form of a pharmaceutically acceptable salt,
optionally together with a pharmaceutically acceptable diluent or
carrier therefor. The composition may contain a co-therapeutic
agent, such as an anti-inflammatory, broncho-dilatory,
antihistamine or anti-tussive drug as hereinbefore described. Such
compositions may be prepared using conventional diluents or
excipients and techniques known in the galenic art. Thus oral
dosage forms may include tablets and capsules. Formulations for
topical administration may take the form of creams, ointments, gels
or transdermal delivery systems, e.g., patches. Compositions for
inhalation may comprise aerosol or other atomizable formulations or
dry powder formulations.
[0133] When the composition comprises an aerosol formulation, it
preferably contains, e.g., a hydro-fluoro-alkane (HFA) propellant,
such as HFA134a or HFA227 or a mixture of these, and may contain
one or more co-solvents known in the art, such as ethanol (up to
20% by weight), and/or one or more surfactants, such as oleic acid
or sorbitan trioleate, and/or one or more bulking agents, such as
lactose. When the composition comprises a dry powder formulation,
it preferably contains, e.g., the compound of formula (I) having a
particle diameter up to 10 microns, optionally together with a
diluent or carrier, such as lactose, of the desired particle size
distribution and a compound that helps to protect against product
performance deterioration due to moisture, e.g., magnesium
stearate. When the composition comprises a nebulised formulation,
it preferably contains, e.g., the compound of formula (I) either
dissolved, or suspended, in a vehicle containing water, a
co-solvent, such as ethanol or propylene glycol and a stabilizer,
which may be a surfactant.
[0134] Further aspects of the invention include:
[0135] (a) a compound of formula (I) in inhalable form, e.g., in an
aerosol or other atomisable composition or in inhalable
particulate, e.g., micronised form;
[0136] (b) an inhalable medicament comprising a compound of formula
(I) in inhalable form;
[0137] (c) a pharmaceutical product comprising a compound of
formula (I) in inhalable form in association with an inhalation
device; and
[0138] (d) an inhalation device containing a compound of formula I
in inhalable form.
[0139] Dosages of compounds of formula (I) employed in practising
the present invention will of course vary depending, e.g., on the
particular condition to be treated, the effect desired and the mode
of administration. In general, suitable daily dosages for
administration by inhalation are of the order of 0.005-10 mg, while
for oral administration suitable daily doses are of the order of
0.05-100 mg.
Pharmaceutical Use and Assay
[0140] Compounds of formula (I) and their pharmaceutically
acceptable salts, hereinafter referred to alternatively as "agents
of the invention", are useful as pharmaceuticals. In particular,
the compounds have good ENaC blocker activity and may be tested in
the following assays.
Cell Culture
[0141] Human Bronchial Epithelial cells (HBECs) (Cambrex) were
cultured under air-liquid interface conditions to provide a well
differentiated mucociliary phenotype.
[0142] HBECs were cultured using a modification of the method
described by Gray and colleagues (Gray et al., 1996). Cells were
seeded in plastic T-162 flasks and were grown in bronchial
epithelial cell growth medium (BEGM; Cambrex) supplemented with
bovine pituitary extract (52 .mu.g/mL), hydrocortisone (0.5
.mu.g/mL), human recombinant epidermal growth factor (0.5
.mu.g/mL), epinephrine (0.5 .mu.g/mL), transferrin (10 .mu.g/mL),
insulin (5 .mu.g/mL), retinoic acid (0.1 .mu.g/mL),
triiodothyronine (6.5 .mu.g/mL), gentamycin (50 .mu.g/mL) and
amphotericin B (50 ng/mL). Medium was changed every 48 hours until
cells were 90% confluent. Cells were then passaged and seeded
(8.25.times.10.sup.5 cells/insert) on polycarbonate Snapwell
inserts (Costar) in differentiation media containing 50% DMEM in
BEGM with the same supplements as above but without
triiodothyronine and a final retinoic acid concentration of 50 nM
(all-trans retinoic acid). Cells were maintained submerged for the
first 7 days in culture, after which time they were exposed to an
apical air interface for the remainder of the culture period. At
this time, media was changed to DMEM:F12 media containing 2% v/v
Ultroser G for the remainder of culture. Amphotericin B was removed
from all media 3 feeds prior to use in the Ussing Chambers. Cells
were used between days 7 and 21 after establishment of the
apical-air interface. At all stages of culture, cells were
maintained at 37.degree. C. in 5% CO.sub.2 in an air incubator.
Short Circuit Current (ISC) Measurements
[0143] Snapwell inserts were mounted in Vertical Diffusion Chambers
(Costar) and were bathed with continuously gassed Ringer solution
(5% CO.sub.2 in O.sub.2; pH 7.4) maintained at 37.degree. C.
containing (in mM): 120 NaCl, 25 NaHCO.sub.3, 3.3 KH.sub.2PO.sub.4,
0.8 K.sub.2HPO.sub.4, 1.2 CaCl.sub.2, 1.2 MgCl.sub.2, and 10
glucose. The solution osmolarity was between 280 and 300 mOsmol/kg
H.sub.2O for all physiological salt solutions used. Cells were
voltage clamped to 0 mV (model EVC4000; WPI). RT was measured by
applying a 1- or 2-mV pulse at 30-s intervals and calculating RT by
Ohm's law. Data were recorded using a PowerLab workstation
(ADInstruments).
[0144] Test compounds were prepared as a 10 mM stock solution in
DMSO (95%). Serial 3-fold dilutions were freshly prepared in an
appropriate vehicle (distilled H.sub.2O or Ringers solution). The
initial concentration was added to the apical chamber as a
1000.times. concentrate in 5 .mu.L, resulting in a final 1.times.
concentration the 5 mL volume of the Ussing chamber. Subsequent
additions of compound were added in a 3.3 .mu.L volume of the
1000.times. serially diluted stock solution. At the completion of
the concentration-response experiment, amiloride (10 .mu.M) was
added into the apical chamber to enable the total
amiloride-sensitive current to be measured. An amiloride control
IC.sub.50 was established at the start of each experiment.
[0145] Results are expressed as the mean % inhibition of the
amiloride-sensitive ISC. Concentration-response curves were plotted
and IC.sub.50 values generated using GraphPad Prism 3.02. Cell
inserts were typically run in duplicate and the IC.sub.50
calculated on the mean % inhibition data.
[0146] Compounds of the Examples, herein below, generally have
IC.sub.50 values in the data measurements described above below 10
.mu.M. For example, the compounds of the Examples shown below have
the indicated IC.sub.50 values.
TABLE-US-00001 IC.sub.50 Ex (.mu.M) 5 0.065 11 1.686 19 0.018 23
0.0335 25 0.270 26 0.011 29 0.005 32 0.018 34 0.095 35 0.031 39
0.0055 40 0.0055 41 0.0095 42 0.011 43 0.013 44 0.0295 45 0.0426 48
0.0165 58 0.143 61 0.3465 62 0.013 64 0.0255 65 0.0395 70 0.074 71
0.042 76 0.012 86 0.008 91 0.0885 94 0.009 96 0.037 99 0.019 118
0.175 126 0.025 128 0.0115 141 0.002 146 0.006 147 0.016 185 0.062
215 0.036 220 0.0085 228 0.0935 232 0.054 235 0.364 238 0.119 246
0.025 252 0.028
The invention is illustrated by the following Examples.
EXAMPLES
[0147] Compounds of Formula Ib
##STR00052##
[0148] are shown in Table 1. Methods for preparing such compounds
are described hereinafter. The table also shows mass spectrometry
[M+H].sup.+ data.
TABLE-US-00002 TABLE 1 M/s Ex. Structure [M + H].sup.+ 1
##STR00053## 284 2 ##STR00054## 270 3 ##STR00055## 270 4
##STR00056## 408 5 ##STR00057## 461 6 ##STR00058## 418 7
##STR00059## 404 8 ##STR00060## 376/378 9 ##STR00061## 400 10
##STR00062## 328 11 ##STR00063## 310 12 ##STR00064## 415 13
##STR00065## 404 14 ##STR00066## 270 15 ##STR00067## 296 16
##STR00068## 310 17 ##STR00069## 390 18 ##STR00070## 390 19
##STR00071## 464 20 ##STR00072## 464 21 ##STR00073## 464 22
##STR00074## 464 23 ##STR00075## 517 24 ##STR00076## 418.2 25
##STR00077## 418.2 26 ##STR00078## 446 27 ##STR00079## 356 28
##STR00080## 506 29 ##STR00081## 506.37 30 ##STR00082## 447.1 31
##STR00083## 313.1 32 ##STR00084## 446.1 33 ##STR00085## 467.0 34
##STR00086## 430.98 35 ##STR00087## 481.0 36 ##STR00088## 445.1 37
##STR00089## 425 38 ##STR00090## 325 39 ##STR00091## 626.4 40
##STR00092## 607.42 41 ##STR00093## 607.98 42 ##STR00094## 510.4 43
##STR00095## 529.05 44 ##STR00096## 499.0 45 ##STR00097## 542.91 46
##STR00098## 552.1 47 ##STR00099## 469.17 48 ##STR00100## 510.23 49
##STR00101## 510.1 50 ##STR00102## 483.1 51 ##STR00103## 535.1 52
##STR00104## 499.1 53 ##STR00105## 469.14 54 ##STR00106## 487.0 55
##STR00107## 472.98 56 ##STR00108## 468.1 57 ##STR00109## 480.1 58
##STR00110## 521.1 59 ##STR00111## 528.2 60 ##STR00112## 469.08 61
##STR00113## 597.07 62 ##STR00114## 530.21 63 ##STR00115## 553.54
64 ##STR00116## 529.54 65 ##STR00117## 530.46 66 ##STR00118##
513.40 67 ##STR00119## 547.42 68 ##STR00120## 561.04 69
##STR00121## 601.10 70 ##STR00122## 564.10 71 ##STR00123## 587.50
72 ##STR00124## 530.10 73 ##STR00125## 599.10 74 ##STR00126##
615.20 75 ##STR00127## 545.10 76 ##STR00128## 529.41 77
##STR00129## 524 78 ##STR00130## 571 79 ##STR00131## 557 80
##STR00132## 543 81 ##STR00133## 529 82 ##STR00134## 588 83
##STR00135## 586/588 84 ##STR00136## 597 85 ##STR00137## 618 86
##STR00138## 644/646 87 ##STR00139## 582/584 88 ##STR00140## 540 89
##STR00141## 568/570 90 ##STR00142## 600/602 91 ##STR00143##
581/583 92 ##STR00144## 512/514 93 ##STR00145## 785 94 ##STR00146##
[M + 2H].sup.2+ = 393 95 ##STR00147## 787 96 ##STR00148## 779 97
##STR00149## 549 98 ##STR00150## 563 99 ##STR00151## 468 100
##STR00152## 468 101 ##STR00153## 443 102 ##STR00154## 675 103
##STR00155## 463 104 ##STR00156## 653 105 ##STR00157## 455 106
##STR00158## 429 107 ##STR00159## 469 108 ##STR00160## 423 109
##STR00161## 453 110 ##STR00162## 419 111 ##STR00163## 395 112
##STR00164## 454 113 ##STR00165## 430 114 ##STR00166## 487 115
##STR00167## 431 116 ##STR00168## 445 117 ##STR00169## 435 118
##STR00170## 420 119 ##STR00171## 430 120 ##STR00172## 430 121
##STR00173## 436 122 ##STR00174## 419
123 ##STR00175## 437 124 ##STR00176## 431 125 ##STR00177## 420 126
##STR00178## 648.4 127 ##STR00179## 651.3 128 ##STR00180## 648.3
129 ##STR00181## 576.3 130 ##STR00182## 633.3 131 ##STR00183##
592.3 132 ##STR00184## 599.3 133 ##STR00185## 610.3 134
##STR00186## 634.3 135 ##STR00187## 613.3 136 ##STR00188## 654.3
137 ##STR00189## 664.3 138 ##STR00190## 645.4 139 ##STR00191##
614.3 140 ##STR00192## 593.4 141 ##STR00193## 702.3 142
##STR00194## 594.3 143 ##STR00195## 643.3 144 ##STR00196## 736.4
145 ##STR00197## 626.3 146 ##STR00198## 559.3 147 ##STR00199##
572.08 148 ##STR00200## 572.0 149 ##STR00201## 538.4 150
##STR00202## 544.4 151 ##STR00203## 569.4 152 ##STR00204## 511.4
153 ##STR00205## 604.3 154 ##STR00206## 528.3 155 ##STR00207##
633.4 156 ##STR00208## 526.3 157 ##STR00209## 556.4 158
##STR00210## 604.4 159 ##STR00211## 617.4 160 ##STR00212## 594.4
161 ##STR00213## 528.4 162 ##STR00214## 478.3 163 ##STR00215##
462.3 164 ##STR00216## 691.04 165 ##STR00217## 573.05 166
##STR00218## 648.06 167 ##STR00219## 545.3 168 ##STR00220## 517.07
169 ##STR00221## 484.04 170 ##STR00222## 511.04 171 ##STR00223##
530.08 172 ##STR00224## 603.99 173 ##STR00225## 530.19 174
##STR00226## 527.99 175 ##STR00227## 555.07 176 ##STR00228## 608.05
177 ##STR00229## 527.07 178 ##STR00230## 524.1 179 ##STR00231##
520.99 180 ##STR00232## 545.95 181 ##STR00233## 514.98 182
##STR00234## 512.01 183 ##STR00235## 478.01 184 ##STR00236## 475.08
185 ##STR00237## 572.09 186 ##STR00238## 634.09 187 ##STR00239##
619.12 188 ##STR00240## 496.02 189 ##STR00241## 685.08 190
##STR00242## 599.2 191 ##STR00243## 542.01 192 ##STR00244## 579.03
193 ##STR00245## 526.05 194 ##STR00246## 553.09 195 ##STR00247##
614.3 196 ##STR00248## 516.06 197 ##STR00249## 496.01 198
##STR00250## 528.04 199 ##STR00251## 560.14 200 ##STR00252## 490.05
201 ##STR00253## 528.06 202 ##STR00254## 527.02 203 ##STR00255##
458.1 204 ##STR00256## 540.02 205 ##STR00257## 539.11 206
##STR00258## 433.05 207 ##STR00259## 635.19 208 ##STR00260## 447.09
209 ##STR00261## 509.09 210 ##STR00262## 542.00 211 ##STR00263##
564.06 212 ##STR00264## 539.11 213 ##STR00265## 445.96 214
##STR00266## 620.1 215 ##STR00267## 458.1 216 ##STR00268## 217
##STR00269## 637.1 218 ##STR00270## 598.05 219 ##STR00271## 554.0
220 ##STR00272## 578.2 221 ##STR00273## 539.2 222 ##STR00274##
557.2 223 ##STR00275## 564.1 224 ##STR00276## 610.2 225
##STR00277## 532.1 226 ##STR00278## 566.1 227 ##STR00279## 539.2
228 ##STR00280## 487.1 229 ##STR00281## 620.2 230 ##STR00282##
564.2 231 ##STR00283## 578.2 232 ##STR00284## 478.98 233
##STR00285## 234 ##STR00286## 517.9 235 ##STR00287## 518.1 236
##STR00288## 540.9 237 ##STR00289## 493.1 238 ##STR00290## 652.2
239 ##STR00291## 615.1 240 ##STR00292## 520.1 241 ##STR00293##
527.0 242 ##STR00294## 581.1 243 ##STR00295## 527.1 244
##STR00296## 616.1 245 ##STR00297## 527.0 246 ##STR00298## 429 247
##STR00299## 445 248 ##STR00300## 416
249 ##STR00301## 443 250 ##STR00302## 421 251 ##STR00303## 451 252
##STR00304## 494.15 253 ##STR00305## 589.20
General Conditions
[0149] LCMS are recorded using a Phenomenex Gemini 50 mm.times.3.0
mm, 3 um column. Low pH methods use a gradient of 5-95%
acetonitrile in water -0.1% TFA, high pH methods use 5-95%
acetonitrile in water -0.1% NH.sub.3. [M+H].sup.+ refer to
monoisotopic molecular weights.
9-BBN 9-Borabicyclo[3.3.1]nonane DBU Diazabicyclo[5.4.0]undec-7-ene
DMF dimethylformamide DMSO dimethyl sulfoxide DCM dichloromethane
DEAD diethyl azodicarboxylate DIAD diisopropyl azodicarboxylate
DIPEA diisopropylethylamine EDCI 1-ethyl-3-(3'-dimethylaminopropyl)
carbodiimide EtOAc ethyl acetate HATU
2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate HPLC high performance liquid chromatography IPA
Isopropyl alcohol (iso-propanol) MeOH methanol MEMCl
2-methoxyethoxymethyl chloride NMR nuclear magnetic resonance PS
polymer supported PPTS Pyridinium para-toluenesulfonate PEAX
PE-anion exchange (e.g. Isolute.RTM. PE-AX columns from Biotage)
SCX-2 strong cation exchange (e.g. Isolute.RTM. SCX-2 columns from
Biotage) TEA triethylamine THF tetrahydrofuran TFA trifluoroacetic
acid
Preparation of Examples
[0150] For clarity in describing the Examples described below.
Examples 2, 9, and 10 are racemic mixtures. Examples 4, 13 and 29
are mixtures of diastereomers. Examples 24 and 25 are single
enantiomers wherein the stereochemistry of the unassigned
stereocentre is not determined. All other examples are single
enantiomers of defined stereochemistry.
[0151] Where not stated, the compounds are recovered from reaction
mixtures and purified using conventional techniques such as flash
chromatography, filtration, recrystallisation and trituration.
Example 1
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[4,4-dimethyl-imidazolidin-(2Z)-ylidene]-amide
[0152] A suspension of
1-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-2-methyl-isothiourea
(Intermediate A) (0.2 g, 0.517 mmol) in EtOH (2 ml) is treated with
triethylamine (0.029 ml, 0.258 mmol) followed by
1,2-diamino-2-methylpropane (0.07 ml, 0.672 mmol) and stirred at
reflux overnight. The resulting suspension is filtered under vacuum
to afford the title compound as a pale yellow solid; [M+H].sup.+
284
Example 2
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[4-methyl-imidazolidin-(2Z)-ylidene]-amide
[0153] This compound is prepared analogously to Example 1 by
replacing 1,2-diamino-2-methylpropane with 1,2diaminopropane;
[M+H].sup.+ 270
Example 3
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[1-methyl-imidazolidin-(2Z)-ylidene]-amide
[0154] This compound is prepared analogously to Example 1 by
replacing 1,2-diamino-2-methylpropane with N-methylenediamine;
[M+H].sup.+ 270
Example 4
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid(4,5-diphenyl-imidazolidin-2-ylidene)-amide
[0155] This compound is prepared analogously to Example 1 by
replacing 1,2-diamino-2-methylpropane with 1,2 diphenylethylene
diamine; [M+H].sup.+ 408
Example 5
[0156]
(4-{2-[(Z)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-imidazoli-
din-4-yl}-butyl)-carbamic acid benzyl ester
[0157] This compound is prepared analogously to Example 1 by
replacing 1,2-diamino-2-methylpropane with
((S)-5,6-Diamino-hexyl)-carbamic acid benzyl ester (Intermediate
B); [M+H].sup.+ 461
Example 6
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[1-[4-(4-methoxy-phenyl)-butyl]-imidazolidin-(2Z)-ylidene]-amide
[0158] This compound is prepared analogously to Example 1 by
replacing 1,2-diamino-2-methylpropane with
N*1*-[4-(4-methoxy-phenyl)-butyl]-ethane-1,2-diamine (Intermediate
C); [M+H].sup.+ 418
Example 7
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[1-[4-(4-hydroxy-phenyl)-butyl]-imidazolidin-(2Z)-ylidene]-amide
[0159] This compound is prepared analogously to Example 1 by
replacing 1,2-diamino-2-methylpropane with
4-[4-(2-amino-ethylamino)-butyl]-phenol (Intermediate C);
[M+H].sup.+ 404
Example 8
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[(S)-4-(4-methoxy-benzyl)-imidazolidin-(2Z)-ylidene]-amide
[0160] This compound is prepared analogously to Example 1 by
replacing 1,2-diamino-2-methylpropane with
(S)-3-(4-methoxy-phenyl)-propane-1,2 diamine (Intermediate D);
[M+H].sup.+ 376
Example 9
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[4-(3,4-dichloro-phenyl)-imidazolidin-(2Z)-ylidene]-amide
[0161] This compound is prepared analogously to Example 1 by
replacing 1,2-diamino-2-methylpropane with
1-(3,4-Dichloro-phenyl)-ethane-1,2-diamine (Intermediate E);
[M+H].sup.+ 400
Example 10
3-{2-[(Z)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-imidazolidin-4-yl-
}-propionic acid
[0162] This compound is prepared analogously to Example 1 by
replacing 1,2-diamino-2-methylpropane with 4,5-Diaminopentanoic
acid dihydrochloride (Intermediate F); [M+H].sup.+ 328
Examples 2-10
[0163] These compounds are recovered from reaction mixtures and
purified using conventional techniques such as flash
chromatography, filtration, capture release resin or preparative
HPLC.
Example 11
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid(octahydro-benzoimidazol-2-ylidene)-amide
[0164] This compound is prepared analogously to Example 1 by
replacing 1,2-diamino-2-methylpropane with cyclohexane-1,2-diamine.
The reaction is carried out in propan-2-ol; [M+H].sup.+ 310
Example 12
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-benzyl-1,3,8-triazaspiro[4.5]dec-(2Z)-ylidene]-amide
[0165] 4-Amino-1-benzyl-piperidine-4-carbonitrile (Intermediate G)
(200 mg, 0.91 mmol) in dry propan-2-ol (10 ml) is treated with
triethylamine (0.25 ml) followed by
1-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-2-methyl-isothiourea
(Intermediate A) (355 mg, 0.91 mmol). The mixture is heated at
70.degree. C. for 5 hours and then allowed to cool to room
temperature. The precipitate is collected and washed with methanol
to afford the title compound as a light yellow solid, 190 mg;
[M+H].sup.+ 415
Example 13
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[4-[3-(4-methoxy-phenyl)-propyl]-imidazolidin-(2Z)-ylidene]-amide
[0166] This compound is prepared analogously to Example 12 by
replacing 4-Amino-1-benzyl-piperidine-4-carbonitrile (Intermediate
G) with 5-(4-methoxy-phenyl)-pentane-1,2-diamine (Intermediate I);
[M+H].sup.+ 404
Example 14
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid(tetrahydro-pyrimidin-2-ylidene)-amide
[0167]
1-(3,5-Diamino-6-chloro-pyrazine-2-carbonyl)-2-methyl-isothiourea
(Intermediate A) (1.0 g, 2.58 mmol) is suspended in propan-2-ol (10
ml) and 1,3-diaminopropane (0.32 ml, 3.9 mmol) is added. The
mixture is heated at 60.degree. C. for 18 hours and then allowed to
cool to room temperature and the solids present are collected by
filtration. The solids are washed with THF and MeOH to yield the
title compound as a yellow solid; [M+H].sup.+ 270
Example 15
3,5-diamino-6-chloro-N-(1H-pyrrolo[1,2-c]imidazol-3 (2H,5H,6H,7H,7
aH)-ylidene)pyrazine-2-carboxamide
[0168]
1-(3,5-Diamino-6-chloro-pyrazine-2-carbonyl)-2-methyl-isothiourea
(Intermediate A) (195 mg, 0.5 mmol) is suspended in propan-2-ol (10
ml) and (S)-2-(aminomethyl)pyrrolidine (100 mg, 1 mmol) is added.
The mixture is heated at 60.degree. C. for 18 hours, allowed to
cool to room temperature and the precipitate is removed by
filtration. The filtrate is concentrated in vacuo and the residue
purified by chromatography (SiO.sub.2, DCM/MeOH) to afford the
title compound as a light, yellow gum; [M+H].sup.+ 296
Example 16
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[1,3-diaza-spiroro[4.4]non-(2Z)-ylidene]-amide
[0169] A solution of crude 1-aminomethyl-cyclopentylamine
(Intermediate J) (80 mg, 0.70 mmol) in propan-2-ol (1.0 ml) is
added to a suspension of
1-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-2-methyl-isothiourea
(Intermediate A) (208 mg, 0.54 mmol) in propan-2-ol (1.08 ml) and
heated at 70.degree. C. for 2 days. After cooling to room
temperature, the reaction mixture is filtered under vacuum, and the
solid is rinsed with MeOH. The filtrate is concentrated in vacuo to
afford a bright yellow residue which is loaded onto a SCX-2
cartridge and eluted with 33% NH.sub.3 (4 drops) in MeOH (5 ml
.times.2). The methanolic ammonia fractions are combined and
concentrated in vacuo. Purification using mass directed preparative
LCMS eluting with 95% Water+0.1% NH.sub.3: 5% Acetonitrile to
affords the title compound; [M+H].sup.+ 310.
Example 17
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[(R)-4-[3-(4-hydroxy-phenyl)-propyl]-imidazolidin-(2E)-ylidene]-amide
[0170] To a stirred solution of (4-((R)-4,5-Diamino-pentyl)-phenol
(intermediate K) (1.5 g, 7.72 mmol) in propan-2-ol (100 ml) at
30.degree. C. is added in one portion
1-(3,5-Diamino-6-chloro-pyrazine-2-carbonyl)-2-methyl-isothiourea
(Intermediate A) and the reaction is heated at 30.degree. C. for 18
hours followed by 50.degree. C. for a further 18 hours. The
reaction mixture is filtered hot and the filtrate solvent is
removed in vacuo to afford a yellow foam. The foam is purified by
chromatography (SiO.sub.2, DCM/MeOH/5% NH.sub.3) to afford the
title compound; [M+H].sup.+ 390
Example 18
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[(S)-4-[3-(4-hydroxy-phenyl)-propyl]-imidazolidin-(2E)-ylidene]-amide
[0171] This compound is prepared analogously to Example 17
replacing (4-((R)-4,5-Diamino-pentyl)-phenol (Intermediate K) with
4-((S)-4,5-Diamino-pentyl)-phenol (intermediate L; [M+H].sup.+
390
Example 19
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[(R)-4-{3-[4-((S)-2,3-dihydroxy-propoxy)-phenyl]-propyl}-imidazolidin-
-(2Z)-ylidene]-amide
[0172] To a stirred solution of
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[(R)-4-[3-(4-hydroxy-phenyl)-propyl]-imidazolidin-(2E)-ylidene]-amide
(Ex. 17) (1.0 g, 2.57 mmol) in 1,4 dioxane (38 ml) at 50.degree. C.
is added in one portion 0.5 M KOH (5.3 ml, 2.7 mmol) followed by
(S)-(-)-Glycidiol (0.170 ml, 2.57 mmol). The resulting mixture is
heated at 50.degree. C. for 18 hours and then further
(S)-(-)-Glycidiol (0.07 ml, 1.05 mmol) is added in one portion. The
resulting mixture is heated at 50.degree. C. for 60 hours and then
allowed to cool to room temperature. The solvent is removed in
vacuo to afford an orange oil which is dissolved in EtOAc/MeOH 9:1
(100 ml) and washed with 1 M NaOH (50 ml). The organic layer is
dried over Na.sub.2SO.sub.4 and the solvent is removed in vacuo to
afford a brown/orange foam. Purification by chromatography
(SiO.sub.2, DCM/MeOH/NH.sub.3) affords the title compound as a
yellow foam; [M+H].sup.+ 464; .sup.1H NMR (400 MHz, DMSO-d6):
1.65-1.40 (m, 4H), 2.52 (m, 2H), 3.13 (dd, J=9.6, 7.1 Hz, 1H), 3.42
(br d, J=4.7 Hz, 2H), 3.62 (dd, J=9.6, 9.6 Hz, 1H), 3.76 (m, 1H),
3.78 (m, 1H), 3.80 (m, 1H), 3.94 (dd, J=9.5, 4.0 Hz, 1H), 4.62 (br
s, 1H), 4.89 (br s, 1H), 6.68 (br s, 2H), 6.82 (d, J=8.5 Hz, 2H),
7.09 (d, J=8.5 Hz, 2H), 7.2-6.0 (br s, 1H), 8.18 (br s, 1H),
9.3-7.5 (br s, 1H),
Example 20
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[(S)-4-{3-[4-((S)-2,3-dihydroxy-propoxy)-phenyl]-propyl}-imidazolidin-
-(2Z)-ylidene]-amide
[0173] To a solution of 3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[(S)-4-[3-(4-hydroxy-phenyl)-propyl]-imidazolidin-(2E)-ylidene]-amide
(Example 18) (37.5 mg, 0.09 mmol) in Ethanol (2 ml) is added
triethylamine (63 l, 0.45 mmol) and (S)-glycidol (6.07 l, 0.09
mmol). The resulting mixture is heated at reflux for 18 hours and
then allowed to cool to room temperature. The reaction mixture is
diluted with MeOH (1 ml) and purified on a Waters 3000 prep HPLC
system, (Microsorb C18, Water (0.1% TFA):MeCN) to afford the title
compound; [M+H].sup.+ 464.
Example 21
(3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[(R)-4-{3-[4-((R)-2,3-dihydroxy-propoxy)-phenyl]propyl}-imidazolidin--
(2Z)-ylidene]-amide
[0174] To a stirred solution of
(R)-3-[4-((R)-4,5-Diamino-pentyl)-phenoxy]-propane-1,2-diol
(Intermediate O) (32.8 mg, 0.122 mmol) in propan-2-ol (3 ml) is
added
1-(3,5-Diamino-6-chloro-pyrazine-2-carbonyl)-2-methyl-isothiourea
(Intermediate A) (45.8 mg, 0.122 mmol) and the resultant reaction
mixture is heated at 90.degree. C. for 18 hours. The reaction is
allowed to cool to room temperature and diluted with DMSO (1.5 ml)
and purified on a Waters 3000 preparative HPLC system
(Microsorb.TM. C18, Water (0.1% TFA):MeCN). The fractions
containing product are passed through a 1 g SCX-2 cartridge which
is eluted with 1:1 Water:MeCN (20 ml), MeCN (20 ml) and 7M NH.sub.3
in MeOH (20 ml). The ammonia elutions are concentrated in vacuo to
afford the title compound; [M+H].sup.+ 464
Example 22
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[(S)-4-{3-[4-((R)-2,3-dihydroxy-propoxy)-phenyl]-propyl}-imidazolidin-
-(2Z)-ylidene]-amide trifluoroacetate
[0175] This compound is prepared analogously to Example 21
replacing
(R)-3-[4-((R)-4,5-Diamino-pentyl)-phenoxy]-propane-1,2-diol
(Intermediate O) with
(R)-3-[4-((S)-4,5-Diamino-pentyl)-phenoxy]-propane-1,2-diol
(Intermediate P); [M+H].sup.+ 464.
Example 23
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[(R)-4-{3-[4-(2-morpholin-4-yl-2-oxo-ethoxy)-phenyl]-propyl}-imidazol-
idin-(2Z)-ylidene]-amide
[0176] This compound is prepared analogously to Example 21
replacing
(R)-3-[4-((R)-4,5-Diamino-pentyl)-phenoxy]-propane-1,2-diol
(Intermediate O) with
2-[4-((R)-4,5-Diamino-pentyl)-phenoxy]-1-morpholin-4-yl-ethanone
(Intermediate Q); [M+H].sup.+ 517
Examples 24 and 25
Both Enantiomers of 3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[4-[3-(4-methoxy-phenyl)-butyl]-imidazolidin-(2Z)-ylidene]-amide
[0177] The racemate of these compounds is prepared analogously to
Example 12 replacing 4-Amino-1-benzyl-piperidine-4-carbonitrile
(Intermediate G) with 5-(4-methoxy-phenyl)-hexane-1,2-diamine
(Intermediate K). The enantiomers are separated by chiral HPLC:
Mobile phase: 100% EtOH (0.2% IPAm) Column: Chirapak-AD 25
cm.times.4.6 mm i.d Flow rate: 1 ml/min
UV 280 nM
[0178] Concentration 1 mg/mL
Inj Vol 10 .mu.L
Example 26
3,5-Diamino-6-chloro-pyrazine-2-carboyxlic
acid[(S)-4-(4-benzyloxy-2,2-dimethyl-butyl-imidazolidin-(2Z)-ylidene]-ami-
de
Step 1
[0179] DEAD (4.49 ml, 28 mmol) is added to a stirred suspension of
((S)-5-benzyloxy-1-hydroxymethyl-3,3-dimethyl-pentyl)-carbamic acid
tert-butyl ester (prepared as described in EP 0702004 A2, Rueger et
al., 10 g, 0.028 mmol), phthalimide (4.19 g, 0.028 mmol) and
PS-triphenylphosphine (29.8 g, 56 mmol) in THF (500 ml), and the
resulting reaction is stirred at room temperature for 3 days. The
reaction is filtered to remove the PS-triphenylphosphine resin and
the resin is washed with EtOAc (2.times.50 ml). The solvent is
removed in vacuo and the residue is purified by flash
chromatography (SiO.sub.2, EtOAc/iso-hexane) to afford
[(S)-5-benzyloxy-1-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-3,3-dimeth-
yl-pentyl]-carbamic acid tert-butyl ester as a white solid;
[M+H].sup.+ 481.
Step 2
[0180] Hydrazine (66.6 ml of a 1M solution in THF, 66.6 mmol) is
added to a suspension of
[(S)-5-benzyloxy-1-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-3,3-dimeth-
yl-pentyl]-carbamic acid tert-butyl ester (4 g, 8.32 mmol) in
ethanol (100 ml), and the resulting solution is heated at
40.degree. C. overnight. A fluffy white precipitate forms. The
reaction is allowed to cool to room temperature and diethyl ether
(100 ml) is added and the resulting white suspension cooled at
0.degree. C. for 30 minutes. The white precipitate is removed by
filtration and the solvent removed in vacuo. The residue is then
stirred with diethyl ether (100 ml) for 1 hour, filtered and the
solvent is removed in vacuo to afford
((S)-1-Aminomethyl-5-benzyloxy-3,3-dimethyl-pentyl)-carbamic acid
tert-butyl ester as a pale yellow oil; [M+H].sup.+ 351.
Step 3
[0181] Iodotrimethylsilane (1.63 ml, 11.94 mmol) is added dropwise
to a solution of
((S)-1-Aminomethyl-5-benzyloxy-3,3-dimethyl-pentyl)-carbamic acid
tert-butyl ester (2.79 g, 7.96 mmol) in DCM (30 ml) and the
resulting yellow solution is stirred for 1 hour at room
temperature. The reaction is filtered and the filtrate diluted with
DCM (50 ml) and washed with 2 M NaOH (100 ml). The aqueous layer is
allowed to stand overnight and any product which has oiled out of
solution is extracted into EtOAc (100 ml). The organic layers are
combined, dried over MgSO.sub.4, and the solvent is removed in
vacuo to yield (S)-Benzyloxy-4,4-dimethyl-hexane-1,2-diamine as a
pale yellow oil; [M+H].sub.+251.
Step 4
[0182] A suspension of
1-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-2-methyl-isothiourea
(Intermediate A) (2.56 g, 6.87 mmol) and
(S)-Benzyloxy-4,4-dimethyl-hexane-1,2-diamine (1.72 g, 6.87 mmol)
in propan-2-ol (50 ml) is heated at 90.degree. C. for 3 hours. The
reaction is allowed to cool to room temperature, filtered to remove
any insoluble material and the filter paper is washed with MeOH (50
ml). The filtrate is loaded on to a SCX-2 cartridge which has been
pre-eluted with MeOH. The cartridge is eluted with MeOH and then 7M
NH.sub.3 in MeOH. Upon standing, a pale yellow solid crystallises
out of the NH.sub.3 in MeOH solution. The solid is collected by
filtration, washed with MeOH (20 ml) and dried in vacuo at
40.degree. C. to afford the title compound. [M+H]+446.
Example 27
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[(S)-4-(hydroxyl-2,2-dimethyl-butyl)-imidazolidin-(2Z)-ylidene]-amide
[0183] To a suspension of
3,5-Diamino-6-chloro-pyrazine-2-carboyxlic
acid[(S)-4-(4-benzyloxy-2,2-dimethyl-butyl-imidazolidin-(2Z)-ylidene]-ami-
de (Ex. 26) (100 mg, 0.22 mmol) in DCM (5 ml) is added dropwise
iodotrimethylsilane (0.061 ml, 0.448 mmol). The resulting yellow
solution is heated at reflux for 2 days. The reaction is allowed to
cool to room temperature and the yellow solid that has formed is
collected by filtration, dissolved in MeOH (3 ml) and loaded onto a
10 g SCX-2 cartridge which has been pre-eluted with MeOH. The
cartridge is eluted with MeOH (30 ml) and 7M NH.sub.3 in MeOH (30
ml). The pale yellow 7M NH.sub.3 in MeOH wash is concentrated in
vacuo to afford the title compound as a yellow solid. [M+H].sup.+
356.
Example 28
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[(S)-4-{4-[4-(S)-2,3-dihydroxy-propoxy)-phenyl]-2,2-dimethyl-butyl}-i-
midazolidin-(2Z)-ylidene]-amide
Step 1
[0184] (S)-Glycidol (0.36 ml, 5.5 mmol) is added to a solution of
4-iodophenol (1 g, 4.5 mmol) and triethylamine (31 ml, 0.2 mmol) in
ethanol (5 ml) and the resulting light brown solution is heated at
reflux for 15 hours. The reaction is allowed to cool to room
temperature and the solvent removed in vacuo. The residue is
purified by chromatography (SiO.sub.2, EtOAc/iso-hexane) to afford
(S)-3-(4-Iodo-phenoxy)-propane-1,2-diol as a colourless oil.
Step 2
[0185] 2,2-Dimethoxypropane (1.94 ml, 15.8 mmol) and PPTS (0.079
mg, 0.32 mmol) are added to a solution of
(S)-3-(4-Iodo-phenoxy)-propane-1,2-diol (0.93 g, 3.16 mmol) in DMF
(20 ml), and the resulting solution is left to stir at room
temperature overnight. The solvent is removed in vacuo and the
residue is purified by chromatography (SiO.sub.2, EtOAc:Iso-hexane)
to afford (R)-4-(4-Iodo-phenoxymethyl)-2,2-dimethyl-[1,3]dioxolane
as a colourless oil.
Step 3
[0186] DEAD (0.63 ml, 4 mmol) is added to a suspension of
((S)-1-Hydroxymethyl-3,3-dimethyl-pent-4-enyl)-carbamic acid
tert-butyl ester (1 g, 4 mmol), phthalimide (588 mg, 4 mmol) and
PS-triphenylphosphine (3.72 g, 8 mmol) in THF (50 ml) and the
resulting solution is stirred at room temperature overnight. The
resin is removed by filtration, and the filtrate concentrated in
vacuo. Purification by flash chromatography (SiO.sub.2,
EtOAc/iso-hexane) yields
[(S)-1-(1,3-Dioxo-1,3-dihydro-isoindol-2-ylmethyl)-3,3-dimethyl-pent-4-en-
yl]-carbamic acid tert-butyl ester as a white solid;
[M+H--BOC].sup.+ 273.
Step 4
[0187] 9-BBN (4.63 ml of a 0.5 M solution in THF, 0.23 mmol) is
added to a solution of
[(S)-1-(1,3-Dioxo-1,3-dihydro-isoindol-2-ylmethyl)-3,3-dimethyl-pent-4-en-
yl]-carbamic acid tert-butyl ester (0.43 g, 0.116 mmol) in THF (15
ml) and the resulting colourless solution is stirred at room
temperature overnight Anhydrous DMF (15 ml) is added to the
solution, followed by 3 M aqueous K.sub.3PO.sub.4 solution (0.77
ml, 2.3 mmol),
(R)-4-(4-Iodo-phenoxymethyl)-2,2-dimethyl-[1,3]dioxolane (267 mg,
0.28 mmol) and Pd(dppf)Cl.sub.2.DCM (47 mg, 0.058 mmol). The
reaction is stirred at room temperature for 3 hours, 50.degree. C.
for 2 hours and then is allowed to cool to room temperature and
filtered through a pad of Celite.TM. (filter material) which is
washed with EtOAc (3.times.50 ml). The combined filtrates are
washed with sat. aq. NaHCO.sub.3 solution (30 ml), dried
(MgSO.sub.4) and the solvent removed in vacuo to afford a black
oil. Multiple chromatography (SiO.sub.2, EtOAc/iso-hexane) yields
[(S)-5-[4-((R)-2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-1-(1,3-dio-
xo-1,3-dihydro-isoindol-2-ylmethyl)-3,3-dimethyl-pentyl]-carbamic
acid tert-butyl ester as a cream solid; [M+H--BOC].sup.+ 481.
Step 5
[0188] Hydrazine (2.2 ml of a 1M solution in THF, 2.2 mmol) is
added to a solution of
[(S)-5-[4-((R)-2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-1-(1,3-dio-
xo-1,3-dihydro-isoindol-2-ylmethyl)-3,3-dimethyl-pentyl]-carbamic
acid tert-butyl ester (0.16 g, 0.28 mmol) in ethanol (5 ml), and
the resulting colourless solution is heated at 45.degree. C.
overnight. The reaction is allowed to cool to room temperature, and
diethyl ether (30 ml) is added and the resulting white suspension
cooled at 0.degree. C. for 30 minutes. The white solid is removed
by filtration, and the solvent removed in vacuo to yield
{(S)-1-Aminomethyl-5-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phen-
yl]-3,3-dimethyl-pentyl}-carbamic acid tert-butyl ester as a
colourless oil; [M+H].sup.+ 451.
Step 6
[0189] A solution of
{(S)-1-Aminomethyl-5-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phen-
yl]-3,3-dimethyl-pentyl}-carbamic acid tert-butyl ester (0.13 g,
0.28 mmol) and TFA (1 ml) in DCM (5 ml) is stirred at room
temperature for 1 hour, then loaded onto an SCX-2 cartridge which
has been pre-eluted with MeOH. The cartridge is eluted with MeOH
(2.times.5 ml), followed by 7M NH.sub.3 in MeOH (2.times.5 ml) to
yield
(S)-3-[4-((S)-5,6-Diamino-3,3-dimethyl-hexyl)-phenoxy]-propane-1,2-diol
in 80% purity as a colourless oil; [M+H].sup.+ 311
Step 7
[0190] A suspension of
(S)-3-[4-((S)-5,6-Diamino-3,3-dimethyl-hexyl)-phenoxy]-propane-1,2-diol
(60 mg, 0.19 mmol) and
1-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-2-methyl-isothiourea
(Intermediate A) (72 mg, 0.19 mmol) in propan-2-ol (3 ml) is heated
at 80.degree. C. for 35 minutes. The reaction mixture is allowed to
cool to room temperature and diluted with MeOH until any solid
dissolves. The solution is passed through a SCX-2 cartridge which
is then eluted with further MeOH. The combined methanol elutions
are concentrated in vacuo. Reverse phase chromatography
(Isolute.TM. C18, Water/CH.sub.3CN/0.1% TFA) yields the title
compound compound as a yellow solid; [M+H]+506
Example 29
(E)-3,5-diamino-6-chloro-N-(4-(3-(4-((S)-2,3-dihydroxypropoxy)phenyl)propy-
l)-5-propylimidazolidin-2-ylidene)pyrazine-2-carboxamide
hydrochloride
Step 1
[0191] 4-(4-Methoxyphenyl)butyric acid (25 g, 129 mmol) is
dissolved in 48% HBr (125 ml) and AcOH (125 ml). The resultant
solution is heated at 150.degree. C. overnight. The resultant
mixture is concentrated in vacuo and the residue taken up in EtOAc
(500 ml). This solution is washed with water (500 ml), dried
(MgSO.sub.4) and concentrated to give 4-(4-Hydroxy-phenyl)-butyric
acid as a tan solid; .sup.1H NMR (d6-DMSO): 1.72 (2H, tt, J=7.4 and
7.8 Hz), 2.18 (2H, t, J=7.4 Hz), 2.45 (2H, t, J=7.8 Hz), 6.66 (2H,
dd, J=1.98 and 9.3 Hz), 6.96 (2H, dd, J=2.8 and 9.3 Hz), 9.12 (1H,
s), 12.0 (1H, s).
Step 2
[0192] 4-(4-Hydroxy-phenyl)-butyric acid (22.1 g, 123 mmol) is
dissolved in THF (750 ml) and borane-dimethyl sulfide (23.3 ml, 245
mmol) is slowly added. The yellow suspension formed is heated at
reflux for 3 hours until most of the solid slowly dissolves. The
flask is removed from the heating mantle, and MeOH is slowly added
until bubbling ceases and the residual solid has dissolved. The
flask is cooled to room temperature and water (1 L) is added. The
pH is corrected to 3 with AcOH, then the mixture is extracted with
EtOAc (2.times.500 ml). The organics are washed with brine, dried
(MgSO.sub.4) and concentrated. The crude product is slurried with
silica (500 g) in 25% EtOAc/iso-hexanes (1 L). This is filtered,
then flushed with 50% EtOAc/iso-hexanes (2 L) to elute the product.
The organics are concentrated to give 4-(4-Hydroxy-butyl)-phenol as
a brown oil which crystallizes on standing; .sup.1H NMR
(CDCl.sub.3): 1.55-1.72 (4H, m), 2.58 (2H, t, J=7.0 Hz), 3.1 (2H,
br signal), 3.70 (2H, t, J=6.4 Hz), 6.77 (2H, d, J=8.4 Hz), 7.05
(2H, d, J=8.4 Hz).
Step 3
[0193] To 4-(4-Hydroxy-butyl)-phenol (32.7 g, 197 mmol) in acetone
(600 ml) is added potassium carbonate (40.8 g, 295 mmol) followed
by (S)-glycidol (13.7 ml, 207 mmol). The mixture is heated at
reflux overnight. Further potassium carbonate (20 g) is added,
followed by (S)-glycidol (5 g) and the mixture is heated at reflux
for 72 hours. The suspension is cooled, filtered and the filtrate
concentrated in vacuo. The residue is partitioned between EtOAc
(500 ml) and 5% citric acid solution (500 ml). The organics are
separated, dried (MgSO.sub.4) and concentrated in vacuo to give
(S)-3-[4-(4-Hydroxy-butyl)-phenoxy]-propane-1,2-diol as a brown
oil; .sup.1H NMR (CDCl.sub.3): 1.56-1.74 (4H, m), 2.20 (1H, t,
J=2.46 Hz), 2.61 (2H, t, J=7.6 Hz), 3.68 (2H, t, J=6.2 Hz), 3.78
(1H, dd, J=5.4 and 11.5 Hz), 3.86 (1H, dd, J=3.9 and 11.5 Hz),
4.0-4.16 (3H, m), 6.85 (2H, d, J=8.6 Hz), 7.12 (2H, d, J=8.6
Hz).
Step 4
[0194] To (S)-3-[4-(4-Hydroxy-butyl)-phenoxy]-propane-1,2-diol (43
g, 179 mmol) in THF (700 ml) is added 2,2-dimethoxypropane (94 ml,
760 mmol) followed by PPTS (4.5 g, 17.9 mmol). The resultant
mixture is stirred at room temperature overnight. The solution is
concentrated in vacuo and the residue taken up in DCM (500 ml).
This is washed with water, dried (MgSO.sub.4) and concentrated in
vacuo. The residue is purified through a silica plug (300 g)
eluting with 10% followed by 25% EtOAc/iso-hexanes. The desired
fractions are concentrated to give
4-[4-((R)-2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-butan-1-ol
as a clear oil; .sup.1H NMR (CDCl.sub.3): 1.42, (3H, s), 1.48 (3H,
s), 1.53-1.73 (4H, m), 2.20 (1H, t, J=2.5 Hz), 2.60 (2H, t, J=7.2
Hz), 3.68 (2H, t, J=6.4 Hz), 3.92 (2H, dt, J=5.8 and 8.5 Hz), 4.07
(1H, dd, J=5.4 and 9.5 Hz), 4.19 (1H, dd, J=6.4 and 8.5 Hz), 4.49
(1H, p, J=5.7 Hz), 6.85 (2H, d, J=8.7 Hz), 7.11 (2H, d, J=8.7
Hz).
Step 5
[0195] To
4-[4-((R)-2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-butan--
1-ol (5.0 g, 17.8 mmol) in DCM (180 ml) is added Dess-Martin
periodinane (7.56 g, 17.8 mmol). The yellowish solution is stirred
at room temperature for 1 hour. The resultant yellow suspension is
treated with 1 N NaOH solution (200 ml) and stirred at room
temperature for 30 minutes. The organic phase is separated, dried
(MgSO.sub.4) and concentrated to give
4-[4-((R)-2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-butyraldeh-
yde as a clear oil; .sup.1H NMR (CDCl.sub.3): 1.42, (3H, s), 1.48
(3H, s), 1.95 (2H, dt, J=7.6 and 14.2 Hz), 2.46 (2H, dt, J=1.5 and
7.3 Hz), 2.62 (2H, t, J=7.6 Hz), 3.90-3.96 (2H, m), 4.07 (1H, dd,
J=5.2 and 9.3 Hz), 4.19 (1H, dd, J=6.4 and 8.1 Hz), 4.49 (1H, p,
J=5.8 Hz), 6.86 (2H, d, J=9.4 Hz), 7.10 (2H, d, J=9.4 Hz), 9.77
(1H, t, J=1.6 Hz).
Step 6
[0196] To
4-[4-((R)-2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-butyra-
ldehyde (4.28 g, 15.4 mmol) in THF (150 ml) is added tert-butyl
sulfinamide (2.05 g, 16.9 mmol) followed by titanium ethoxide (6.5
ml, 30.8 mmol). The yellow solution formed is stirred at room
temperature overnight. The solution is quenched with 1 N NaOH (200
ml) and EtOAc (100 ml) and stirred for 30 minutes at room
temperature. The resultant mixture is filtered through Celite.TM.
(filter material) and the organic phase is separated and dried
(MgSO.sub.4). Concentration in vacuo gives
2-Methyl-propane-2-sulfinic acid
[4-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-but-(E)-yliden-
e]-amide as a yellow oil; [M+H].sup.+ 382.23
Step 7
[0197] To a solution of 2-Methyl-propane-2-sulfinic acid
[4-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-but-(E)-yliden-
e]-amide (4.51 g, 11.8 mmol) in THF (120 ml) at 0.degree. C. is
added vinylmagnesium bromide (11.8 ml of a 1 M solution in THF,
11.8 mmol) dropwise. After addition is complete, the mixture is
stirred at 0.degree. C. for 30 minutes then quenched with sat. aq.
NH.sub.4Cl solution (20 ml). This mixture is allowed to warm to
room temperature and diluted with water (50 ml) and EtOAc (50 ml).
The organic phase is separated, dried (MgSO.sub.4) and concentrated
in vacuo. Purification by chromatography (SiO.sub.2,
EtOAc/iso-hexane) affords 2-Methyl-propane-2-sulfinic acid
{4-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-1-vinyl-butyl}-
-amide as a mixture of diastereomers as a gum; [M+H].sup.+
410.39
Step 8
[0198] A solution of 2-methyl-propane-2-sulfinic acid
{4-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-1-vinyl-butyl}-
-amide (1.0 g, 2.4 mmol) in DCM (25 ml) at -78.degree. C. is
saturated with oxygen, then ozone (generated using Fischer
Technology Ozon Generator 500m) until a blue solution is obtained.
Dimethyl sulfide (1.8 ml, 24 mmol) is then added and the mixture
stirred to room temperature over 30 minutes. The resultant solution
is washed with water (25 ml) and the organic phase is concentrated
under high vacuum at low temperature to give
2-Methyl-propane-2-sulfinic acid
{4-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-1-formyl-butyl-
}-amide as an oil; [M+H].sup.+ 412.36
Step 9
[0199] To a solution of 2-methyl-propane-2-sulfinic acid
{4-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-1-formyl-butyl-
}-amide in THF (20 ml) is added tert-butyl sulfinamide (323 mg, 2.7
mmol) followed by titanium ethoxide (1.0 ml, 4.8 mmol). The yellow
solution formed is stirred at room temperature overnight. The
solution is quenched with 1N NaOH (50 ml) and EtOAc (50 ml) and
stirred for 30 minutes at room temperature. The resultant mixture
is filtered through Celite.TM. (filter material) and the organic
phase separated and dried (MgSO.sub.4). Concentration gives
2-Methyl-propane-2-sulfinic acid
(4-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-1-{[(E)-2-meth-
yl-propane-2-sulfinylimino]-methyl}-butyl)-amide as a mixture of
diastereomers as a yellow oil; [M+H].sup.+ 515.38
Step 10
[0200] To a solution of 2-methyl-propane-2-sulfinic acid
(4-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-1-{[(E)-2-meth-
yl-propane-2-sulfinylimino]-methyl}-butyl)-amide (907 mg, 1.7 mmol)
in THF (20 ml) at 0.degree. C. n-propylmagnesium chloride (1.76 ml
of a 2M solution in diethyl ether, 3.52 mmol). The solution is
stirred at 0.degree. C. for 30 minutes then at room temperature for
3 hours. A further portion of n-propylmagnesium (1.76 ml of a 2M
solution in diethyl ether, 3.52 mmol) is added and the mixture is
stirred at room temperature overnight. The resulting mixture is
quenched with sat. aq. NH.sub.4Cl solution (50 ml) and extracted
with EtOAc (2.times.50 ml). The organic phase is dried (MgSO.sub.4)
and concentrated in vacuo. The residue is dissolved in EtOAc (10
ml) and treated with 4M HCl/dioxan (10 ml). After 10 minutes, the
solution is concentrated in vacuo and the residue diluted with DCM
(100 ml). This is treated with sat. aq. NaHCO.sub.3 solution (100
ml) and the organic phase is removed and dried (MgSO.sub.4). The
DCM solution is applied to a SCX-2 cartridge (10 g) and this is
eluted with DCM and MeOH. The product is released with 2M NH.sub.3
in MeOH, and the methanolic ammonia fraction concentrated to give
(S)-3-[4-(4,5-Diamino-octyl)-phenoxy]-propane-1,2-diol as a mixture
of diastereomers as a gum; [M+H].sup.+ 515.38
Step 11
[0201] To a solution of
(S)-3-[4-(4,5-Diamino-octyl)-phenoxy]-propane-1,2-diol (100 mg,
0.32 mmol) in propan-2-ol (5 ml) is added
1-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-2-methyl-isothiourea
(Intermediate A) (121 mg, 0.32 mmol). The resulting suspension is
heated at 90.degree. C. for 2 hours then cooled and concentrated in
vacuo. The residue is dissolved in MeOH (20 ml) and applied to a 10
g SCX-2 cartridge. This is washed well with MeOH, water and MeCN,
and then 2M NH.sub.3 in MeOH. The methanolic ammonia fraction is
concentrated then purified by chromatography (SiO.sub.2, 5-10% 2M
NH.sub.3 in MeOH/DCM). Concentration of the relevant fractions
gives the free base as a gum. This is dissolved in MeOH (10 ml) and
treated with 1M HCl in diethyl ether (2 ml). Concentration yields
the dihydrochloride salt of
(E)-3,5-diamino-6-chloro-N-(4-(3-(4-((S)-2,3-dihydroxypropoxy)phenyl)
propyl)-5-propylimidazolidin-2-ylidene)pyrazine-2-carboxamide as a
yellow solid; [M+H].sup.+ 506.37, 508.36 for Cl isotopes
Example 30
(3-{(S)-2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-imidazolidin-
-4-yl}-propyl)-carbamic acid benzyl ester
[0202]
1-(3,5-Diamino-6-chloro-pyrazine-2-carbonyl)-2-methyl-isothiourea
(Intermediate A) (0.97 g, 3.72 mmol) is stirred in a three necked
round bottom flask fitted with a bleach trap and condenser and
((S)-4,5-Diamino-pentyl)-carbamic acid benzyl ester (Intermediate
S) (0.85 g, 3.38 mmol) in propan-2-ol (20 ml) is added. The
reaction mixture is stirred at 85.degree. C. for 66 hours.
Purification by catch and release resin (SCX-2) followed by elution
through a silica pad flushed with EtOAc, ethanol and MeOH yields
the title compound as an orange foam; [M+H].sup.+ 447.1
Example 31
3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid
[(S)-4-(3-amino-propyl)-imidazolidin-(2E)-ylidene]-amide
[0203] To a solution of
(3-{(S)-2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-imidazolidi-
n-4-yl}-propyl)-carbamic acid benzyl ester (Ex. 30) (0.44 g, 0.98
mmol) in DCM (20 ml) is added iodotrimethylsilane (0.27 ml, 1.96
mmol) in a dropwise manner. The orange suspension is stirred at
room temperature for 65 minutes. Purification by catch and release
resin (SCX-2) eluting with MeOH followed by 7M NH.sub.3 in MeOH
yields the title compound as a yellow foam; [M+H].sup.+ 313.1
Example 32
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[(S)-4-[3-(3-benzyl-ureido)-propyl]-imidazolidin-(2E)-ylidene]-amide
[0204] To a solution of 3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[(S)-4-(3-amino-propyl)-imidazolidin-(2E)-ylidene]-amide (Ex.
31) (0.040 g, 0.128 mmol) in DMF (2 ml) is added
1,1'-carbonyldiimidazole (0.023 g, 0.141 mmol) and the reaction
mixture is stirred for 1 hour at room temperature. Benzylamine
(0.014 ml, 0.128 mmol) is added and additional benzylamine (0.014
ml, 0.128 mmol) is added at hourly intervals for a total of 3
hours. Purification is by diluting the reaction with 2N NaOH (30
ml) and extracting the product into EtOAc (40 ml). The organic
phase is washed with 2N NaOH (30 ml), dried over MgSO.sub.4 and the
solvent evaporated in vacuo to yield a yellow oil. The oil is
dissolved in methanol (0.75 ml) and diethyl ether (5 ml) added to
triturate a yellow solid. This solid is filtered off and the
filtrate formed a further precipitate. This yellow solid is
collected by filtration and rinsed with diethyl ether to give the
title compound; [M+H].sup.+ 446.1
Example 33
3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[(S)-4-(3-phenyl
methanesulfonylamino-propyl)-imidazolidin-(2E)-ylidene]-amide
[0205] To a solution of 3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[(S)-4-(3-amino-propyl)-imidazolidin-(2E)-ylidene]-amide (Ex.
31) (0.030 g, 0.096 mmol) in DMF (5 ml) at 5.degree. C. is added
alpha-toluensulfonyl chloride (0.018 g, 0.096 mmol) and
triethylamine (0.013 ml, 0.096 mmol). The solution is stirred for
10 minutes. Purification by reverse phase chromatography
(Isolute.TM. C18, 0-100% MeCN in water -0.1% TFA) to affords the
title compound as a yellow solid; [M+H].sup.+ 467.0
Example 34
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[(S)-4-(3-phenylacetylamino-propyl)-imidazolidin-(2E)-ylidene]-amide
[0206] To a solution of 3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[(S)-4-(3-amino-propyl)-imidazolidin-(2E)-ylidene]-amide (Ex.
31) (0.030 g, 0.96 mmol) in DMF (2 ml), phenylacetyl chloride
(0.013 ml, 0.096 mmol) is added. The yellow solution is stirred at
room temperature for 10 minutes. Purification by catch and release
resin (SCX-2) eluting with MeOH and 7M NH.sub.3 in MeOH affords the
title compound; [M+H].sup.+ 430.98
Example 35
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[(S)-4-(4-phenylmethanesulfonylamino-butyl)-imidazolidin-(2E)-ylidene-
]-amide
[0207] To a suspension of
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[(S)-4-(4-amino-butyl)-imidazolidin-(2E)-ylidene]-amide
(Intermediate T) (0.023 g, 0.071 mmol) in DMF (2 ml) is added
triethylamine (0.010 ml, 0.071 mmol) followed by
alpha-toluenesulfonyl chloride (0.014 g, 0.071 mmol). The
suspension is stirred at room temperature for 30 minutes.
Purification by reverse phase chromatography (Isolute.TM. C18,
0-100% MeCN in water -0.1% TFA) followed by catch and release resin
(SCX-2) eluting with MeOH and 7M NH.sub.3 in MeOH gives the title
compound as a yellow solid; [M+H]+481.0
Example 36
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[(S)-4-(4-phenylacetyl
amino-butyl)-imidazolidin-(2E)-ylidene]-amide
[0208] To a suspension of
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[(S)-4-(4-amino-butyl)-imidazolidin-(2E)-ylidene]-amide
(Intermediate T) (0.032 g, 0.098 mmol) in DMF (1 ml) is added
triethylamine (0.014 ml, 0.098 mmol) followed by phenylacetyl
chloride (0.013 ml, 0.098 mmol). The suspension is stirred at room
temperature for 90 minutes before a further 0.5 equivalents of
phenylacetyl chloride (0.006 ml, 0.049 mmol) is added. The reaction
is left to stir at room temperature for a further 18 hours.
Purification by reverse phase chromatography (Isolute.TM. C18,
0-100% MeCN in water -0.1% TFA) followed by catch and release resin
(SCX-2) eluting with MeOH and 7M NH.sub.3 in MeOH affords the title
compound as an off-white solid; [M+H]+445.1
Example 37
2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4-
.5]decane-8-carboxylic acid tert-butyl ester trifluoroacetate
[0209] A suspension of
4-amino-4-aminomethyl-piperidine-1-carboxylic acid tert-butyl ester
(Intermediate U) (218 g, 0.95 mol) in tert-butanol (6 L) and
1-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-2-methyl-isothiourea
(Intermediate A) (338 g, 0.82 mol) is stirred at 40.degree. C.
overnight. The temperature is then raised to 85.degree. C. and the
suspension stirred at this temperature for a further 4 days. The
reaction mixture is concentrated in vacuo and the residue is taken
up in water (1 L), sonicated and heated to 45-50.degree. C. The
solid is collected by vacuum filtration and washed with ice cold
water, then dried under vacuum at 50.degree. C. overnight to afford
the title compound as a yellow solid; [M+H].sup.+ 425.1.
Example 38
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide
dihydrochloride
[0210] To a stirred solution of 4M HCl in dioxane (1 L) is added
2-[(E)-3,5-diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[-
4.5]decane-8-carboxylic acid tert-butyl ester trifluoroacetate (Ex.
37) (104 g, 193 mmol). The resulting thick suspension is stirred at
room temperature for 2 hours. The product is isolated by vacuum
filtration, rinsing with dioxane. The solid is dried under vacuum
at 50.degree. C. to afford the title compound as a dihydrochloride
salt as a dark yellow solid; [M+H].sup.+=325.
Example 39
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[((S)-3-phenyl-2-(toluene-4-sulfonylamino)-propionyl]-1,3,8-triaza-
-spiro[4.5]dec-(2E)-ylidene]-amide
[0211] To a solution of Tosyl-L-phenylalanine (1.0 g, 3.13 mmol) in
DMF (25 ml) is added N-methyl morpholine (1.033 ml, 9.39 mmol) and
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride
(Ex. 38) (1.37 g, 3.44 mmol), followed by HATU (1.31 g, 3.44 mmol)
and the resulting solution is stirred at room temperature for 20
minutes. The crude product is diluted with water (300 ml) and the
resultant solid is isolated. Purification by reverse phase
chromatography (Isolute.TM. C18, 0-100% MeCN in water -0.1% TFA)
followed by catch and release resin (SCX-2) eluted with MeOH and 7M
NH.sub.3 in MeOH yields a yellow solid which is triturated with
MeOH and diethyl ether to give the title compound as a free base.
The free base is stirred in 5M HCl at 100.degree. C. for 30 minutes
forming a gum. MeOH (5 ml) is added to the gum and then all solvent
is removed in vacuo. The residue is triturated with MeOH and
diethyl ether to give the title compound; [M+H].sup.+ 626.4;
.sup.1H NMR (DMSO-d6): 1.12-1.71 (4H, m), 2.36-2.38 (3H, s),
2.59-2.83 (2H, m), 2.93-3.52 (4H, m), 3.41-3.60 (2H, m), 4.42 (1H,
m), 7.12 (2H, d, J=6.9 Hz), 7.17-7.28 (3H, m), 7.35 (2H, d, J=7.7
Hz), 7.54-7.37 (2H, br), 7.57 (2H, d, J=7.7 Hz), 8.12 (1H, d, J=9.0
Hz), 7.70-8.26 (2H, br), 9.22 (1H, s), 9.95 (1H, s), 10.99 (1H,
s).
Example 40
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(1-benzenesulfonyl-1H-indole-3-carbonyl)-1,3,8-triaza-spiro[4.5]de-
c-(2E)-ylidene]-amide
[0212] To a solution of 1-(phenylsulfonyl)-1H-indole-3-carboxylic
acid (1.0 g, 3.32 mmol) in DMF (15 ml) is added HATU (1.388 g, 3.65
mmol) and N-methyl morpholine (1.095 ml, 9.96 mmol) and the
solution is stirred at room temperature for 5 minutes.
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride
(Ex. 38) (1.452 g, 3.65 mmol) is added and the reaction stirred at
room temperature for 45 minutes. The reaction mixture is diluted
with water (100 ml) and the precipitate that forms is isolated by
filtration. The crude product is suspended in 2N NaOH and extracted
into EtOAc. The organic portion is dried over MgSO.sub.4 and
concentrated in vacuo to yield a brown solid. The solid is
suspended in a 1:1 mixture of water (+0.1% TFA) and acetonitrile. A
fine brown solid is removed by filtration and the yellow filtrate
is concentrated in vacuo until 10 ml of solvent remains and a pale
yellow solid has precipitated. This solid is washed with 2N NaOH
(60 ml) and then suspended in 2N NaOH (100 ml) and extracted into
EtOAc (2.times.100 ml). The organic phases are combined, dried over
MgSO.sub.4 and concentrated in vacuo to yield a pale cream solid.
The cream solid is suspended in a 1:4 mixture of EtOAc:iso-hexane
(100 ml) and the solid filtered off to give the free base of the
title compound, which is suspended in 5 N HCl (20 ml) and stirred
for 2 hours. MeOH (20 ml) is added to dissolve all solid and the
solvent is concentrated in vacuo until a yellow solid precipitates.
This solid is filtered off, rinsed with water and dried at
40.degree. C. for 18 hours to give the title compound; [M+H].sup.+
607.42; .sup.1H NMR (DMSO-d6): 1.86-1.92 (4H, m), 3.42-3.63 (4H,
m), 3.68 (2H, s), 7.34 (1H, dd, J+7.5 Hz, J=7.5 Hz), 7.43 (1H, dd,
J=7.5 Hz, J=7.5 Hz), 7.36-7.55 (2H, br), 7.62 (1H, d, J=7.5 Hz),
7.63 (2H, m), 7.73 (1H, m), 7.99 (1H, d, J=7.5 Hz), 8.06 (2H, obs),
8.07 (1H, s), 7.50-8.16 (2H, br), 9.18 (1H, s), 9.77 (1H, s), 11.09
(1H, s).
Example 41
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[3-(3-isopropoxy-propylsulfamoyl)-benzoyl]-1,3,8-triaza-spiro[4.5]-
dec-(2E)-ylidene]-amide
[0213] To a solution of 3-(3-Isopropoxy-propylsulfamoyl)-benzoic
acid (Intermediate V) (1.10 g, 3.65 mmol) in DMF (20 ml) is added
HATU (1.53 g, 4.02 mmol) and N-methyl morpholine (1.204 ml, 10.95
mmol) and the solution is stirred at room temperature for 5
minutes. 3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride
(Ex. 38) (1.60 g, 4.02 mmol) is added and the reaction stirred at
room temperature for 45 minutes. The reaction mixture is diluted
with 2N NaOH (150 ml) and the crude product extracted into EtOAc
(2.times.250 ml). The organic phase is dried over MgSO.sub.4 and
the solvent evaporated in vacuo to yield a yellow oil. Purification
on a Waters preparative Delta 3000 HPLC using a gradient of water
(+0.1% TFA) and acetonitrile yields a yellow oil. 2N NaOH is added
to the oil and the product is extracted into EtOAc (2.times.400
ml). The organic phases are combined, dried over MgSO.sub.4 and the
solvent concentrated in vacuo to a volume of approximately 150 ml.
To this solution is added iso-hexane (400 ml) and a pale yellow
solid precipitates. This solid is collected by filtration and
rinsed with iso-hexane to afford the title compound; [M+H].sup.+
607.98; .sup.1H Nmr (DMSO): 1.00 (6H, d, J=6.0 Hz), 1.55 (2H, m),
1.69-1.79 (4H, m), 2.81 (2H, t, 5.9 Hz), 3.29 (2H, tr, J=6.0 Hz),
3.42 (1H, m), 3.44 (2H, br), 3.29-3.82 (4H, m), 6.15-7.30 (3H, br),
7.66 (1H, d, J=7.4 Hz), 7.70 (1H, dd, J=7.4 Hz, J=7.4 Hz), 7.76
(1H, s), 7.86 (1H, d, J=7.4 Hz), 7.44-8.00 (1H, br), 8.00-9.05 (3H,
br).
Example 42
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[2-(5-phenyl-4H-[1,2,4]triazol-3-yl)-acetyl]-1,3,8-triaza-spiro[4.-
5]dec-(2E)-ylidene]-amide
[0214] (5-Phenyl-4H[1,2,4]traizol-3-yl)acetic acid (0.48 g, 2.364
mmol), HATU (0.988 g, 2.6 mmol),
5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride
(Ex. 38) (1.033 g, 2.60 mmol), DMF (20 ml) and N-methyl morpholine
(0.78 ml, 7.08 mmol) are added to a round bottomed flask and
stirred at room temperature for 20 minutes. The crude product is
precipitated from the reaction mixture by adding water (200 ml) and
is isolated by filtration. Purification by reverse phase
chromatography (Isolute.TM. C18, 0-100% MeCN in water -0.1% TFA)
yields a yellow semi-solid. This is dissolved in MeOH (100 ml) and
left to stand. An off white solid precipitates and this is
collected by filtration to give the title compound; [M+H].sup.+
510.0; .sup.1H NMR (DMSO-d6): 1.78-1.94 (4H, m), 3.67 (2H, s),
3.30-3.82 (4H, m), 4.05-4.08 (2H, m), 7.45-7.55 (3H m), 7.01-7.75
(3H, br), 8.05 (2H, d, J=7.1 Hz), 7.78-8.33 (2H, br), 9.24 (1H, s),
9.85 (1H, s), 11.04 (1H, s).
Example 43
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[3-(3-isopropyl-ureido)-benzoyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-y-
lidene]-amide
[0215] 3-(3-Isopropyl-ureido)-benzoic acid (Intermediate W) (1.08
g, 4.86 mmol) and HATU (2.03 g, 5.35 mmol) are stirred in DMF (25
ml) at room temperature and N-methyl morpholine (1.60 ml, 14.59
mmol) is added. The solution is stirred at room temperature for 5
minutes and 5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride
(Ex. 38) (2.13 g, 5.35 mmol) is added. The brown solution is
stirred at room temperature for 45 minutes. The crude product is
precipitated by the addition of 2N NaOH and collected by
filtration. The solid is purified by reverse phase chromatography
(Isolute.TM. C18, 0-100% MeCN in water -0.1% TFA). The clean
fractions are concentrated in vacuo to approximately 30 ml and 2N
NaOH added. The off white solid is collected by filtration and
rinsed with water to give the title compound; [M+H].sup.+ 529.05;
.sup.1H NMR (DMSO-d6): 1.09 (6H, d, J=6.5 Hz), 1.67-1.73 (4H, m),
3.42 (2H, br), 3.75 (1H, septet, J=6.5 Hz), 3.31-3.79 (4H, br),
6.15 (1H, d, J=7.5 Hz), 6.70 (2H, br), 6.40-7.01 (1H, br), 6.86
(1H, d, J=7.2 Hz), 7.26 (1H, dd, J=8.3 Hz, J=7.2 Hz), 7.31 (1H, d,
J=8.3 Hz), 7.53 (1H, s), 8.36 (1H, br), 8.48 (1H, br), 8.55 (1H,
s), 8.00-9.00 (1H, br).
Example 44
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(2-Benzo[b]thiophen-3-yl-acetyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-y-
lidene]-Amide
[0216] This compound is prepared analogously to Example 43 by
replacing 3-(3-Isopropyl-ureido)-benzoic acid (Intermediate W) with
benzo[b]thiophene-3-acetic acid. [M+H].sup.+499.0; .sup.1H NMR
(DMSO-d6): 1.59-1.74 (4H, m), 3.42 (2H, s), 3.48-3.95 (4H, m), 3.97
(2H, s), 6.20-7.11 (3H, br), 7.38 (1H, m), 7.39 (1H, m), 7.50 (1H,
s), 7.83 (1H, d, J=7.3 Hz), 7.97 (1H, d, J=7.6 Hz), 7.75-9.30 (3H,
br).
Example 45
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[5-oxo-1-(3-pyrrol-1-yl-propyl)-pyrrolidine-3-carbonyl]-1,3,8-tria-
za-spiroro[4.5]dec-(2E)-ylidene]-amide
[0217] A solution of
5-Oxo-1-(3-pyrrol-1-yl-propyl)-pyrrolidine-3-carboxylic acid
(Intermediate X) (1.15 g, 4.85 mmol), HATU (2.03 g, 5.33 mmol), DMF
(20 ml) and N-methyl morpholine (1.60 ml, 14.54 mmol) is stirred at
room temperature for 5 minutes before
5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride
(Ex. 38) (1.731 g, 5.33 mmol) is added. After stirring for 60
minutes at room temperature EtOAc (200 ml) is added and the organic
phase is washed with 2N NaOH (2.times.100 ml) and brine (100 ml).
The organic phase is dried over MgSO.sub.4 and the solvent
evaporated in vacuo. Purification by reverse phase chromatography
(Isolute.TM. C18, 0-100% MeCN in water -0.1% TFA) followed by catch
and release resin (SCX-2) eluting with MeOH and 7M NH.sub.3 in MeOH
yields a yellow oil. The oil is dissolved in DCM (10 ml) and
product is precipitated out of solution by the addition of
iso-hexane to yield a yellow solid which is filtered and rinsed
with iso-hexane to yield the title product; [M+H].sup.+ 542.8;
.sup.1H NMR (DMSO-d6): 1.64-1.70 (4H, m), 1.84-1.89 (2H, m),
2.43-2.51 (2H, m), 3.39-3.43 (2H, m), 3.43-3.50 (2H, m), 3.55 (1H,
m), 3.40-3.69 (4H, m), 3.84 (2H, m), 5.97 (2H, m), 6.65-6.74 (2H,
br), 6.75 (2H, m), 6.2-7.6 (1H, br), 7.6-9.5 (1H, br).
Example 46
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(6,7,8,9-tetrahydro-5H-carbazole-3-carbonyl)-1,3,8-triaza-spiro[4.-
5]dec-(2E)-ylidene]-amide
[0218] To a stirring solution of
6,7,8,9-Tetrahydro-5H-carbazole-3-carboxylic acid (0.05 g, 0.25
mmol) and HATU (0.11 g, 0.28 mmol) in dry DMF (5 ml) is added
N-methyl morpholine (0.08 ml, 0.76 mmol). After 5 minutes stirring
at room temperature, 5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride
(Ex. 38) (0.10 g, 0.28 mmol) is added and the reaction is left to
stir at room temperature for 1 hour. Purification by reverse phase
chromatography (Isolute.TM. C18, 0-100% MeCN in water) yields the
title compound as a yellow powder; [M+H].sup.+ 524.2
Example 47
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(1H-indazole-3-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]--
amide
[0219] To a stirring solution of 1H-indazole-3-carboxylic acid
(0.041 g, 0.25 mmol) and HATU (0.096 g, 0.25 mmol) in dry DMF (4
ml) is added N-methyl morpholine (0.08 ml, 0.76 mmol). After 5
minutes, 5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride
(Ex. 38) (0.10 g, 0.25 mmol) is added and the reaction left to stir
at room temperature for 1 hour. Purification by reverse phase
chromatography (Isolute.TM. C18, 0-100% MeCN in water -0.1% TFA)
yields an oily residue that is ultrasonicated in acetonitrile to
give a yellow suspension. The yellow solid is collected by
filtration and rinsed with acetonitrile to afford the title
compound; [M+H].sup.+ 469.17
Example 48
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[2-(2,3-dimethyl-1H-indol-5-yl)-acetyl]-1,3,8-triaza-spiro[4.5]dec-
-(2E)-ylidene]-amide
[0220] This compound is prepared analogously to Example 47 by
replacing 1H-indazole-3-carboxylic acid with
2-(2,3-dimethyl-1H-indol-5-yl)acetic acid with
2-(2,3-dimethyl-1H-indol-5-yl)acetic acid. [M+H].sup.+ 510.23
Example 49
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(1,2,3-trimethyl-1H-indole-5-carbonyl)-1,3,8-triaza-spiro[4.5]dec--
(2E)-ylidene]-amide
[0221] To a stirring solution of
1,2,3-trimethyl-1H-indole-5-carboxylic acid (0.051 g, 0.25 mmol)
and HATU (0.11 g, 0.28 mmol) in dry DMF (5 ml) is added N-methyl
morpholine (0.083 ml, 0.76 mmol). After 5 minutes
5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride
(Ex. 38) (0.10 g, 0.28 mmol) is added and the reaction left to stir
at room temperature for 1 hour. Purification by chromatography
(SiO.sub.2, MeOH/DCM) yields the title compound; [M+H].sup.+
510.1
Example 50
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(1-methyl-1H-indazole-3-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)--
ylidene]-amide
[0222] This compound is prepared analogously to Example 46 by
replacing 6,7,8,9-Tetrahydro-5H-carbazole-3-carboxylic acid with
1-methyl-1H-indazole-3-carboxylic acid. [M+H].sup.+ 483.1
Example 51
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(4-benzyloxy-benzoyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-ami-
de
[0223] 5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride
(Ex. 38) (0.05 g, 0.13 mmol), 4-(benzyloxy)benzoic acid (0.029 g,
0.13 mmol), HATU (0.05 g, 0.13 mmol), N-methyl morpholine (0.041
ml, 0.38 mmol) and DMF (2 ml) are stirred together at room
temperature for 72 hours. The reaction mixture is diluted with
EtOAc (25 ml) and washed with water (25 ml) and sat. NaHCO.sub.3
(25 ml). The organic phase is dried over MgSO.sub.4 and evaporated
in vacuo to yield a yellow oil. The oil is dissolved in ethyl
acetate and a drop of methanol and iso-hexane are added. The
resulting pale yellow solid is collected by filtration to give the
title compound; [M+H].sup.+ 535.1
Example 52
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(3-2,3-dihydro-benzo
furan-5-yl-propionyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide
[0224] This compound is prepared analogously to Example 51 by
replacing 4-(benzyloxy)benzoic acid with
3-(2,3-dihydrobenzofuran-5-yl)propanoic acid. [M+H].sup.+ 499.1
Example 53
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(1H-pyrrolo[2,3-b]pyridine-4-carbonyl)-1,3,8-triaza-spiro[4.5]dec--
(2E)-ylidene]-amide
[0225] This compound is prepared analogously to Example 47 by
replacing 1H-indazole-3-carboxylic acid with
1H-pyrrolo[2,3-b]pyridine-4-carboxylic acid; [M+H].sup.+ 469.14
Example 54
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[3-(4-methoxy-phenyl)-propionyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-y-
lidene]-amide
[0226] 5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride
(Ex. 38) (0.05 g, 0.13 mmol), 3-(4-methoxyphenyl)-propionic acid
(0.023 g, 0.13 mmol), HATU (0.048 g, 0.13 mmol), N-methyl
morpholine (0.041 ml, 0.38 mmol) and DMF (2 ml) are stirred
together at room temperature for 48 hours. The reaction mixture is
diluted with EtOAc (50 ml) and product is extracted into 1 M HCl.
The aqueous phase is basified to pH 12 with 2 N NaOH and product
extracted into EtOAc (50 ml). The organic phase is dried over
MgSO.sub.4 and the solvent evaporated in vacuo to yield a brown
glass. The product is triturated with MeOH and EtOAc to give a pale
brown solid as the title compound; [M+H].sup.+ 487.0
Example 55
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[3-(4-hydroxy-phenyl)-propionyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-y-
lidene]-amide
[0227] This compound is prepared analogously to Example 49 by
replacing 1,2,3-trimethyl-1H-indole-5-carboxylic acid with
13-(4-hydroxyphenyl)propionic acid; [M+H].sup.+ 472.98
Example 56
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(1H-indole-2-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-am-
ide
[0228] This compound is prepared analogously to Example 46 by
replacing 6,7,8,9-Tetrahydro-5H-carbazole-3-carboxylic acid with
1H-indole-2-carboxylic acid; [M+H].sup.+ 468.1
Example 57
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(quinoline-5-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-am-
ide
[0229] This compound is prepared analogously to Example 46 by
replacing 6,7,8,9-Tetrahydro-5H-carbazole-3-carboxylic acid with
quinoline-5-carboxylic acid; [M+H].sup.+ 480.1
Example 58
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(4-methyl-2-phenyl-pyrimidine-5-carbonyl)-1,3,8-triaza-spiro[4.5]d-
ec-(2E)-ylidene]-amide
[0230] This compound is prepared analogously to Example 45 by
replacing 5-Oxo-1-(3-pyrrol-1-yl-propyl)-pyrrolidine-3-carboxylic
acid (Intermediate X) with 4-methyl-2-phenylpyrimidine-5-carboxylic
acid; [M+H].sup.+ 521.1
Example 59
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(4-benzyl-morpholine-2-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-y-
lidene]-amide
[0231] This compound is prepared analogously to Example 51 by
replacing 4-(benzyloxy)benzoic acid with
4-benzyl-2-morpholinecarboxylic acid hydrochloride; [M+H].sup.+
528.2
Example 60
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(1H-pyrrolo[2,3-b]pyridine-5-carbonyl)-1,3,8-triaza-spiro[4.5]dec--
(2E)-ylidene]-amide
[0232] This compound is prepared analogously to Example 47 by
replacing 1H-indazole-3-carboxylic acid with
1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid; [M+H].sup.+ 469.1
Example 61
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[4-(4,6-dimethoxy-pyrimidin-2-ylmethoxy)-benzoyl]-1,3,8-triaza-spi-
ro[4.5]dec-(2E)-ylidene]-amide
[0233] This compound is prepared analogously to Example 51 by
replacing 4-(benzyloxy)benzoic acid with
4-((4,6-dimethoxypyrimidin-2-yl)methoxy)benzoic acid; [M+H].sup.+
597.07
Example 62
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[2-(3-isopropyl-ureido)-pyridine-4-carbonyl]-1,3,8-triaza-spiro[4.-
5]dec-(2E)-ylidene]-amide
[0234] This compound is prepared analogously to Example 51 by
replacing 4-(benzyloxy)benzoic acid with
2-(3-Isopropyl-ureido)-isonicotinic acid (intermediate Y)
[M+H].sup.+ 530.2; .sup.1H NMR (DMSO-d6): 1.13 (6H, d, J=6.5),
1.77-1.94 (4H, m), 3.66 (2H, d, J=11), 3.25-3.99 (5H, m), 6.97 (1H,
br m), 7.50 (1H, br s), 7.31-7.60 (2H, br s), 7.61 (1H, br s),
7.74-8.25 (2H, br s), 8.28 (1H, d, J=5.5), 9.08-9.21 (1H, br s),
9.60-9.80 (1H, br s), 9.70-10.25 (1H, br s), 11.07 (s, 1H)
Example 63
4-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spir-
o[4.5]decane-8-carbonyl}-indole-1-carboxylic acid
isopropylamide
[0235] This compound is prepared analogously to Example 51 by
replacing 4-(benzyloxy)benzoic acid with
1-isopropylcarbamoyl-1H-indole-4-carboxylic acid (Intermediate Z):
[M+H].sup.+ 553.5
Example 64
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[4-(3-isopropyl-ureido)-benzoyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-y-
lidene]-amide
[0236] This compound is prepared analogously to Example 51 by
replacing 4-(benzyloxy)benzoic acid with
4-(3-isopropyl-ureido)-benzoic acid (Intermediate AA); [M+H].sup.+
529.5
Example 65
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[6-(3-isopropyl-ureido)-pyridine-3-carbonyl]-1,3,8-triaza-spiro[4.-
5]dec-(2E)-ylidene]-amide
[0237] This compound is prepared analogously to Example 51 by
replacing 4-(benzyloxy)benzoic acid with
6-(3-isopropyl-ureido)-nicotinic acid (Intermediate AB);
[M+H].sup.+ 530.5
Example 66
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[3-(4-allyloxy-phenyl)-propionyl]-1,3,8-triaza-spiro[4.5]dec-(2E)--
ylidene]-amide
[0238] This compound is prepared analogously to Example 51 by
replacing 4-(benzyloxy)benzoic acid with
3-(4-allyloxy)phenyl)propanoic acid; [M+H].sup.+ 513.4
Example 67
3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid
[8-{2-[4-(2-methoxy-ethoxymethoxy)-phenyl]-acetyl}-1,3,8-triaza-spiro[4.5-
]dec-(2E)-ylidene]-amide
[0239] This compound is prepared analogously to Example 51 by
replacing 4-(benzyloxy)benzoic acid with
[4-(2-methoxy-ethoxymethoxy)-phenyl]-acetic acid (Intermediate AC);
547.4
Example 68
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-{3-[4-(2-methoxy-ethoxymethoxy)-phenyl]-propionyl}-1,3,8-triaza-sp-
iro[4.5]dec-(2E)-ylidene]-amide
[0240] This compound is prepared analogously to Example 2.13 by
replacing 4-(benzyloxy)benzoic acid with
3-[4-(2-Methoxy-ethoxymethoxy)-phenyl]-propionic acid (Intermediate
AD); [M+H].sup.+ 561.0
Example 69
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(3-{4-[2-(tetrahydro-pyran-2-yloxy)-ethoxy]-phenyl}-propionyl)-1,3-
,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide
[0241] This compound is prepared analogously to Example 51 by
replacing 4-(benzyloxy)benzoic acid with
3-{4-[2-(tetrahydro-pyran-2-yloxy)-ethoxy]-phenyl}-propionic acid
(Intermediate AE); [M+H].sup.+ 601.1
Example 70
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-{3-[4-(pyridin-4-ylmethoxy)-phenyl]-propionyl}-1,3,8-triaza-spiro[-
4.5]dec-(2E)-ylidene]-amide
[0242] This compound is prepared analogously to Example 51 by
replacing 4-(benzyloxy)benzoic acid with
3-[4-(Pyridin-4-ylmethoxy)-phenyl]-propionic acid (Intermediate
AF); [M+H].sup.+ 564.1
Example 71
[4-(3-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza--
spiro[4.5]dec-8-yl}-3-oxo-propyl)-phenoxy]-acetic acid
tert-butyl
[0243] This compound is prepared analogously to Example 51 by
replacing 4-(benzyloxy)benzoic acid with
3-(4-tert-butoxycarbonylmethoxy-phenyl)-propionic acid
(Intermediate AG); [M+H].sup.+ 587.5
Example 72
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[3-(4-carbamoylmethoxy-phenyl)-propionyl]-1,3,8-triaza-spiro[4.5]d-
ec-(2E)-ylidene]-amide
[0244] This compound is prepared analogously to Example 51 by
replacing 4-(benzyloxy)benzoic acid with
3-(4-Carbamoylmethoxy-phenyl)-propionic acid (Intermediate AH);
[M+H].sup.+ 530.1
Example 73
1-[4-(3-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaz-
a-spiro[4.5]dec-8-yl}-3-oxo-propyl)-phenoxy]-cyclobutanecarboxylic
acid ethyl ester
[0245] This compound is prepared analogously to Example 51 by
replacing 4-(benzyloxy)benzoic acid with
1-[4-(2-Carboxy-ethyl)-phenoxy]-cyclobutanecarboxylic acid ethyl
ester (Intermediate AI); [M+H].sup.+ 599.1
Example 74
2-[4-(3-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaz-
a-spiro[4.5]dec-8-yl}-3-oxo-propyl)-phenoxy]-2-methyl-propionic
acid tert-butyl ester
[0246] This compound is prepared analogously to Example 51 by
replacing 4-(benzyloxy)benzoic acid with
2-[4-(2-Carboxy-ethyl)-phenoxy]-2-methyl-propionic acid tert-butyl
ester (Intermediate AJ); [M+H].sup.+ 615.2
Example 75
[4-(3-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza--
spiro[4.5]dec-8-yl}-3-oxo-propyl)-phenoxy]-acetic acid methyl
ester
[0247] This compound is prepared analogously to Example 51 by
replacing 4-(benzyloxy)benzoic acid with
3-(4-Methoxycarbonylmethoxy-phenyl)-propionic acid (Intermediate
AK); [M+H].sup.+ 545.1
Example 76
4-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spir-
o[4.5]decane-8-carbonyl}-benzoic acid tert-butyl ester
[0248] This compound is prepared analogously to Example 51 by
replacing 4-(benzyloxy)benzoic acid with
4-(tert-Butoxycarbonyl)benzoic acid; [M+H].sup.+ 529.4
Example 77
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(3-isopropyl-2-methyl-1H-indole-5-carbonyl)-1,3,8-triaza-spiro[4.5-
]dec-(2E)-ylidene]-amide
[0249] This compound is prepared analogously to Example 51 by
replacing 4-(benzyloxy)benzoic acid with
3-isopropyl-2-methyl-1H-indole-5-carboxylic acid; [M+H].sup.+
524
Example 78
3-[4-(3-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaz-
a-spiro[4.5]dec-8-yl}-3-oxo-propyl)-phenyl]-propionic acid propyl
ester
[0250] This compound is prepared analogously to Example 51 by
replacing 4-(benzyloxy)benzoic acid with
3-[4-(2-Propoxycarbonyl-ethyl)-phenyl]-propionic acid (intermediate
AL); [M+H].sup.+ 571
Example 79
3-[4-(3-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaz-
a-spiro[4.5]dec-8-yl}-3-oxo-propyl)-phenyl]-propionic acid ethyl
ester
[0251] This compound is prepared analogously to Example 51 by
replacing 4-(benzyloxy)benzoic acid with
3-[4-(2-Ethoxycarbonyl-ethyl)-phenyl]-propionic acid (intermediate
AM); [M+H].sup.+ 557
Example 80
3-[4-(3-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaz-
a-spiro[4.5]dec-8-yl}-3-oxo-propyl)-phenyl]-propionic acid methyl
ester
[0252] This compound is prepared analogously to Example 51 by
replacing 4-(benzyloxy)benzoic acid with
3-[4-(2-Methoxycarbonyl-ethyl)-phenyl]-propionic acid (intermediate
AN); [M+H].sup.+ 543
Example 81
3-[4-(3-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaz-
a-spiro[4.5]dec-8-yl}-3-oxo-propyl)-phenyl]-propionic acid
[0253] This compound is prepared analogously to Example 51 by
replacing 4-(benzyloxy)benzoic acid with
3,3'-(1,4-phenylene)dipropanoic acid; [M+H].sup.+ 529
Example 82
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[1-(2-phenoxy-ethyl)-1H-indole-4-carbonyl]-1,3,8-triaza-spiro[4.5]-
dec-(2E)-ylidene]-amide
[0254] This compound is prepared analogously to Example 51 by
replacing 4-(benzyloxy)benzoic acid with
1-(2-Phenoxy-ethyl)-1H-indole-4-carboxylic acid (Intermediate AO);
[M+H].sup.+ 588
Example 83
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[1-(2-p-tolyl-ethyl)
1H-indole-4-carbonyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide
[0255] This compound is prepared analogously to Example 51 by
replacing 4-(benzyloxy)benzoic acid with
1-(2-p-Tolyl-ethyl)-1H-indole-4-carboxylic acid (Intermediate AP);
[M+H].sup.+ 586
Example 84
3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid
[8-{1-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1H-indole-4-carbonyl}-1,3,8-tr-
iaza-spiro[4.5]dec-(2E)-ylidene]-amide
[0256] This compound is prepared analogously to Example 51 by
replacing 4-(benzyloxy)benzoic acid with
1-[2-(Tetrahydro-pyran-2-yloxy)-ethyl]-1H-indole-4-carboxylic acid
(Intermediate AQ); [M+H].sup.+ 597
Example 85
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-{1-[2-(4-methoxy-phenoxy)-ethyl]-1H-indole-4-carbonyl}-1,3,8-triaz-
a-spiro[4.5]dec-(2E)-ylidene]-amide
[0257] This compound is prepared analogously to Example 51 by
replacing 4-(benzyloxy)benzoic acid with
1-[2-(4-Methoxy-phenoxy)-ethyl]-1H-indole-4-carboxylic acid
(Intermediate AR); [M+H].sup.+ 618
Example 86
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-{1-[2-(4-tert-butyl-phenoxy)-ethyl]-1H-indole-4-carbonyl}-1,3,8-tr-
iaza-spiro[4.5]dec-(2E)-ylidene]-amide
[0258] This compound is prepared analogously to Example 51 by
replacing 4-(benzyloxy)benzoic acid with
1-[2-(4-tert-Butyl-phenoxy)-ethyl]-1H-indole-4-carboxylic acid
(Intermediate AS); [M+H].sup.+ 644
Example 87
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[1-(2-[1,3]dioxan-2-yl-ethyl)-1H-indole-4-carbonyl]-1,3,8-triaza-s-
piro[4.5]dec-(2E)-ylidene]-amide
[0259] This compound is prepared analogously to Example 51 by
replacing 4-(benzyloxy)benzoic acid with
1-(2-[1,3]Dioxan-2-yl-ethyl)-1H-indole-4-carboxylic acid
(Intermediate AT; [M+H].sup.+ 582
Example 88
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[1-(2-hydroxy-ethyl)-2,3-dimethyl-1H-indole-5-carbonyl]-1,3,8-tria-
za-spiro[4.5]dec-(2E)-ylidene]-amide
[0260] This compound is prepared analogously to Example 51 by
replacing 4-(benzyloxy)benzoic acid with
2,3-Dimethyl-1-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1H-indole-5-carboxyli-
c acid (Intermediate AU); [M+H].sup.+ 540
Example 89
4-(4-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-s-
piro[4.5]decane-8-carbonyl}-indol-1-yl)-butyric acid methyl
ester
[0261] This compound is prepared analogously to Example 51 by
replacing 4-(benzyloxy)benzoic acid with
1-(4,4,4-Trimethoxy-butyl)-1H-indole-4-carboxylic acid
(Intermediate AW); [M+H].sup.+ 568
Example 90
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-{1-[2-(2-methoxy-ethoxymethoxy)-ethyl]-1H-indole-4-carbonyl}-1,3,8-
-triaza-spiro[4.5]dec-(2E)-ylidene]-amide
[0262] This compound is prepared analogously to Example 51 by
replacing 4-(benzyloxy)benzoic acid with
1-[2-(2-Methoxy-ethoxymethoxy)-ethyl]-1H-indole-4-carboxylic acid
(Intermediate AW); [M+H].sup.+ 600
Example 91
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(1-diethylcarbamoylmethyl-1H-indole-4-carbonyl)-1,3,8-triaza-spiro-
[4.5]dec-(2E)-ylidene]-amide
[0263] This compound is prepared analogously to Example 51 by
replacing 4-(benzyloxy)benzoic acid with
1-Diethylcarbamoylmethyl-1H-indole-4-carboxylic acid (Intermediate
AX); [M+H].sup.+ 581
Example 92
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[1-(2-hydroxy-ethyl)-1H-indole-4-carbonyl]-1,3,8-triaza-spiro[4.5]-
dec-(2E)-ylidene]-amide
[0264] p-Toluenesulfonic acid monohydrate (1.6 mg, 0.0084 mmol) is
added to a stirred solution of
3,5-diamino-6-chloro-pyrazine-2-carboxylic
acid[8-{1-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1H-indole-4-carbonyl}-1,3,-
8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide (Ex. 84) (50 mg, 0.084
mmol) in MeOH (3 ml) and the resulting solution is stirred at room
temperature for 3 hrs, then heated at 50.degree. C. for 16 hours.
The solvent is removed in vacuo and the residue is dissolved in
MeOH (3 ml) and loaded onto a 1 g PEAX cartridge which is eluted
with MeOH (20 ml). The filtrate is concentrated in vacuo to afford
the title compound; [M+H].sup.+ 512/514
Example 93
##STR00306##
[0266] A mixture of 3,5-diamino-6-chloro-pyrazine-2-carboxylic
acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride
(Ex. 38) (300 mg, 0.83 mmol), cis-1,4-cyclohexanedicarboxylic acid
(72 mg, 0.42 mmol), N-methyl morpholine (0.30 ml, 2.73 mmol) and
HATU (315 mg, 0.83 mmol) in anhydrous DMF is stirred at room
temperature for 16 hours. The reaction mixture is concentrated in
vacuo and is subjected to column chromatography (basic alumina,
0-3% MeOH in DCM) to obtain off-white solid. The product is
dissolved in DCM and re-precipitated by addition of diethyl ether.
The supernatant solvent mixture is decanted and the product is
washed again with diethyl ether and dried under vacuum to afford
the compound shown as off-white solid; [M+H].sup.+ 785.
Example 94
##STR00307##
[0268] This compound is prepared analogously to Example 93 by
replacing cis-1,4-cyclohexanedicarboxylic acid with
trans-1,4-cyclohexanedicarboxylic acid; [M+2H].sup.2+ 393
Example 95
##STR00308##
[0270] This compound is prepared analogously to Example 93 by
replacing cis-1,4-cyclohexanedicarboxylic acid with suberic acid;
[M+H].sup.+ 787
Example 96
##STR00309##
[0272] This compound is prepared analogously to Example 93 by
replacing cis-1,4-cyclohexanedicarboxylic acid with terephthalic
acid; [M+H].sup.+ 779
Example 97
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[2-(4-benzyloxy-phenyl)-acetyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-yl-
idene]-amide
[0273] A mixture of 3,5-diamino-6-chloro-pyrazine-2-carboxylic
acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride
(Ex. 38) (300 mg, 0.83 mmol), 4-benzyloxyphenylacetic acid (200 mg,
0.83 mmol), N-methyl morpholine (0.40 ml, 3.64 mmol) and HATU (315
mg, 0.83 mmol) in anhydrous DMF (20 ml) is stirred at room
temperature for 16 hours. The reaction mixture is concentrated in
vacuo and subjected to column chromatography (basic alumina, 0-3%
MeOH in DCM) to obtain pale yellow solid. The product is dissolved
in DCM and MeOH and re-precipitated by adding diethyl ether. The
supernatant solvent mixture is decanted and the product is washed
again with diethyl ether and dried under vacuum to afford the title
compound as a pale yellow solid; [M+H].sup.+ 549.
Example 98
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[3-(4-benzyloxy-phenyl)-propionyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-
-ylidene]-amide
[0274] This compound is prepared analogously to Example 97 by
replacing 4-benzyloxyphenylacetic acid with
3-(4-benzyloxyphenyl)propionic acid; [M+H].sup.+ 563
Example 99
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(1H-indole-4-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-am-
ide
[0275] This compound is prepared analogously to Example 97 by
replacing 4-benzyloxyphenylacetic acid with indole-4-carboxylic
acid; [M+H].sup.+ 468
Example 100
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(1H-indole-5-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-am-
ide
[0276] This compound is prepared analogously to Example 97 by
replacing 4-benzyloxyphenylacetic acid with indole-5-carboxylic
acid; [M+H].sup.+ 468
Example 101
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-phenylacetyl-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide
[0277] This compound is prepared analogously to Example 97 by
replacing 4-benzyloxyphenylacetic acid with phenylacetic acid;
[M+H].sup.+ 443
Example 102
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-{4-[6-((S)-2,3-dihydroxy-propoxy)-naphthalen-2-ylmethoxy]-benzoyl}-
-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide
Step 1
[0278] 3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-{4-[6-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-naphthalen-2-yl-
methoxy]-benzoyl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide is
prepared analogously to Example 97 by replacing
4-benzyloxyphenylacetic acid with
4-[6-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-naphthalen-2--
ylmethoxy]-benzoic acid (Intermediate AY); [M+H].sup.+ 715
Step 2:
[0279] To a solution of 3,5-diamino-6-chloro-pyrazine-2-carboxylic
acid[8-{4-[6-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-naphthalen-2-yl-
methoxy]-benzoyl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide
(0.16 g, 0.22 mmol) in MeOH (10 ml) is added SCX-2 resin (-2 g),
the resultant slurry is stirred for 0.5 hours and then the solvent
is removed in vacuo. The slurry is loaded onto a column of SCX-2
resin (-3 g) and eluted with MeOH and then with 2 M NH.sub.3 in
MeOH. The methanolic ammonia fractions are concentrated in vacuo
and the residue is triturated with diethyl ether to obtain
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-{4-[6-((S)-2,3-dihydroxy-propoxy)-naphthalen-2-ylmethoxy]-benzoyl}-
-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide as yellow solid;
[M+H].sup.+ 675
Example 103
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(4-chloro-benzoyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide
[0280] This compound is prepared analogously to Example 97 by
replacing 4-benzyloxyphenylacetic acid with p-chlorobenzoic acid;
[M+H].sup.+ 463
Example 104
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(4-{3-[4-((S)-2,3-dihydroxy-propoxy)-phenyl]-propoxy}-benzoyl)-1,3-
,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide
[0281] This compound is prepared analogously to Example 102 by
replacing
4-[6-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-naphthalen-2-ylmethoxy]-
-benzoic acid, (Intermediate AY) with
4-{3-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-propoxy}-ben-
zoic acid (Intermediate AZ); [M+H].sup.+ 653
Example 105
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[(E)-(3-phenyl-acryloyl)]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-
-amide
[0282] This compound is prepared analogously to Example 97 by
replacing 4-benzyloxyphenylacetic acid with trans-cinnamic acid;
[M+H].sup.+ 455
Example 106
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-benzoyl-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide
[0283] This compound is prepared analogously to Example 97 by
replacing 4-benzyloxyphenylacetic acid with benzoic acid;
[M+H].sup.+ 429
Example 107
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(benzofuran-5-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-a-
mide
[0284] This compound is prepared analogously to Example 97 by
replacing 4-benzyloxyphenylacetic acid with benzofuran-5-carboxylic
acid; [M+H].sup.+ 469
Example 108
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-hexanoyl-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide
[0285] This compound is prepared analogously to Example 97 by
replacing 4-benzyloxyphenylacetic acid with hexanoic acid;
[M+H].sup.+ 423
Example 109
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(3-phenyl-propynoyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amid-
e
[0286] This compound is prepared analogously to Example 97 by
replacing 4-benzyloxyphenylacetic acid with phenylpropiolic acid;
[M+H].sup.+ 453
Example 110
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(1H-imidazole-2-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-
-amide
[0287] This compound is prepared analogously to Example 97 by
replacing 4-benzyloxyphenylacetic acid with 2-imidazolecarboxylic
acid; [M+H].sup.+ 419
Example 111
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-isobutyryl-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide
[0288] This compound is prepared analogously to Example 97 by
replacing 4-benzyloxyphenylacetic acid with isobuteric acid;
[M+H].sup.+ 395
Example 112
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(4-cyano-benzoyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide
[0289] This compound is prepared analogously to Example 97 by
replacing 4-benzyloxyphenylacetic acid with p-cyanobenzoic acid;
[M+H].sup.+ 454
Example 113
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(pyridine-3-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-ami-
de
[0290] This compound is prepared analogously to Example 97 by
replacing 4-benzyloxyphenylacetic acid with nicotinic acid;
[M+H].sup.+ 430
Example 114
4-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spir-
o[4.5]decane-8-carbonyl}-benzoic acid methyl ester
[0291] This compound is prepared analogously to Example 97 by
replacing 4-benzyloxyphenylacetic acid with monomethyl
terephthalate; [M+H].sup.+ 487
Example 115
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(pyrimidine-5-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-a-
mide
[0292] This compound is prepared analogously to Example 97 by
replacing 4-benzyloxyphenylacetic acid with pyrimidine-5-carboxylic
acid; [M+H].sup.+ 431
Example 116
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(4-hydroxy-benzoyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide
[0293] This compound is prepared analogously to Example 97 by
replacing 4-benzyloxyphenylacetic acid with 4-hydroxybenzoic acid;
[M+H].sup.+ 445
Example 117
3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid[8-cyclohexane
carbonyl-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide
[0294] This compound is prepared analogously to Example 97 by
replacing 4-benzyloxyphenylacetic acid with cyclohexanecarboxylic
acid; [M+H].sup.+ 435
Example 118
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(oxazole-4-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amid-
e
[0295] This compound is prepared analogously to Example 97 by
replacing 4-benzyloxyphenylacetic acid with oxazole-4-carboxylic
acid; [M+H].sup.+ 420
Example 119
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(pyridine-2-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-ami-
de
[0296] This compound is prepared analogously to Example 97 by
replacing 4-benzyloxyphenylacetic acid with 2-picolinic acid;
[M+H].sup.+ 430
Example 120
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(pyridine-4-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-ami-
de
[0297] This compound is prepared analogously to Example 97 by
replacing 4-benzyloxyphenylacetic acid with isonicotinic acid;
[M+H].sup.+ 430
Example 121
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(piperidine-4-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-a-
mide hydrochloride
[0298] 4 M HCl in dioxane (5 ml) is added to a solution of
4-{2-[(E)-3,5-diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spi-
ro[4.5]decane-8-carbonyl}-piperidine-1-carboxylic acid tert-butyl
ester (Intermediate BA) (0.14 g, 0.26 mmol) in dioxane (10 ml) and
the reaction mixture is stirred at room temperature for 3 hours.
The reaction mixture is concentrated in vacuo and the yellow solid
obtained is triturated with DCM. The DCM layer is decanted and the
compound is washed with MeOH and dried under vacuum to afford the
title compound as yellow solid; [M+H].sup.+ 436
Example 122
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(1H-imidazole-4-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-
-amide
[0299] This compound is prepared analogously to Example 97 by
replacing 4-benzyloxyphenylacetic acid with 4-imidazolecarboxylic
acid; [M+H].sup.+ 419
Example 123
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(tetrahydro-pyran-4-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylid-
ene]-amide
[0300] This compound is prepared analogously to Example 97 by
replacing 4-benzyloxyphenylacetic acid with
tetrahydropyran-4-carboxylic acid; [M+H].sup.+ 437
Example 124
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(pyrimidine-4-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-a-
mide
[0301] This compound is prepared analogously to Example 97 by
replacing 4-benzyloxyphenylacetic acid with pyrimidine-4-carboxylic
acid; [M+H].sup.+ 431
Example 125
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(oxazole-5-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amid-
e
[0302] This compound is prepared analogously to Example 97 by
replacing 4-benzyloxyphenylacetic acid with oxazole-5-carboxylic
acid; [M+H].sup.+ 420
Example 126
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[3-(4-isobutoxy-piperidine-1-sulfonyl)-benzoyl]-1,3,8-triaza-spiro-
[4.5]dec-(2E)-ylidene]-amide
Step 1
[0303] A solution of N,N-Diisopropylethylamine (0.0078 ml, 0.045
mmol) in THF (1 ml) is added to 4-Isobutoxy-piperidine (0.008 g,
0.05 mmol) followed by a solution of 3-(Chlorosulfonyl)benzoic acid
(9.93 mg, 0.045 mmol) and shaken at room temperature for 48 hours.
The solution is evaporated under vacuum to afford
3-(4-Isobutoxy-piperidine-1-sulfonyl)-benzoic acid which is used
without purification; [M+H].sup.+ 342.00
Step 2
[0304] 3-(4-Isobutoxy-piperidine-1-sulfonyl)-benzoic acid (0.03
mmol, 10.2 mg) is treated with a solution of HATU (11.4 mg, 0.03
mmol) in DMF (1 ml) followed by a solution of
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride
(Ex. 38) (11.9 mg, 0.03 mmol) and N-methyl morpholine (0.010 ml,
0.03 mmol) in DMF (1 ml) and shaken at room temperature overnight.
The solution is evaporated under vacuum, redissolved in DMSO (0.5
ml) and purified by mass-directed preparative HPLC. The purified
fractions are evaporated under vacuum to afford the title compound;
[M+H].sup.+ 648.4
Examples 127-145
[0305] These compounds, namely [0306]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-{3-[2-(1H-indol-3-yl)-ethylsulfamoyl]-benzoyl}-1,3,8-triaza-spiro[-
4.5]dec-(2E)-ylidene]-amide (Ex. 127); [0307]
1-(3-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza--
spiro[4.5]decane-8-carbonyl}-benzenesulfonyl)-piperidine-3-carboxylic
acid ethyl ester (Ex. 128); [0308]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(3-cyclopentylsulfamoyl-benzoyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-y-
lidene]-amide (Ex. 127); [0309]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[3-(1-acetyl-piperidin-4-ylsulfamoyl)-benzoyl]-1,3,8-triaza-spiro[-
4.5]dec-(2E)-ylidene]-amide (Ex. 130); [0310]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-{3-[(tetrahydro-furan-2-ylmethyl)-sulfamoyl]-benzoyl}-1,3,8-triaza-
-spiro[4.5]dec-(2E)-ylidene]-amide (Ex. 131); [0311]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-{3-[(pyridin-3-ylmethyl)-sulfamoyl]-benzoyl}-1,3,8-triaza-spiro[4.-
5]dec-(2E)-ylidene]-amide (Ex. 132); [0312]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-{3-[(2,2-dimethoxy-ethyl)-methyl-sulfamoyl]-benzoyl}-1,3,8-triaza--
spiro[4.5]dec-(2E)-ylidene]-amide (Ex. 133); [0313]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[3-(2,4-difluoro-benzylsulfamoyl)-benzoyl]-1,3,8-triaza-spiro[4.5]-
dec-(2E)-ylidene]-amide (Ex. 134); [0314]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[3-(1-pyridin-4-yl-ethylsulfamoyl)-benzoyl]-1,3,8-triaza-spiro[4.5-
]dec-(2E)-ylidene]-amide (Ex. 135); [0315]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[3-(2-phenyl-morpholine-4-sulfonyl)-benzoyl]-1,3,8-triaza-spiro[4.-
5]dec-(2E)-ylidene]-amide (Ex. 136); [0316]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[3-(3-difluoromethoxy-benzylsulfamoyl)-benzoyl]-1,3,8-triaza-spiro-
[4.5]dec-(2E)-ylidene]-amide (Ex. 137); [0317]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[3-(4-pyrrolidin-1-yl-piperidine-1-sulfonyl)-benzoyl]-1,3,8-triaza-
-spiro[4.5]dec-(2E)-ylidene]-amide (Ex. 138); [0318]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-{3-[(5-methyl-pyrazin-2-ylmethyl)-sulfamoyl]-benzoyl}-1,3,8-triaza-
-spiro[4.5]dec-(2E)-ylidene]-amide (Ex. 139); [0319]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[3-(dimethylcarbamoylmethyl-sulfamoyl)-benzoyl]-1,3,8-triaza-spiro-
[4.5]dec-(2E)-ylidene]-amide (Ex. 140); [0320]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[3-(3-benzenesulfonyl-pyrrolidine-1-sulfonyl)-benzoyl]-1,3,8-triaz-
a-spiro[4.5]dec-(2E)-ylidene]-amide (Ex. 141); [0321]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-{3-[([1,3]dioxolan-2-ylmethyl)-sulfamoyl]-benzoyl}-1,3,8-triaza-sp-
iro[4.5]dec-(2E)-ylidene]-amide (Ex. 142); [0322]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-{3-[2-(pyridin-3-yloxy)-propylsulfamoyl]-benzoyl}-1,3,8-triaza-spi-
ro[4.5]dec-(2E)-ylidene]-amide (Ex. 143); [0323]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-{3-[4-(5-trifluoromethyl-pyridin-2-yl)-[1,4]diazepane-1-sulfonyl]--
benzoyl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide (Ex. 144);
[0324] 3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[3-(1,1-dioxo-tetrahydro-1lambda*6*-thiophen-3-ylsulfamoyl)-benzoy-
l]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide (Ex. 145); are
made analogously to Examples 126 replacing 4-isobutoxy-piperidine
in step 1 with the appropriate amines which are all commercially
available. The compounds are recovered from the reaction mixture
and purified using conventional techniques.
Example 146
3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid
[8-{3-[3-(4-chlorophenyl)-[1,2,4]oxadiazol-5-yl]-propionyl}-1,3,8-triaza--
spiro[4.5]dec-(2E)-ylidene-amide trifluoroacetate
[0325] N-methyl morpholine (33 l, 0.3 mmol) is added to
3-(3-p-Tolyl-[1,2,4]oxadiazol-5-yl)-propionic acid (0.1 mmol),
followed by HATU (41.8 mg, 0.11 mmol) dissolved in peptide grade
DMF (250 l) and 3,5-Diamino-6-chloro-pyrazine-2-carboxylic acid
[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride
(Ex. 38) (40 mg, 0.1 mmol) dissolved in peptide grade DMF (250 l).
The reaction is sealed and shaken overnight at room temperature.
Purification is by mass-directed preparative HPLC to give the title
compound; [M+H].sup.+ 559.3
Example 147
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[1-(toluene-4-sulfonyl)-1H-pyrrole-3-carbonyl]-1,3,8-triaza-spiro[-
4.5]dec-(2E)-ylidene]-amide
[0326] A solution of 1-(Toluene-4-sulfonyl)-1H-pyrrole-3-carboxylic
acid (0.023 g, 0.085 mmol) in NMP (850 l) is added to
PS-carbodiimide (190 mg of 1.3 mmol/g loading, 0.24 mmol), followed
by a solution of 3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride
(Ex. 38) (0.08 mmol) and N-methyl morpholine (8 l, 0.08 mmol) in
NMP (1 ml), and the resulting reaction mixture is shaken at room
temperature. The reaction mixture is filtered and the resin is
washed with NMP (1 ml). The collected filtrate is concentrated in
vacuo and the residues are purified by mass-directed preparative
HPLC. The purified fractions are evaporated under vacuum to afford
the title compound; [M+H].sup.+ 572.08
Example 148
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[1-(3,4-difluoro-benzyl)-6-oxo-1,6-dihydro-pyridine-3-carbonyl]-1,-
3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide
[0327] A solution of
1-(3,4-Difluoro-benzyl)-6-oxo-1,6-dihydro-pyridine-3-carboxylic
acid (0.15 mmol) in NMP (0.5 ml) is added to a solution of
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride
(Ex. 38) (0.049 g, 0.15 mmol) and N-methyl morpholine (0.033 ml,
0.30 mmol) in NMP (1 ml), followed by a solution of HATU (0.11 g,
0.3 mmol) in NMP (0.5 ml). The reaction mixture is shaken at room
temperature overnight. The reaction mixture is purified by
mass-directed preparative HPLC. Fractions containing pure product
are eluted through SCX-2 cartridges (Biotage 1 g/6 ml cartridge),
and the cartridge is washed with MeOH (4 ml), followed by 3M
NH.sub.3 in MeOH solution (4 ml) to afford the title compound;
[M+H].sup.+ 572.0
Examples 149-213
[0328] These compounds, namely [0329]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[4-(3-phenyl-isoxazol-5-yl)-butyryl]-1,3,8-triaza-spiro[4.5]dec-(2-
E)-ylidene-amide (Ex. 149); [0330]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[4-(5-fluoro-2,3-dihydro-indol-1yl)-4-oxo-butyryl]-1,3,8-triaza-sp-
iro[4.5]dec-(2E)-ylidene-amide (Ex. 150); [0331]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-{4-[3-(4-methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-butyryl}-1,3,8-tri-
aza-spiro[4.5]dec-(2E)-ylidene-amide (Ex. 151); [0332]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(4-1H-indazol-3-yl-butyryl)-1,3,8-triaza-spiro[4.5]dec-(2E)-yliden-
e-amide (Ex. 152); [0333]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[4-(5-methanesulfonyl-2,3-dihydro-indol-1yl)-4-oxo-butyryl]-1,3,8--
triaza-spiro[4.5]dec-(2E)-ylidene-amide (Ex. 153); [0334]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(4-benzothiazol-2-yl-butyryl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylid-
ene-amide (Ex. 154); [0335]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[4-(5-dimethylsulfamoyl-2,3-dihydro-indol-1yl)-4-oxo-butyryl]-1,3,-
8-triaza-spiro[4.5]dec-(2E)-ylidene-amide (Ex. 155); [0336]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[4-(2-oxo-2,3-dihydro-1H-indol-3-yl)-butyryl]-1,3,8-triaza-spiro[4-
.5]dec-(2E)-ylidene-amide (Ex. 156); [0337]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[4-(6-dimethylamino-9H-purin-8-yl)-butryrl]-1,3,8-triaza-spiro[4.5-
]dec-(2E)-ylidene-amide (Ex. 157); [0338]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[4-(2-oxo-3-pyridin-3yl-2,3-dihydro-benzoimidazol-1-yl)-butyryl]-1-
,3,8-triaza-spiro[4.5]dec-(2E)-ylidene-amide (Ex. 158); [0339]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[4-(2-oxo-3-pyridine-3-ylmethyl-2,3-dihydro-indol-1-yl)-butryrl]-1-
,3,8-triaza-spiro[4.5]dec-(2E)-ylidene-amide (Ex. 159); [0340]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[4-(9-oxo-3,3a,4,9,10,10a-hexahydro-1H-2-aza-benzol[F]azulen-2-yl)-
-butyryl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene-amide (Ex. 160);
[0341] 3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[4-(6-amino-9H-purine-8-yl)-butyryl]-1,3,8-triaza-spiro[4.5]dec-(2-
E)-ylidene-amide (Ex. 161); [0342]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(4-oxo-4-pyrrolidin-1-yl-butyryl)-1,3,8-triaza-spiro[4.5]dec-(2E)--
ylidene-amide (Ex. 162); [0343]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(4-[1,2,4]triazol-1-yl-butyryl)-1,3,8-triaza-spiro[4.5]dec-(2E)-yl-
idene-amide (Ex. 163); [0344]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(5-dibenzylsulfamoyl-1-methyl-1H-pyrrole-2-carbonyl)-1,3,8-triaza--
spiro[4.5]dec-(2E)-ylidene]-amide (Ex. 164); [0345]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-{4-[3-(4-chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-butyryl}-1,3,8-tria-
za-spiro[4.5]dec-(2E)-ylidene]-amide (Ex. 165); [0346]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-{4-[(naphthalene-1-sulfonylamino)-methyl]-benzoyl}-1,3,8-triaza-sp-
iro[4.5]dec-(2E)-ylidene]-amide (Ex. 166); [0347]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-{2[3-(4-chlorophenyl)-[1,2,4]oxadiazol-5-yl]-acetyl}-1,3,8-triaza--
spiro[4.5]dec-(2E)-ylidene-amide (Ex. 167); [0348]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[3-(3-methoxy-propoxy)-benzoyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-yl-
idene]-amide (Ex. 168); [0349]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(2-benzotriazol-2-yl-acetyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylide-
ne]-amide (Ex. 169) [0350]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(2-benzotriazol-2-yl-acetyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylide-
ne]-amide (Ex. 170); [0351]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[4-(2-isopropoxy-ethylamino)-benzoyl]-1,3,8-triaza-spiro[4.5]dec-(-
2E)-ylidene]-amide (Ex. 171); [0352]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[6-oxo-1-(3-trifluoromethyl-benzyl)-1,6-dihydro-pyridine-3-carbony-
l]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide (Ex. 172); [0353]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[6-(4-methyl-piperazin-1-yl)-pyridine-3-carbonyl]-1,3,8-triaza-spi-
ro[4.5]dec-(2E)-ylidene]-amide (Ex. 173); [0354]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[3-(4-fluoro-phenyl)-5-methyl-isoxazole-4-carbonyl]-1,3,8-triaza-s-
piro[4.5]dec-(2E)-ylidene]-amide (Ex. 174); [0355]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-{3-[3-(4-methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-propionyl}-1,3,8-t-
riaza-spiro[4.5]dec-(2E)-ylidene]-amide (Ex. 175); [0356]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[2-(4-trifluoromethoxy-phenoxy)-acetyl]-1,3,8-triaza-spiro[4.5]dec-
-(2E)-ylidene]-amide (Ex. 176); [0357]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-{2-[4-(2-oxo-imidazolidin-1-yl)-phenyl]-acetyl}-1,3,8-triaza-spiro-
[4.5]dec-(2E)-ylidene]-amide (Ex. 177); [0358]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[3-(3-phenyl-isoxazol-5-yl)-propionyl]-1,3,8-triaza-spiro[4.5]dec--
(2E)-ylidene]-amide (Ex. 178); [0359]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[2-(4-methanesulfonyl-phenyl)-acetyl]-1,3,8-triaza-spiro[4.5]dec-(-
2E)-ylidene]-amide (Ex. 179); [0360]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[2-(4-chloro-phenyl)-thiazole-4-carbonyl]-1,3,8-triaza-spiro[4.5]d-
ec-(2E)-ylidene]-amide (Ex. 180); [0361]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-1,3,8-triaza--
spiro[4.5]dec-(2E)-ylidene]-amide (Ex. 181); [0362]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[5-(pyridin-3-yloxy)-furan-2-carbonyl]-1,3,8-triaza-spiro[4.5]dec--
(2E)-ylidene]-amide (Ex. 182); [0363]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[3-(4-methyl-thiazol-5-yl)-propionyl]-1,3,8-triaza-spiro[4.5]dec-(-
2E)-ylidene]-amide (Ex. 183); [0364]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(2-methyl-5-propyl-2H-pyrazole-3-carbonyl)-1,3,8-triaza-spiro[4.5]-
dec-(2E)-ylidene]-amide (Ex. 184); [0365]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[(S)-2-acetylamino-3-(4-isopropoxy-phenyl)-propionyl]-1,3,8-triaza-
-spiro[4.5]dec-(2E)-ylidene]-amide (Ex. 185); [0366]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[3-(cyclohexyl-methyl-sulfamoyl)-4-methoxy-benzoyl]-1,3,8-triaza-s-
piro[4.5]dec-(2E)-ylidene]-amide (Ex. 186); [0367]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-{2-[4-(3,5-dimethyl-benzenesulfonyl)-piperazin-1-yl]-acetyl}-1,3,8-
-triaza-spiro[4.5]dec-(2E)-ylidene]-amide (Ex. 187); [0368]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(3-1H-indol-3-yl-propionyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-yliden-
e]-amide (Ex. 188); [0369]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-{3-[4-(4,6-dimethyl-pyrimidin-2-ylsulfamoyl)-phenylcarbamoyl]-prop-
ionyl}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide (Ex.
189);
(Ex. 190);
[0369] [0370] 3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[3-(2-oxo-5-trifluoromethyl-2H-pyridin-1-yl)-propionyl]-1,3,8-tria-
za-spiro[4.5]dec-(2E)-ylidene]-amide (Ex. 191); [0371]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[3-(4-sulfamoyl-phenylcarbamoyl)-propionyl]-1,3,8-triaza-spiro[4.5-
]dec-(2E)-ylidene]-amide (Ex. 192); [0372]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(1-benzyl-5-oxo-pyrrolidine-3-carbonyl)-1,3,8-triaza-spiro[4.5]dec-
-(2E)-ylidene]-amide (Ex. 193); [0373]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[(R)-2-acetylamino-3-(1H-indol-3-yl)-propionyl]-1,3,8-triaza-spiro-
[4.5]dec-(2E)-ylidene]-amide (Ex. 194); [0374]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[4-(1-benzenesulfonyl-1H-pyrrol-3-yl)-4-oxo-butyryl]-1,3,8-triaza--
spiro[4.5]dec-(2E)-ylidene-amide (Ex. 195); [0375]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(1-furan-2-ylmethyl-5-oxo-pyrrolidine-3-carbonyl)-1,3,8-triaza-spi-
ro[4.5]dec-(2E)-ylidene]-amide (Ex. 196); [0376]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(6-pyrazol-1-yl-pyridine-3-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2-
E)-ylidene]-amide (Ex. 197); [0377]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[3-((R)-1-phenyl-ethylcarbamoyl)-propionyl]-1,3,8-triaza-spiro[4.5-
]dec-(2E)-ylidene]-amide (Ex. 198); [0378]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[1-(4-chloro-benzyl)-5-oxo-pyrrolidine-3-carbonyl]-1,3,8-triaza-sp-
iro[4.5]dec-(2E)-ylidene]-amide (Ex. 199); [0379]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[2-(3-tert-butyl-isoxazol-5-yl)-acetyl]-1,3,8-triaza-spiro[4.5]dec-
-(2E)-ylidene]-amide (Ex. 200); [0380]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[6-(2,2,2-trifluoro-ethoxy)-pyridine-3-carbonyl]-1,3,8-triaza-spir-
o[4.5]dec-(2E)-ylidene]-amide (Ex. 201); [0381]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(4-methyl-2-pyridin-3-yl-thiazole-5-carbonyl)-1,3,8-triaza-spiro[4-
.5]dec-(2E)-ylidene]-amide (Ex. 202); [0382]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(3-pyridin-3-yl-propionyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene-
]-amide (Ex. 203); [0383]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(5-dimethylsulfamoyl-2-methyl-furan-3-carbonyl)-1,3,8-triaza-spiro-
[4.5]dec-(2E)-ylidene]-amide (Ex. 204); [0384]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(1-ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carbonyl)-
-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide (Ex. 205); [0385]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(2-pyrazol-1-yl-acetyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-a-
mide (Ex. 206); [0386] 3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-{3-chloro-5-methoxy-4-[2-(4-methyl-piperazin-1-yl)-ethoxy]-benzoyl-
}-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide (Ex. 207); [0387]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(3-imidazol-1-yl-propionyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-yliden-
e]-amide (Ex. 208); [0388]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(1-benzyl-1H-imidazole-4-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-
-ylidene]-amide (Ex. 209); [0389]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[2-(1,1-dioxo-1lambda*6*-thiomorpholin-4-yl)-3-methyl-butyryl]-1,3-
,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide (Ex. 210); [0390]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[4-(toluene-4-sulfonylamino)-butyryl]-1,3,8-triaza-spiro[4.5]dec-(-
2E)-ylidene]-amide (Ex. 211); [0391]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carbonyl)-1-
,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide (Ex. 212); [0392]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(3-hydroxy-pyridine-2-carbonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-yl-
idene]-amide (Ex. 213); are made analogously to Examples 146, 147
or 148 replacing the carboxylic acid reagents with the appropriate
carboxylic acids which are all commercially available or prepared
as described in section `Preparation of Intermediate Compounds`.
The compounds are recovered from the reaction mixture and purified
using conventional techniques.
Example 214
1-(3-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triayraz-
ine-2-carbonylimino]-1,3,8-triazenesulfonyl)-piperidine-3-carboxylic
acid
[0393]
1-(3-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-t-
riaza-spiro[4.5]decane-8-carbonyl}-benzenesulfonyl)-piperidine-3-carboxyli-
c acid ethyl ester (Ex. 128) (0.29 g, 0.45 mmol) is dissolved in
THF (4 ml) and 2M LiOH (0.22 ml, 0.45 mmol) added. The yellow
solution is stirred at room temperature for 5 hours. On
concentration in vacuo the resulting sticky yellow solid is
ultrasonicated in water (15 ml) until complete dissolution. The pH
is adjusted to pH 2 by addition of 1 N HCl. The resultant yellow
solid is collected by filtration and rinsed with water to yield the
title compound; [M+H].sup.+ 620.1
Example 215
2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[4-
.5]decane-8-carboxylic acid benzylamide
[0394] To a solution of benzylamine (0.017 ml, 0.154 mmol) in DMF
(1 ml) is added 1,1'-carbonyldiimidazole (0.03 g, 0.17 mmol) and
the resulting solution is stirred at room temperature for 45
minutes. To this is added 5-Diamino-6-chloro-pyrazine-2-carboxylic
acid [1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide
dihydrochloride (Ex. 38) (0.05 g, 0.15 mmol) and the yellow
suspension is stirred for 24 hours. Purification by reverse phase
chromatography (Isolute.TM. C18, 0-100% MeCN in water -0.1% TFA)
followed by catch and release resin (SCX-2) eluting with MeOH and
7M NH.sub.3 in MeOH affords the title compound as an off white
solid; [M+H].sup.+ 458.1
Examples 216-231
[0395] These compounds, namely [0396]
2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[-
4.5]decane-8-carboxylic acid phenylamide (Ex. 216), [0397]
2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[-
4.5]decane-8-carboxylic
acid[1-(toluene-4-sulfonyl)-1H-indol-5-yl]-amide (Ex. 217); [0398]
2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[-
4.5]decane-8-carboxylic acid 3-(4-chloro-phenoxymethyl)-benzylamide
(Ex. 218); [0399]
2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[-
4.5]decane-8-carboxylic acid[3-(2,4-dichloro-phenyl)-propyl]-amide
(Ex. 219); [0400]
2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[-
4.5]decane-8-carboxylic acid[2-(3-benzyloxy-phenyl)-ethyl]-amide
(Ex. 220); [0401]
2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[-
4.5]decane-8-carboxylic
acid[2-(5,6-dimethyl-1H-indol-3-yl)-ethyl]-amide (Ex. 221); [0402]
2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[-
4.5]decane-8-carboxylic acid 4-morpholin-4-ylmethyl-benzylamide
(Ex. 222); [0403]
2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-
-spiro[4.5]decane-8-carboxylic acid 3-benzyloxy-benzylamide (Ex.
223); [0404]
2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-
-spiro[4.5]decane-8-carboxylic
acid(2-{4-[2-(4-fluoro-phenyl)-ethoxy]-phenyl}-ethyl)-amide (Ex.
224); [0405]
2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-
-spiro[4.5]decane-8-carboxylic
acid[2-(3,5-dimethoxy-phenyl)-ethyl]-amide (Ex. 225); [0406]
2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[-
4.5]decane-8-carboxylic
acid[3-(4-methoxy-naphthalen-1-yl)-propyl]-amide (Ex. 226); [0407]
2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[-
4.5]decane-8-carboxylic
acid[2-(4,6-dimethyl-1H-indol-3-yl)-ethyl]-amide (Ex. 227); [0408]
2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[-
4.5]decane-8-carboxylic acid(3-pyridin-2-yl-propyl)-amide (Ex.
228); [0409]
2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-
-spiro[4.5]decane-8-carboxylic acid
{2-[4-(4-phenyl-butoxy)-phenyl]-ethyl}-amide (Ex. 229); [0410]
2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spiro[-
4.5]decane-8-carboxylic acid[2-(4-phenoxy-phenyl)-ethyl]-amide (Ex.
230); [0411]
2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-
-spiro[4.5]decane-8-carboxylic
acid[2-(4-benzyloxy-phenyl)-ethyl]-amide (Ex. 231); are prepared by
an analogous procedure to Example 215, replacing benzylamine with
the appropriate amines which are either commercially available or
synthesized as described in the section `Preparation of
Intermediate compounds`. The compounds are recovered from reaction
mixtures and purified using conventional techniques such as flash
chromatography, filtration, recrystallisation and trituration.
Example 232
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-phenylmethanesulfonyl-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-ami-
de
[0412] To a solution of 5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide dihydrochloride
(Ex. 38) (0.05 g, 0.15 mmol) in DMF (2 ml) is added
alpha-toluenesulfonyl chloride (0.04 g, 0.20 mmol) and
triethylamine (0.02 ml, 0.15 mmol) and the yellow solution is
stirred at room temperature for 2 hours. Purification by reverse
phase chromatography (Isolute.TM. C18, 0-100% MeCN in water -0.1%
TFA) followed by catch and release resin (SCX-2) eluting with MeOH
and 7M NH.sub.3 in MeOH affords the title compound as a yellow
solid; [M+H].sup.+ 478.98
Examples 233-245
[0413] The following compounds, namely [0414]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-benzenesulfonyl-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide
(Ex. 233); [0415] 3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(1-methyl-1H-indole-4-sulfonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-yl-
idene]-amide (Ex. 234); [0416]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(1-methyl-1H-indole-5-sulfonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-yl-
idene]-amide (Ex. 235); [0417]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(7-chloro-benzo[1,2,5]oxadiazole-4-sulfonyl)-1,3,8-triaza-spiro[4.-
5]dec-(2E)-ylidene]-amide (Ex. 236); [0418]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(2-phenyl-ethanesulfonyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-
-amide (Ex. 237); [0419] 3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonyl]-1,3,8-t-
riaza-spiro[4.5]dec-(2E)-ylidene]-amide (Ex. 238); [0420]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(4-phenyl-5-trifluoromethyl-thiophene-3-sulfonyl)-1,3,8-triaza-spi-
ro[4.5]dec-(2E)-ylidene]-amide (Ex. 239); [0421]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(5-cyano-2-methoxy-benzenesulfonyl)-1,3,8-triaza-spiro[4.5]dec-(2E-
)-ylidene]-amide (Ex. 240); [0422]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[2-(4-chloro-phenyl)-ethanesulfonyl]-1,3,8-triaza-spiro[4.5]dec-(2-
E)-ylidene]-amide (Ex. 241); [0423]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(2-phenyl-3H-benzoimidazole-5-sulfonyl)-1,3,8-triaza-spiro[4.5]dec-
-(2E)-ylidene]-amide (Ex. 242); [0424]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[2-(2-chloro-phenyl)-ethanesulfonyl]-1,3,8-triaza-spiro[4.5]dec-(2-
E)-ylidene]-amide (Ex. 243); [0425]
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[2-(2,2,2-trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulf-
onyl]-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide (Ex. 244);
[0426] 3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-[2-(3-chloro-phenyl)-ethanesulfonyl]-1,3,8-triaza-spiro[4.5]dec-(2-
E)-ylidene]-amide (Ex. 245); are prepared by an analogous procedure
to Example 232, replacing alpha-toluenesulfonyl chloride with the
appropriate sulfonyl chlorides which are either commercially
available or synthesized as described in the section `Preparation
of Intermediate compounds`. The compounds are recovered from
reaction mixtures and purified using conventional techniques such
as flash chromatography, filtration, recrystallisation and
trituration.
Example 246
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(1-phenyl-ethyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide
[0427] A mixture of
1-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-2-methyl-isothiourea
(Intermediate A) (1.7 g, 4.54 mmol) and
4-aminomethyl-1-(1-phenyl-ethyl)-piperidin-4-ylamine (Intermediate
BM) (1.6 g, 4.59 mmol) in propan-2-ol (50 ml) is stirred at
80.degree. C. for 16 hours. The reaction mixture is concentrated in
vacuo and purified by column chromatography (basic alumina, 0-2%
MeOH in DCM) to obtain pale yellow solid. The compound obtained is
further dissolved in MeOH and precipitated by adding diethyl ether.
The supernatant solvent mixture is decanted and the product is
washed again with diethyl ether and dried under vacuum to afford
the title compound as off-white solid; [M+H].sup.+ 429
Example 247
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(4-methoxy-benzyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide
[0428] This compound is prepared analogously to Example 246 by
replacing 4-aminomethyl-1-(1-phenyl-ethyl)-piperidin-4-ylamine
(Intermediate BM) with
4-aminomethyl-1-(4-methoxy-benzyl)-piperidin-4-ylamine
(Intermediate BN) [M+H].sup.+ 445.
Example 248
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-pyridin-4-ylmethyl-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide
[0429] This compound is prepared analogously to Example 246 by
replacing 4-aminomethyl-1-(1-phenyl-ethyl)-piperidin-4-ylamine
(Intermediate BM) with
4-aminomethyl-1-pyridin-4-ylmethyl-piperidin-4-ylamine
(Intermediate BO); [M+H].sup.+=416
Example 249
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-(3-phenyl-propyl)-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide
[0430] This compound is prepared analogously to Example 246 by
replacing 4-aminomethyl-1-(1-phenyl-ethyl)-piperidin-4-ylamine
(Intermediate BM) with
4-aminomethyl-1-(3-phenyl-propyl)-piperidin-4-ylamine (Intermediate
BP) [M+H].sup.+ 443
Example 250
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[8-cyclohexylmethyl-1,3,8-triaza-spiro[4.5]dec-(2E)-ylidene]-amide
[0431] This compound is prepared analogously to Example 246 by
replacing 4-aminomethyl-1-(1-phenyl-ethyl)-piperidin-4-ylamine
(Intermediate BM) with
4-aminomethyl-1-cyclohexylmethyl-piperidin-4-ylamine (Intermediate
BQ) [M+H].sup.+ 421
Example 251
(E)-tert-Butyl
2'-(3,5-diamino-6-chloropyrazine-2-carbonylimino)-8-azaspiro[bicyclo[3.2.-
1]octane-3,4'-imidazolidine]-8-carboxylate
[0432] This compound is prepared analogously to Example 246 by
replacing 4-aminomethyl-1-(1-phenyl-ethyl)-piperidin-4-ylamine
(Intermediate BM) with
3-amino-3-aminomethyl-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid
tert-butyl ester (Intermediate BR) [M+H].sup.+ 451
Example 252
(E)-N-(8-(1H-indole-4-carbonyl)-8-azaspiro[bicyclo[3.2.1]octane-3,4'-imida-
zolidine]-2'-ylidene)-3,5-diamino-6-chloropyrazine-2-carboxamide
Step 1
[0433] Iodotrimethylsilane (0.23 ml, 1.66 mmol) is added to a
suspension of (E)-tert-Butyl
2'-(3,5-diamino-6-chloropyrazine-2-carbonylimino)-8-azaspiro[bicyclo[3.2.-
1]octane-3,4'-imidazolidine]-8-carboxylate (Ex. 251) (500 mg, 1.11
mmol) in DCM (10 ml). DMF (5 ml) is then added and the reaction is
stirred at room temperature overnight. Iodotrimethylsilane (0.5 ml)
is added and the reaction mixture is concentrated in vacuo. The
yellow solid is suspended in DCM and collected by filtration. The
solid is dissolved in 1:1 MeOH/DCM and loaded onto an SCX-2
cartridge eluted with DCM followed by MeOH and NH3/MeOH. The
methanolic ammonia fractions are concentrated in vacuo to afford
(E)-3,5-diamino-6-chloro-N-(8-azaspiro[bicyclo[3.2.1]octane-3,4'-imidazol-
idine]-2'-ylidene)pyrazine-2-carboxamide as a yellow gum;
[M+H]+351
Step 2
[0434]
(E)-3,5-diamino-6-chloro-N-(8-azaspiro[bicyclo[3.2.1]octane-3,4'-im-
idazolidine]-2'-ylidene)pyrazine-2-carboxamide (170 mg, 0.49 mmol)
is dissolved in DMF (10 ml) along with HATU (184 mg, 0.49 mmol) and
4-indole-carboxylic acid (78 mg, 0.49 mmol). N-Methyl morpholine
(160 ml, 1.45 mmol) is added and the solution stirred at room
temperature overnight. The mixture is then concentrated in vacuo.
EtOAc (100 ml) is added and the solution washed with water (100
ml). The organic phase is dried (MgSO.sub.4) and concentrated in
vacuo. Purification by flash chromatography (SiO.sub.2, DCM/MeOH)
gives the title compound as a yellow solid; [M+H].sup.+ 494.15,
496.27 for Cl isotopes.
Example 253
(E)-3,5-diamino-N-(8-(3-(4-(benzyloxy)phenyl)propanoyl)-8-azaspiro[bicyclo-
[3.2.1]octane-3,4'-imidazolidine]-2'-ylidene)-6-chloropyrazine-2-carboxami-
de
[0435]
(E)-3,5-diamino-6-chloro-N-(8-azaspiro[bicyclo[3.2.1]octane-3,4'-im-
idazolidine]-2'-ylidene)pyrazine-2-carboxamide (prepared as
described for Ex. 252) (280 mg, 0.798 mmol) is dissolved in DMF (8
ml) along with HATU (303 mg, 0.798 mmol) and
3-(4-benzyloxy-phenyl)-propionic acid (205 mg, 0.798 mmol).
N-Methyl morpholine (0.263 ml, 2.394 mmol) is added and the
solution stirred at room temperature for 6 hours. The mixture is
then concentrated in vacuo. EtOAc (100 ml) is added and the
solution washed with water (100 ml). The organic phase is dried
(MgSO.sub.4) and concentrated. The residue is dissolved in MeOH (20
ml) and dry loaded onto silica (5 g). Purification by flash
chromatography (SiO.sub.2, DCM/MeOH) gives the title compound as a
tan solid; [M+H].sup.+ 589.20, 591.19 for Cl isotopes.
Preparation of Intermediate Compounds
Intermediate A
1-(3,5-Diamino-6-chloro-pyrazine-2-carbonyl)-2-methyl-isothiourea
hydroiodide
Method 1
[0436] This compound is prepared according to Cragoe, Edward J.,
Jr.; Woltersdorf, Otto W., Jr.; De Solms, Susan Jane.
Heterocyclic-substituted pyrazinoylguanidines, and a pharmaceutical
composition containing them. EP 17152 Page 4
Method 2
Step 1
[0437] A stirred suspension of
3,5-diamino-6-chloro-pyrazine-2-carboxylic acid methyl ester (110
g, 542.9 mmol) in MeOH (500 ml) at 5-10.degree. C. (ice-bath) is
treated dropwise with a suspension of lithium hydroxide (46.6 g,
1111 mmol) in water (500 ml). The reaction mixture is heated to
50.degree. C. for 5 hours then cooled to room temperature and
stirred overnight. The resulting precipitate is collected by
filtration and dried in a vacuum oven to afford Lithium
3,5-diamino-6-chloro-pyrazine-2-carboxylic acid as the lithium salt
(di-hydrate); [M-Li].sup.- 187
Step 2
[0438] A stirred suspension of S-methyl-iso-thiourea sulphate (10
g, 35.9 mmol) in toluene (75 ml) is treated with 4 M NaOH (15 ml)
at room temperature. To the two-phase mixture is added di-tert
butyl dicarbonate (3.27 g, 15 mmol) in one portion. The reaction
mixture is stirred at room temperature for 1 hour, then heated to
60.degree. C. overnight. The organic portion is separated, washed
with brine solution, then dried over Na.sub.2SO.sub.4, filtered and
concentrated in vacuo to a viscous oil, which crystallised under
high vacuum to afford tert-Butyl
amino(methylthio)methylenecarbamate as a colourless solid.
Step 3
[0439] A stirring suspension of lithium
3,5-diamino-6-chloro-pyrazine-2-carboxylic acid (22.6 g, 98.03
mmol) in DMF (400 ml) is treated portionwise with HATU (41 g,
107.83 mmol), under an inert atmosphere of nitrogen. The reaction
mixture is stirred at room temperature for 2 hours and then
tert-butyl amino(methylthio)methylenecarbamate (20.5 g, 107.83
mmol) is added portion wise over a period of 10 minutes. The
reaction mixture is stirred at room temperature for a further 1.5
hours then heated to 50.degree. C. and stirred overnight. The
resulting precipitate is hot filtered, washing with water and dried
in a vacuum oven (40.degree. C.) overnight to afford tert-Butyl
(3,5-diamino-6-chloropyrazine-2-carboxamido)(methylthio) methylene
carbamate; [M+H].sup.+ 361
Step 4
[0440] tert-Butyl
(3,5-diamino-6-chloropyrazine-2-carboxamido)(methylthio) methylene
carbamate (50 g, 139 mmol) is slurried in DCM (500 ml). TFA (53.4
ml, 693 mmol) is dissolved in DCM (100 ml) and added dropwise over
45 mins to form a brown solution. The solution is stirred at room
temperature overnight, after which time a yellow precipitate has
formed. The solid is collected by filtration, and dried in vacuo to
yield the title compound; [M+H].sup.+ 261.1
Intermediate B
((S)-5,6-Diamino-hexyl)-carbamic acid benzyl ester
Step 1
[0441] A solution of BOC-lysinol-(Z)--OH (0.5 g, 1.36 mmol) in dry
THF (1 ml) under an inert atmosphere of argon is treated with
PS-triphenylphosphine (0.91 g, 3.00 mmol/g loading). To this
mixture is added phthalimide (0.2 g, 1.36 mmol) and DEAD (0.24 ml,
1.50 mmol) in dry THF (4 ml) and the reaction mixture is stirred at
room temperature overnight. The resin is removed by filtration
under vacuum and the filtrate is concentrated in vacuo.
Purification of the crude white solid by chromatography on silica
eluting with 20-50% EtOAc in iso-hexane (1% TEA) affords
[(S)-5-Benzyloxycarbonylamino-1-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethy-
l)-pentyl]-carbamic acid tert-butyl ester as a white crystalline
solid; [M+H].sup.+ 496
Step 2
[0442] A solution of
[(S)-5-benzyloxycarbonylamino-1-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethy-
l)-pentyl]-carbamic acid tert-butyl ester (0.63 g, 1.27 mmol) in
DCM (5.1 ml) and EtOH (5.1 ml) is treated with hydrazine hydrate
(0.318 g, 6.35 mmol) and the reaction mixture is stirred at room
temperature overnight. A white precipitate forms which is removed
by filtration and washed with DCM (3.times.10 ml). The filtrate is
concentrated in vacuo and redissolved in DCM (15 ml) and MeOH (2
ml). Undissolved material is removed by filtration and the filtrate
is concentrated in vacuo. The resulting oily yellow solid is
purified by chromatography on silica eluting with 10-50% MeOH in
DCM (1% TEA) to afford
((S)-1-Aminomethyl-5-benzyloxycarbonylamino-pentyl)-carbamic acid
tert-butyl ester as a clear oil; [M+H].sup.+ 366
Step 3
[0443] A solution of
((S)-1-aminomethyl-5-benzyloxycarbonylamino-pentyl)-carbamic acid
tert-butyl ester (0.24 g, 0.657 mmol) in DCM (2.4 ml) is treated
dropwise with TFA (0.6 ml) and stirred at room temperature for 3
days. The solvent is removed in vacuo to afford
((S)-5,6-Diamino-hexyl)-carbamic acid benzyl ester as a yellow oil;
[M+H].sup.+ 266
Intermediate C
A Mixture of 4-[4-(2-amino-ethylamino)-butyl]-phenol and
N*1*-[4-(4-methoxy-phenyl)-butyl]-ethane-1,2-diamine
Step 1
[0444] A solution of 4-methoxyphenylbutryric acid (6.99 g, 36 mmol)
in THF (70 ml) is treated with EDCI (7.6 g, 36.9 mmol) followed by
N-ethylmorpholine (9.2 ml, 72 mmol). After stirring at room
temperature for 1 hour, N--BOC-ethylene diamine (5.84 g, 36 mmol)
is added and the resulting mixture is stirred at room temperature
overnight. The reaction is quenched by addition of saturated sodium
hydrogen carbonate solution and extracted with EtOAc. The organic
portion is washed with citric acid solution, brine, dried
(MgSO.sub.4) and concentrated in vacuo until 25 ml of solvent
remained. The suspension is filtered to afford
{2-[4-(4-Methoxy-phenyl)-butyrylamino]-ethyl}-carbamic acid
tert-butyl ester: as a white solid.
Step 2
[0445] A solution of
{2-[4-(4-methoxy-phenyl)-butyrylamino]-ethyl}-carbamic acid
tert-butyl ester (6 g, 17.88 mmol) in dry THF (60 ml) under an
inert atmosphere of Argon is treated carefully with borane.THF
complex (53.88 ml, 1M Borane in THF). The reaction mixture is
heated at reflux for 2 hours and then allowed to cool to room
temperature overnight. The mixture is quenched by addition of MeOH
and then heated to 70.degree. C. for a further 2 hours. After
cooling to room temperature, the solvent is removed in vacuo to
afford {2-[4-(4-Methoxy-phenyl)-butylamino]-ethyl}-carbamic acid
tert-butyl ester as a viscous oil; [M+H].sup.+ 323
Step 3
[0446] A suspension of
{2-[4-(4-methoxy-phenyl)-butylamino]-ethyl}-carbamic acid
tert-butyl ester (5.85 g, 18.1 mmol) in HBr (30 ml of a 48%
solution) is heated at reflux for 2 hours. After cooling to room
temperature, the solvent is removed in vacuo. The crude residue is
suspended in EtOAc and filtered to afford a solid which consisted
of a mixture of 4-[4-(2-amino-ethylamino)-butyl]-phenol and
N*1*-[4-(4-methoxy-phenyl)-butyl]-ethane-1,2-diamine in
approximately 1:1 ratio; [M+H].sup.+ 209 and 223.
Intermediate D
(S)-3-(4-methoxy-phenyl)-propane-1,2 diamine
[0447] (S)-2-Amino-3-(4-methoxy-phenyl)-propionamide is prepared
according to the procedure described on page 3880, Method 2.1.3 of
Journal of Physical Chemistry B, 108(12), 3879-3889; 2004 and is
reduced analogously to Intermediate C.
Intermediate E
1-(3,4-Dichloro-phenyl)-ethane-1,2-diamine
[0448] This compound is prepared according to the procedure
described on page 907, Method 5 in the Journal of Medicinal
Chemistry (1973), 16(8), 901-8.
Intermediate F
4,5-Diaminopentanoic acid dihydrochloride
[0449] This compound is prepared according to the procedure
described in `Radiolabeling chelating compounds comprising sulfur
atoms, with metal radionuclides.` EP 300431 page 12, Intermediate
3.
Intermediate G
4-Amino-1-benzyl-piperidine-4-carbonitrile
Step 1
[0450] To a solution of ammonium chloride (1.73 g, 32.3 mmol) in
water (20 ml) is added a 30% ammonia solution (2 ml) followed by
1-benzyl-4-piperidone. After 20 minutes sodium cyanide (1.47 g, 30
mmol) is added portionwise over 15 minutes. After stirring for one
hour, water (50 ml) is added and the products are extracted with
DCM (3.times.50 ml), dried (MgSO.sub.4) filtered and concentrated
in vacuo. Purification by chromatography on silica eluting with
50-100% EtOAc in iso-hexane affords
4-Aminomethyl-1-benzyl-piperidine-4-ylamine; [M+H].sup.+ 216
Step 2
[0451] To a solution of lithium aluminium hydride (1 M in THF, 10.4
ml) in dry diethyl ether (15 ml), cooled to 0.degree. C., under an
argon atmosphere is added dropwise 4-amino
methyl-1-benzyl-piperidine-4-ylamine (900 mg, 4.18 mmol) in dry
diethyl ether (15 ml). The reaction mixture is heated at reflux for
24 h and then cooled to 0.degree. C. Water (0.25 ml) is added
followed by a 15% aqueous NaOH (0.25 ml) and then water (0.7 ml).
After warming to room temperature MgSO.sub.4 (150 mg) is added and
stirred for 15 minutes. The solids are removed by suction
filtration and the filtrate evaporated to give an oil. The solids
are extracted with refluxing diethyl ether (80 ml) using a Soxhlet
extractor for 14 hours. The diethyl ether is removed in vacuo and
the two oils combined and purified by chromatography on silica
eluting with 10-25% 2M ammonia in methanol solution in
dichloromethane to give 4-Amino-1-benzyl-piperidine-4-carbonitrile;
[M+H].sup.+ 220
Intermediate H
5-[4-((R)-2,2-Dimethyl-[1,3]-dioxolane-4-ylmethoxy)-phenyl]-pentane-1,2-di-
amine
Step 1
[0452] To 3-(4-hydroxyphenyl)-1-propanol (10 g, 66 mmol) and
potassium carbonate (13.5 g, 100 mmol) in acetone (200 ml) is added
(S)-glycidol (6.5 ml, 100 mmol). The mixture is heated at reflux
for 18 hours. After cooling to room temperature the solvent is
removed in vacuo and the residue partitioned between EtOAc and
water. The aqueous layer is further extracted twice with EtOAc and
the combined organic portions are washed with water, brine, dried
(MgSO.sub.4), filtered and concentrated in vacuo. The crude residue
is purified by flash column chromatography on silica eluting with
1:1 EtOAc/iso-hexane to afford
(S)-3-[4-(3-Hydroxy-propyl)-phenoxy]-propane-1,2-diol as a white
solid; .sup.1H NMR (CDCl.sub.3): 1.20 (1H, br), 1.85 (2H, pent,
J=6.8 Hz), 1.98 (1H, br), 2.58 (1H, br), 2.65 (2H, tr, J=6.9 Hz),
3.56 (2H, tr, J=6.8 Hz), 3.72 (1H, m), 3.83 (1H, m), 4.00 (2H, dd,
J=2.1 Hz, J=6.5 Hz), 4.09 (1H, br), 6.82 (2H, d, J=7.4 Hz), 7.10
(2H, d, J=7.4 Hz).
Step 2
[0453] To (S)-3-[4-(3-hydroxy-propyl)-phenoxy]-propane-1,2-diol
(11.5 g, 50.9 mmol) in dry DMF (150 ml) is added pyridinium
p-toluenesulfonate (1.28 g, 5 mmol) and 2,2-dimethoxypropane (31
ml, 250 mmol). The mixture is stirred at room temperature for 18
hours and then the solvent is removed in vacuo. The residue is
dissolved in EtOAc (150 ml) and washed with water, saturated
aqueous sodium hydrogen carbonate solution, brine, dried
(MgSO.sub.4) and concentrated in vacuo. The residue is purified by
chromatography on silica eluting with 1:4 EtOAc/iso-hexane to 1:1
EtOAc/iso-hexane to afford
(3-[4-((R)-2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-propan-1-ol
as a colourless oil; .sup.1H NMR (CDCl.sub.3): 1.25 (1H, br), 1.39
(3H, s), 1.43 (3H, s), 1.85 (2H, pent, J=6.9 Hz), 2.63 (2H, tr,
J=6.9 Hz), 3.63 (2H, tr, J=6.9 Hz), 3.90 (2H, m), 4.02 (1H, m),
4.12 (1H, m), 4.50 (1H, pent, J=6.8 Hz), 6.82 (2H, d, J=7.4 Hz),
7.10 (2H, d, J=7.4 Hz).
Step 3
[0454] To
(3-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-propa-
n-1-ol (12.2 g, 46 mmol) in dry ether (150 ml) is added TEA (12.8
ml, 92 mmol). The mixture is cooled to 0.degree. C. and treated
dropwise with methanesulfonyl chloride (5.3 ml, 69 mmol). The
reaction mixture is allowed to warm to room temperature and then
stirring continued for 3 hours. The resulting mixture is washed
with water (2.times.100 ml), saturated aqueous sodium
hydrogencarbonate, brine, dried (MgSO.sub.4) and concentrated in
vacuo to give Methanesulfonic acid
3-[4-((R)-2,2-dimethyl[1,3]dioxolan-4-ylmethoxy)-phenyl]-propylester
as a white solid; .sup.1H NMR (CDCl.sub.3): 1.39 (3H, s), 1.43 (3H,
s), 2.02 (2H, pent, J=6.9 Hz), 2.63 (2H, tr, J=6.9 Hz), 3.00 (3H,
s), 3.90 (2H, m), 4.05 (1H, m), 4.14 (3 h, m), 4.46 (1H, pent,
J=6.8 Hz), 6.82 (2H, d, J=7.4 Hz), 7.10 (2H, d, J=7.4 Hz).
Step 4
[0455] Methanesulfonic acid
3-[4-((R)-2,2-dimethyl[1,3]dioxolan-4-ylmethoxy)-phenyl]-propylester
(11.8 g, 34.2 mmol) in acetone (200 ml) is treated with lithium
bromide (8.9 g, 100 mmol) and then heated at reflux for 5 h. After
cooling to room temperature, the mixture is concentrated in vacuo.
The resulting residue is dissolved in EtOAc (150 ml), washed with
water (2.times.50 ml), brine, dried (MgSO.sub.4), filtered and
concentrated in vacuo to give an oil. Purification by
chromatography on silica eluting with 4:1 iso-hexane/EtOAc gives
(R)-4-[4-(3-Bromo-propyl)-phenoxymethyl]-2,2-dimethyl-[1,3]dioxolane
as a colourless oil which solidifies; .sup.1H NMR (CDCl.sub.3):
1.39 (3H, s), 1.43 (3H, s), 2.02 (2H, pent, J=6.9 Hz), 2.63 (2H,
tr, J=6.9 Hz), 3.38 (2H, tr, J=6.9 Hz), 3.90 (2H, m), 4.02 (1H, m),
4.15 (1H, m), 4.46 (1H, pent, J=6.9 Hz), 6.82 (2H, d, J=7.4 Hz),
7.10 (2H, d, J=7.4 Hz).
Step 5
[0456] A solution of N-(diphenylmethylene)aminoacetonitrile (5.14
g, 23.4 mmol) in DCM (12 ml) is treated with
(R)-4-[4-(3-bromo-propyl)-phenoxymethyl]-2,2-dimethyl-[1,3]dioxolane
(8.1 g, 24 mmol) in DCM (12 ml) and cooled to 0.degree. C. 48%
aqueous NaOH (20 ml) is added followed by benzyltriethylammonium
chloride (530 mg, 2.4 mmol) and the resulting mixture is allowed to
warm to room temperature. After stirring vigorously for 4 hours
mixture is diluted with DCM (100 ml) and the aqueous portion is
removed. The organic layer is washed with water (2.times.50 ml),
brine, dried (MgSO.sub.4), filtered and concentrated in vacuo. The
crude product is purified by chromatography on silica eluting with
15:1 iso-hexane/diethyl ether to 4:1 iso-hexane/diethyl ether to
yield
2-(Benzhydrylidene-amino)-5-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethox-
y)-phenyl]pentanenitrile as a yellow oil; .sup.1H NMR (CDCl.sub.3):
mix of diastereoisomers 1.39 (3H, s), 1.43 (3H, s), 1.71 (2H, m),
1.80-1.98 (2H, m), 2.52 (2H, tr, J=7.0 Hz) 3.90, (2H, m), 4.02 (1H,
m), 4.10-4.22 (2H, m), 4.47 (1H, pent, J=6.9 Hz), 6.82 (2H, d,
J=7.4 Hz), 7.05 (2H, d, J=7.4 Hz), 7.19 (2H, m), 7.35 (2H, tr,
J=7.2 Hz), 7.40-7.50 (4H, m), 7.60 (2H, d, J=7.1 Hz).
Step 6
[0457] To a solution of
2-(benzhydrylidene-amino)-5-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethox-
y)-phenyl]pentanenitrile (7.2 g, 15.5 mmol) in THF (50 ml) is added
a 2M HCl (aq) (5 ml). The solution is heated at 40.degree. C. for 4
hours and then allowed to cool to room temperature. The pH is
adjusted to pH 9-10 using saturated aqueous sodium hydrogen
carbonate solution and the organic solvent is removed in vacuo. The
crude residue is dissolved in EtOAc (100 ml) and washed with water,
brine, dried (MgSO.sub.4), filtered and concentrated in vacuo. The
resulting residue is purified by chromatography on silica eluting
with 5:1 to 1:1 iso-hexane/ethyl aEtOAc and 1% triethylamine to
yield
2-Amino-5-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-pentane-
nitrile as a colourless oil which solidifies; .sup.1H NMR
(CDCl.sub.3): mixture of diastereoisomers 1.39 (3H, s), 1.43 (3H,
s), 1.70-1.87 (4H, m), 2.60 (2H, tr, J=7.1 Hz), 3.62 (1H, br), 3.90
(2H, m), 4.00-4.18 (2H, m), 4.48 (1H, pent, J=6.9 Hz), 6.82 (2H, d,
J=7.4 Hz), 7.10 (2H, d, J=7.4 Hz). [M+H].sup.+ 305
Step 7
[0458] A solution of
2-amino-5-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-pentane-
nitrile (1.7 g, 4.28 mmol) in a 2M ammonia in methanol solution (50
ml) is passed through a H-CUBE apparatus fitted with a Raney nickel
CatCart at 50.degree. C. and a hydrogen pressure of 50 bar and a
flow rate of 1.5 ml/min. After 5 hours of continuous cycling of the
solution the reaction mixture is concentrated in vacuo to give
5-[4-((R)-2,2-Dimethyl-[1,3]dioxolane-4-ylmethoxy)-phenyl]-pentane-1,2-di-
amine as a light-yellow oil; [M+H].sup.+ 309
Intermediate I
5-(4-Methoxy-phenyl)-pentane-1,2-diamine
[0459] This compound is prepared analogously to Intermediate H by
replacing
(3-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-prop-
an-1-ol with 4-(4-methoxyphenyl)-1-butanol.
Intermediate J
1-Aminomethyl-cyclopentylamine
Step 1
[0460] To a cooled 0.degree. C. solution of
(1-cyano-cyclopentyl)-carbamic acid tert-butyl ester (430 mg, 2.04
mmol) in dry THF (4.3 ml) under an atmosphere of argon is added
dropwise 1.0 M LiAlH.sub.4 (6.13 ml, 6.13 mmol). The reaction
mixture is allowed to warm to room temperature and stirred for 3.5
hours. The mixture is then re-cooled to 0.degree. C. and cautiously
quenched with water (0.4 ml): 15% NaOH (0.8 ml):water (1.2 ml)
(1:2:3 eq). The resultant mixture is filtered through Celite.RTM.
(filter material) to remove the inorganic solids and rinsed with
MeOH. The filtrate is concentrated in vacuo, to yield a white
solid, which is purified by chromatography on silica eluting with
30% MeOH in DCM to afford (1-Aminomethyl-cyclopentyl)-carbamic acid
tert-butyl ester; [M+H].sup.+ 215.
Step 2
[0461] Iodotrimethylsilane (0.091 ml, 0.67 mmol) is added dropwise
to a solution of (1-aminomethyl-cyclopentyl)-carbamic acid
tert-butyl ester (120 mg, 0.56 mmol) in DCM (2.4 ml) and left to
stir overnight. The resulting suspension is quenched with MeOH (2.4
ml) and concentrated in vacuo to yield
1-Aminomethyl-cyclopentylamine as a dark oil, which is used without
further purification.
Intermediate K
(4-((R)-4,5-Diamino-pentyl)-phenol
Steps 1 and 2
[0462]
(R)-2-tert-Butoxycarbonylamino-5-(4-tert-butoxy-phenyl)-pentanoic
acid ethyl ester is prepared according to the procedure of Ding,
Chuanyong.; Ma, Rujian.; Rong, Guobin. Preparation of
w-Phenyl-(2S)-N-Boc-amino Acid Ethyl esters; Chinese Journal of
Organic Chemistry Vol 26(12) 2006, 1694 &1695, replacing Ethyl
Boc-L-pyroglutamate with Ethyl Boc-D-pyroglutamate &
Bromomethyl-benzene with 1-Bromo-4-tert-butoxy-benzene in Example
2a, using preparation steps 2.2, 2.3, and 2.5; [M+H].sup.+ 394
Step 3
[0463]
(R)-2-tert-Butoxycarbonylamino-5-(4-tert-butoxy-phenyl)-pentanoic
acid ethyl ester (179 g, 460 mmol) is dissolved in 7M NH.sub.3 in
MeOH (400 ml, 2800 mmol) and stirred at room temperature for 4
days. The reaction is concentrated in vacuo keeping the temperature
below 30.degree. C. to afford
[(R)-4-(4-tert-Butoxy-phenyl)-1-carbamoyl-butyl]-carbamic acid
tert-butyl ester [M+H].sup.+ 364
Step 4
[0464] A solution of
[(R)-4-(4-tert-Butoxy-phenyl)-1-carbamoyl-butyl]-carbamic acid
tert-butyl ester (167 g, 458 mmol) in 1 M HCl in Et.sub.2O (4000
ml) is stirred at room temperature for 3 days. After this time, a
white solid forms which is collected by filtration and washed with
Et.sub.2O to yield (R)-2-Amino-5-(4-hydroxy-phenyl)-pentanoic acid
amide; [M+H].sup.+ 209
Step 5
[0465] To a stirred solution of
(R)-2-Amino-5-(4-hydroxy-phenyl)-pentanoic acid amide (5 g, 24.01
mmol) in THF (250 ml) is added imidazole (4.90 g, 72 mmol),
followed by tert-butyldimethylchlorosilane (3.98 g, 26.4 mmol). The
resulting solution is heated at 70.degree. C. for 4 hours and then
allowed to cool to room temperature. Dilution with Et.sub.2O (200
ml) washing with water (2.times.100 ml) and brine (100 ml), drying
MgSO.sub.4, and concentration in vacuo yields
(R)-2-Amino-5-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-pentanoic
acid amide; [M+H].sup.+ 323
Step 6
[0466] A solution of
(R)-2-Amino-5-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-pentanoic
acid amide (7.74 g, 24 mmol) in THF is stirred at 5.degree. C. and
borane (96 ml of a 1 M solution in THF, 96 mmol) is added. The
mixture is stirred at 5.degree. C. until a homogeneous mixture is
obtained and then stirred at room temperature for 30 minutes and
35.degree. C. for 3 hours. After this time, further borane (24 ml
of a 1 M solution in THF, 24 mmol) is added and the reaction is
heated at 35.degree. C. for 18 hours. After this time, a further
portion of borane (24 ml of a 1 M solution in THF, 24 mmol) is
added and the reaction heated at 35.degree. C. for a further 24
hours. After this time, the reaction is cooled to 10.degree. C.,
and quenched by adding dropwise to MeOH (50 ml) at -5.degree. C.
After allowing to warm to room temperature the solvent is removed
in vacuo to afford a yellow oil. The oil is dissolved in MeOH (250
ml) and SCX-2 silica (180 g, 0.63 mmol/g, 120 mmol) is added. The
silica suspension is shaken for 18 hours, the silica is removed by
filtration, washed with MeOH (3.times.100 ml), then suspended in 7M
NH.sub.3 in MeOH and shaken for 18 hours. The silica is removed by
filtration and the 7M NH.sub.3 in MeOH is removed in vacuo to
afford the title compound as a yellow oil; [M+H].sup.+ 195
Intermediate L
4-((S)-4,5-Diamino-pentyl)-phenol
[0467] This compound is prepared analogously to Intermediate K
(NVP-QBM333), replacing Ethyl Boc-D-pyroglutamate in step 1 with
Ethyl Boc-L-pyroglutamate; [M+H].sup.+ 195
Intermediate M
(R)-tert-butyl 5-(4-hydroxyphenyl)pentane-1,2-diyldicarbamate
[0468] To a solution of (4-((R)-4,5-Diamino-pentyl)-phenol
(Intermediate K) (775 mg, 1.99 mmol) in DCM (10 ml) is added
triethylamine (1.14 ml, 8.08 mmol) and a solution of di-tert-butyl
dicarbonate (1.33 g, 6.08 mmol) in DCM (10 ml) and the resulting
solution is stirred at room temperature for 18 hours. The solvent
is removed in vacuo and the residue purified by chromatography
(SiO.sub.2, EtOAc/iso-hexane) to afford the title compound;
[M+H].sup.+ 395
Intermediate N
(S)-tert-butyl 5-(4-hydroxyphenyl)pentane-1,2-diyldicarbamate
[0469] This compound is prepared analogously to Intermediate M,
(R)-tert-butyl 5-(4-hydroxyphenyl)pentane-1,2-diyldicarbamate
replacing Intermediate K, (4-((R)-4,5-Diamino-pentyl)-phenol with
Intermediate L, 4-((S)-4,5-Diamino-pentyl)-phenol; [M+H].sup.+
395
Intermediate O
(R)-3-[4-((R)-4,5-Diamino-pentyl)-phenoxy]-propane-1,2-diol
Step 1
[0470] Triethylamine (8.37 l, 0.06 mmol) and (R)-(+)-glycidol (96
l, 1.442 mmol) are added to a solution of (R)-tert-butyl
5-(4-hydroxyphenyl)pentane-1,2-diyldicarbamate (Intermediate M)
(474 mg, 1.20 mmol) in EtOH (5 ml) and the resulting solution is
heated at 90.degree. C. for 18 hours. The reaction is allowed to
cool to room temperature and concentrated in vacuo. Purification by
chromatography (SiO.sub.2, EtOAc/iso-hexane) affords
{(R)-2-tert-Butoxycarbonylamino-5-[4-((R)-2,3-dihydroxy-propoxy)-phenyl]--
pentyl}-carbamic acid tert-butyl ester; [M+H].sup.+ 469
Step 2
[0471]
{(R)-2-tert-Butoxycarbonylamino-5-[4-((R)-2,3-dihydroxy-propoxy)-ph-
enyl]-pentyl}-carbamic acid tert-butyl ester (94 mg, 0.201 mmol) is
stirred with a solution of 1 M HCl in Et.sub.2O (3 ml) for 18 hours
and then loaded onto a 1 g SCX-2 cartridge washed with MeOH (30
ml), followed by 7M NH.sub.3 in MeOH (30 ml). The NH.sub.3 fraction
is concentrated in vacuo to give the title compound,
(R)-3-[4-((R)-4,5-Diamino-pentyl)-phenoxy]-propane-1,2-diol
Intermediate H
(R)-3-[4-((R)-4,5-Diamino-pentyl)-phenoxy]-propane-1,2-diol;
[M+H].sup.+ 269
Intermediate P
(R)-3-[4-((S)-4,5-Diamino-pentyl)-phenoxy]-propane-1,2-diol
[0472] This compound is prepared analogously to Intermediate O
replacing (R)-tert-butyl
5-(4-hydroxyphenyl)pentane-1,2-diyldicarbamate (Intermediate M with
(S)-tert-butyl 5-(4-hydroxyphenyl)pentane-1,2-diyldicarbamate
(Intermediate N); [M+H}.sup.+ 269
Intermediate Q
2-[4-((R)-4,5-Diamino-pentyl)-phenoxy]-1-morpholin-4-yl-ethanone
[0473] (R)-tert-butyl
5-(4-hydroxyphenyl)pentane-1,2-diyldicarbamate (Intermediate M)
(446 mg, 0.565 mmol) is dissolved in DMF (10 ml) and
Cs.sub.2CO.sub.3 (368 mg, 1.131 mmol) and
2-bromo-1-morpholinethanone (118 mg, 0.565 mmol) are added. The
reaction is stirred at room temperature for 40 minutes, then
diluted with water (20 ml) and extracted with EtOAc (2.times.50
ml). The organic layers are dried over MgSO.sub.4 and the solvent
concentrated in vacuo to give a clear oil. Purification by
chromatography on a Waters 3000 prep HPLC system (Microsorb.TM. C18
Water/MeCN +0.1% TFA) yields a clear oil, which is dissolved in
dioxane (4 ml) and treated with 4 M HCl in dioxane (4 ml) and
stirred at room temperature for 4 days. Concentration in vacuo
affords a white foam which is dissolved in MeOH (3 ml) and loaded
onto a 10 g SCX-2 cartridge which is washed with MeOH (60 ml) and
7M NH.sub.3 in MeOH (60 ml). The NH.sub.3 fractions are combined
and concentrated in vacuo to give the title compound as a
colourless oil; [M+H}.sup.+ 322
Intermediate R
5-(4-Methoxy-phenyl)-hexane-1,2-diamine
[0474] This compound is prepared analogously to Intermediate I by
replacing 4-(4-methoxyphenyl)-1-butanol with
4-(4-methoxyphenyl)-1-pentanol.
Intermediate S
((S)-4,5-Diamino-pentyl)-carbamic acid benzyl ester
Step 1
[0475] Concentrated HCl (15 ml) is added to a suspension of
N--BOC--N--Z-L-ornithine (5.00 g, 13.65 mmol) in
2,2-dimethoxypropane (150 ml). An endotherm occurs and the
resulting solution is left to stir at room temperature for 6 hours.
The solvent is then reduced in vacuo to approximately 50 ml and
diethyl ether (100 ml) is added to turn the solution turbid. On
stirring a thick white suspension forms. The white solid is
collected by filtration and rinsed with diethyl ether (100 ml). The
white solid is dissolved in MeOH (30 ml) and diethyl ether (200 ml)
is added to precipitate a white solid that is collected by
filtration and rinsed with diethyl ether. The solid is dissolved in
DCM and washed with 2 N NaOH (75 ml). The organic phase is dried
over MgSO.sub.4 and the solvent evaporated in vacuo to yield
(S)-2-Amino-5-benzyloxycarbonylamino-pentanoic acid methyl ester as
a colourless oil; [M+H].sup.+ 280.78
Step 2
[0476] (S)-2-Amino-5-benzyloxycarbonylamino-pentanoic acid methyl
ester (2.80 g, 9.99 mmol) and 7M NH.sub.3 in MeOH (20 ml) is
stirred at room temperature for 72 hours. The reaction mixture is
evaporated to dryness in vacuo to yield a white solid. The white
solid is suspended in diethyl ether before filtration and drying to
yield ((S)-4-Amino-4-carbamoyl-butyl)-carbamic acid benzyl
ester.
Step 3
[0477] ((S)-4-Amino-4-carbamoyl-butyl)-carbamic acid benzyl ester
(1.87 g, 7.071 mmol) is suspended in dry THF (40 ml) and cooled to
10.degree. C. in an ice bath under nitrogen. Borane (28.3 ml of a 1
M solution in THF, 28.3 mmol) is added. The ice bath is removed and
the suspension heated to 70.degree. C. and then left to stir at
this temperature for 3 hours. Further borane (28.3 ml of a 1 M
solution in THF, 28.3 mmol) is added and then after an hour the
same amount of 1M borane in THF is added again. After a final hour
at 70.degree. C. the reaction mixture is quenched with MeOH (40
ml). The solvent is reduced in vacuo to approximately 50 ml. This
is diluted with 5 M HCl (100 ml) and washed with diethyl ether
(3.times.100 ml). The aqueous phase is basified to pH 12 with 2N
NaOH and product extracted into EtOAc (3.times.100 ml). The organic
phases are combined, dried over MgSO.sub.4 and the solvent
evaporated in vacuo to yield the title compound as a colourless
oil.
Intermediate T
3,5-Diamino-6-chloro-pyrazine-2-carboxylic
acid[(S)-4-(4-amino-butyl)-imidazolidin-(2E)-ylidene]-amide
[0478] To a suspension of
(4-{(S)-2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-imidazolidi-
n-4-yl}-butyl)-carbamic acid benzyl ester (Ex. 5) (0.110 g, 0.239
mmol) in dry DCM (20 ml) is added iodotrimethylsilane (0.130 ml,
0.956 mmol). The reaction mixture is stirred at room temperature
for 3.5 hours. MeOH is added to the suspension yielding a solution.
Purification by catch and release resin (SCX-2) eluting with MeOH
and 7 M NH.sub.3 in MeOH yields the title compound as a brown oil;
[M+H].sup.+ 327.1
Intermediate U
4-Amino-4-aminomethyl-piperidine-1-carboxylic acid tert-butyl
ester
Step 1
[0479] To a solution of 4-amino-4-cyano-piperidine-1-carboxylic
acid tert-butyl ester (11.5 g, 51.0 mmol) in pyridine (20 ml) at
0.degree. C. is added trifluoroacetic anhydride (11.0 ml) slowly
and the reaction mixture is stirred at 0.degree. C. for 4 h. The
reaction mixture is diluted with DCM, washed with brine, dried over
Na.sub.2SO.sub.4 and concentrated in vacuo. The residue obtained is
dissolved in DCM and re-precipitated by adding petroleum ether. The
supernatant solvent mixture is decanted and the product is washed
again with petroleum ether and dried under vacuum to afford
4-Cyano-4-(2,2,2-trifluoro-acetylamino)-piperidine-1-carboxylic
acid tert-butyl ester as an oil; .sup.1H NMR (d.sub.6-DMSO): 1.40
(9H, s), 1.81-1.88 (2H, m), 2.26-2.32 (2H, m), 2.99-3.15 (2H, m),
3.79-3.82 (2H, m), 10.1 (1H, s).
Step 2
[0480] To a solution of
cyano-4-(2,2,2-trifluoro-acetylamino)-piperidine-1-carboxylic acid
tert-butyl ester (10.0 g, 31.0 mmol) in EtOH (150 ml) is added
Raney nickel (-1.5 g) and the reaction mixture is stirred under an
atmosphere of hydrogen for 3 days. A further quantity of Raney
nickel (.about.1.5 g) is added and the reaction mixture is further
stirred for 2 days. The reaction mixture is filtered through a plug
of Celite.TM. (filter material) and the filtrate is concentrated in
vacuo to obtain
4-Aminomethyl-4-(2,2,2-trifluoro-acetylamino)-piperidine-1-carboxylic
acid tert-butyl ester as a viscous oil that is used crude without
further purification.
Step 3
4-Amino-4-aminomethyl-piperidine-1-carboxylic acid tert-butyl
ester
[0481] To a solution of
4-aminomethyl-4-(2,2,2-trifluoro-acetylamino)-piperidine-1-carboxylic
acid tert-butyl ester in MeOH (70 ml) is added a 30% aqueous
solution of ammonia (70 ml) and the reaction mixture is stirred at
80.degree. C. overnight. The reaction mixture is concentrated in
vacuo to 4-Amino-4-aminomethyl-piperidine-1-carboxylic acid
tert-butyl ester as a brown oil that is used crude without further
purification; [M+H].sup.+ 230.
Intermediate V
3-(3-Isopropoxy-propylsulfamoyl)-benzoic acid
[0482] 3-Isopropoxypropylamine (1.1 eq.) is dissolved in THF with
stirring at room temperature. N,N-diisopropylethylamine (1 eq.) is
added followed by methyl 3-(chlorosulfonyl)benzoic acid (1 eq.).
The reaction mixture is stirred at room temperature for 2 hours
before the solvent is evaporated in vacuo to yield the crude titled
product.
Intermediate W
3-(3-Isopropyl-ureido)-benzoic acid
[0483] A suspension of 3-Aminobenzoic acid (20 g, 145.8 mmol) in
THF (300 ml) is heated to 60.degree. C. to form a clear solution.
I-propylisocyanate (14.9 g, 175 mmol) is added over 30 minutes.
During the addition the product starts to precipitate. After
complete addition toluene (300 ml) is added. The reaction mixture
is stirred at 60.degree. C. for 4.5 hours. The heating bath is
removed and the mixture is stirred overnight at room temperature.
Finally the suspension is filtered and washed with a mixture of 1:1
THF:toluene (200 ml). The product is dried at 60.degree. C. for 18
hours to yield 3-(3-Isopropyl-ureido)-benzoic acid
Intermediate X
5-Oxo-1-(3-pyrrol-1-yl-propyl)-pyrrolidine-3-carboxylic acid
Step 1
[0484] To a solution of 5-Oxo-pyrrolidine-3-carboxylic acid methyl
ester (1 eq.) in dry DMF is added NaH (1.1 eq.) followed by
1-(3-bromo-propyl)-1H-pyrrole (1 eq.). The reaction mixture is
stirred at room temperature overnight. Purification is by normal
phase chromatography to yield
5-Oxo-1-(3-pyrrol-1-yl-propyl)-pyrrolidine-3-carboxylic acid methyl
ester.
Step 2
[0485] To a cooled solution (0.degree. C.) of
5-Oxo-1-(3-pyrrol-1-yl-propyl)-pyrrolidine-3-carboxylic acid methyl
ester in THF, 0.2M LiOH is added and RM is stirred for 3 hours
gradually warming to room temperature. Reaction mixture is
acidified with 1N HCl and product extracted into ethyl acetate. The
organic phase is washed with brine, dried over magnesium sulphate
and the solvent evaporated in vacuo to yield
5-Oxo-1-(3-pyrrol-1-yl-propyl)-pyrrolidine-3-carboxylic acid.
Intermediate Y
2-(3-Isopropyl-ureido)-isonicotinic acid
Step 1
[0486] To a solution of ethyl 2-aminoisonicotinate (500 mg, 3.01
mmol) in DMF (10 ml) is added triethylamine (1.26 ml, 9.03 mmol)
and then isopropyl isocyanate (512 mg, 6.02 mmol). The reaction
mixture is heated in a microwave at 140.degree. C. for 2 hours.
[0487] The reaction mixture is diluted with EtOAc, washed with
water (.times.5), brine, dried (MgSO.sub.4) and concentrated in
vacuo. Chromatography (SiO.sub.2, MeOH/DCM) affords
2-(3-Isopropyl-ureido)-isonicotinic acid ethyl ester; [M+H].sup.+
252
Step 2
[0488] To a solution of 2-(3-Isopropyl-ureido)-isonicotinic acid
ethyl ester (130 mg, 0.52 mmol) in MeOH (5 ml) is added 2 M NaOH
(2.5 ml) and the resulting solution is stirred for 1.5 hours at
room temperature. The solvent is removed in vacuo and sat. aq.
NH.sub.4Cl solution is added. The pH of the aqueous phase is
adjusted to 1 using 1 M HCl and the product extracted into EtOAc,
dried (MgSO.sub.4) the solvent removed in vacuo to afford
2-(3-Isopropyl-ureido)-isonicotinic acid as a white solid;
[M+H].sup.+ 224
Intermediate Z
1-Isopropylcarbamoyl-1H-indole-4-carboxylic acid
[0489] This compound is prepared analogously to Intermediate Y by
replacing ethyl 2-aminoisonicotinate in step 1 with methyl
indol-4-carboxylate; [M+H].sup.+ 247
Intermediate AA
4-(3-Isopropyl-ureido)-benzoic acid
[0490] This compound is prepared analogously to Intermediate Y by
replacing ethyl 2-aminoisonicotinate in step 1 with methyl
4-aminobenzoate; [M+H].sup.+ 237.
Intermediate AB
6-(3-Isopropyl-ureido)-nicotinic acid
[0491] This compound is prepared analogously to Intermediate Y by
replacing ethyl 2-aminoisonicotinate in step 1 with methyl
6-aminonicotinate; [M+H].sup.+ 224.
Intermediate AC
[4-(2-Methoxy-ethoxymethoxy)-phenyl]-acetic acid
Step 1
[0492] To a solution of methyl 4-hydroxyphenylacetate (200 mg, 1.20
mmol) in DCM (5 ml) is added DIPEA (0.315 ml, 1.81 mmol), and then
MEMCl (0.204 ml, 1.81 mmol), and the resulting reaction mixture is
stirred for 2 hours at room temperature. An additional portion of
MEMCl (0.102 ml, 1 mmol) and of DIPEA (0.158 ml, 1 mmol) are added,
and the reaction mixture is stirred for a further 16 hours. An
additional portion of MEMCl (0.102 ml, 1 mmol) and of DIPEA (0.158
ml, 1 mmol) are added and the reaction mixture is stirred for 3
hours. The reaction mixture is diluted with DCM and washed with 0.5
M HCl, 1 M NaOH and then 0.5 M HCl, dried (MgSO.sub.4) and
concentrated in vacuo to afford
[4-(2-Methoxy-ethoxymethoxy)-phenyl]-acetic acid methyl ester
Step 2
[0493] To a solution of [4-(2-Methoxy-ethoxymethoxy)-phenyl]-acetic
acid methyl ester (192 mg, 0.76 mmol) in MeOH (3 ml) is added 2 M
NaOH (3 ml). The reaction mixture is stirred for 16 hours at room
temperature. The solvent is removed in vacuo and the residue
dissolved in EtOAc and washed with sat. aq. NH.sub.4Cl solution,
dried (MgSO.sub.4) and concentrated in vacuo to yield
[4-(2-Methoxy-ethoxymethoxy)-phenyl]-acetic acid
Intermediate AD
3-[4-(2-Methoxy-ethoxymethoxy)-phenyl]-propionic acid
[0494] This compound is prepared analogously to Intermediate AC by
replacing methyl 4-hydroxyphenylacetate in step 1 with
methyl-3-(4-hydroxyphenyl)propionate.
Intermediate AE
3-{4-[2-(Tetrahydro-pyran-2-yloxy)-ethoxy]-phenyl}-propionic
acid
Step 1
[0495] Methyl 3-(4-hydroxyphenyl)propianoate (0.1 g, 0.55 mmol) is
dissolved in DMF (5 ml) and NaH (0.033 g of a 60% dispersion in
mineral oil, 0.83 mmol) is added. The reaction mixture is stirred
at room temperature for 15 minutes then
2-(2-bromethoxy)tehtrahydro-2-H-pyran (0.109 ml, 0.72 mmol) is
added and the reaction mixture is left to stir for 18 hours.
Dilution with EtOAc (50 ml), washing with water (25 ml), saturated
NaHCO.sub.3 (25 ml) and brine (25 ml), drying over MgSO.sub.4, and
concentration in vacuo yields
3-{4-[2-(Tetrahydro-pyran-2-yloxy)-ethoxy]-phenyl}-propionic acid
methyl ester as a colourless oil; [M+H].sup.+ 309
Step 2
[0496] 3-{4-[2-(Tetrahydro-pyran-2-yloxy)-ethoxy]-phenyl}-propionic
acid methyl ester (0.12 g, 0.39 mmol) is dissolved in MeOH (3 ml)
and 2M NaOH solution (3 ml) is added and the resulting solution is
stirred at room temperature for 18 hours. The reaction mixture is
diluted with saturated ammonium chloride solution (20 ml) and
extracted with EtOAc (100 ml.times.2). The organic phased are
combined, dried over MgSO.sub.4, the solvent removed in vacuo to
yield the title compound as a colourless oil; [M+H].sup.+=295
Intermediate AF
3-[4-(Pyridin-4-ylmethoxy)-phenyl]-propionic acid
Step 1
[0497] To a solution of Methyl 3-(4-hydroxyphenyl)propanoate (0.5
g, 2.77 mmol) in dry DMF (10 ml) is added potassium carbonate (0.76
g, 5.55 mmol) followed by 4-(bromomethyl)pyridine hydrobromide (0.7
g, 2.77 mmol). The reaction mixture is stirred at room temperature
overnight then poured into water (80 ml) and extracted with EtOAc
(40 ml). The organic phase is washed with brine, dried (MgSO.sub.4)
and the solvent removed in vacuo to yield a dark brown oil.
Chromatography (SiO.sub.2, EtOAc) yields
3-[4-(Pyridin-4-ylmethoxy)-phenyl]-propionic acid methyl ester as a
colourless oil; [M+H]+272.0
Step 2
[0498] To a solution of
3-[4-(Pyridin-4-ylmethoxy)-phenyl]-propionic acid methyl ester
(0.28 g, 1.03 mmol) in THF (5 ml) and MeOH (5 ml) at room
temperature is added 2 N LiOH (0.52 ml, 1.032 mmol) and the
resulting solution is stirred overnight. Further 2 N LiOH (0.103
ml) is added and the reaction mixture stirred for a further 1 hour.
The reaction mixture is concentrated in vacuo and the residue is
diluted with water (50 ml) followed by EtOAc. The aqueous phase is
acidified to pH 2 with 1 N HCl, and extracted with DCM. The organic
phase is concentrated to a third of its volume in vacuo until a
white powder precipitates which is collected by filtration to yield
the title compound; [M+H].sup.+ 258.0
Intermediate AG
3-(4-tert-Butoxycarbonylmethoxy-phenyl)-propionic acid
Step 1
[0499] To a stirring solution of methyl
3-(4-hydroxyphenyl)propanoate (2 g, 11.10 mmol) in dry DMF (30 ml)
at room temperature is added potassium carbonate (1.53 g, 11.10
mmol) followed by tert-butyl 2-bromoacetate (2.17 g, 11.10 mmol).
The reaction mixture is purged with nitrogen, then stoppered and
left stirring at room temperature for 7 days. The reaction mixture
is poured into water (200 ml) and extracted with EtOAc (100 ml),
washed with brine, dried (MgSO.sub.4), filtered and evaporated in
vacuo to yield a pale yellow oil. Flash chromatography (SiO.sub.2,
EtOAc/iso-hexane) yields
3-(4-tert-Butoxycarbonylmethoxy-phenyl)-propionic acid methyl ester
as a clear oil.
Step 2
[0500] To a solution of
3-(4-tert-Butoxycarbonylmethoxy-phenyl)-propionic acid methyl ester
(2.70 g, 9.17 mmol) in THF (80 ml) is added 0.2N lithium hydroxide
(45.9 ml, 9.17 mmol) at 0.degree. C. and the reaction mixture is
stirred at 0.degree. C. for 4.5 hours. 1M HCl (15 ml) is added and
the product is extracted using EtOAc (.times.3). The organic phase
is dried (Na.sub.2SO.sub.4) and concentrated in vacuo to yield a
white solid. Flash chromatography (SiO.sub.2, 10% EtOAc in
CH.sub.2Cl.sub.2, then 20% EtOAc in CH.sub.2Cl.sub.2) yields
3-(4-tert-Butoxycarbonylmethoxy-phenyl)-propionic acid as a white
solid.
Intermediate AH
3-(4-Carbamoylmethoxy-phenyl)-propionic acid
[0501] This compound is prepared analogously to Intermediate AG by
replacing tert-butyl 2-bromoacetate in step 1 with
2-bromoacetamide; [M+H].sup.+530.1
Intermediate AI
1-[4-(2-Carboxy-ethyl)-phenoxy]-cyclobutanecarboxylic acid ethyl
ester
[0502] This compound is prepared analogously to Intermediate AG by
replacing tert-butyl 2-bromoacetate in step 1 with ethyl
1-bromocyclobutane-carboxylate; [M+H].sup.+293.0
Intermediate AJ
2-[4-(2-Carboxy-ethyl)-phenoxy]-2-methyl-propionic acid tert-butyl
ester
[0503] This compound is prepared analogously to Intermediate AG by
replacing tert-butyl 2-bromoacetate in step 1 with tert-butyl
2-bromoisobutyrate. .sup.1H NMR (DMSO-d6): 1.40 (9H, s), 1.48 (6H,
s), 2.49 (2H, t, J=7.5), 2.75 (2H, t, J=7.5), 6.71 (2H, d, J=8.5),
7.11 (2H, d, J=8.50), 12.10 (1H, s).
Intermediate AK
3-(4-Methoxycarbonylmethoxy-phenyl)-propionic acid
Step 1
[0504] To a solution of 3-(4-hydroxyphenyl)propanoic acid (3.32 g,
20 mmol) in dry DMF (20 ml) is carefully added
1,1'-carbonyldiimidazole (3.24 g, 20 mmol) portionwise. The
reaction mixture is stirred at 40.degree. C. for 2 hours after
which time DBU (6.02 ml, 40 mmol) and tert-butanol (4.78 ml, 50
mmol) are added and the reaction mixture is now stirred at
65.degree. C. for 2 days. The reaction mixture is allowed to cool
to room temperature and poured into water (50 ml) and the product
is extracted with diethyl ether (3.times.30 ml). The organics are
combined, dried (MgSO.sub.4) and the solvent removed in vacuo to
give a yellow oil. Purification by flash chromatography (SiO.sub.2,
EtOAc/iso-hexane) yields 3-(4-Hydroxy-phenyl)-propionic acid
tert-butyl ester as a colourless oil. 1H NMR (DMSO-d6) 9.1 (1H, s),
7.0 (2H, d, J=8.45), 6.65 (2H, d, J=8.45), 2.7 (2H, t, J=7.28), 2.4
(2H, t, J=7.28), 1.4 (9H, s).
Step 2
[0505] To a solution of -(4-Hydroxy-phenyl)-propionic acid
tert-butyl ester (1 g, 4.50 mmol) in dry DMF (20 ml) at room
temperature under argon is added potassium carbonate (0.62 g, 4.50
mmol) followed by methyl bromoacetate (0.43 ml, 4.50 mmol) and the
reaction mixture is stirred at room temperature. The reaction
mixture is diluted with EtOAc and washed with water, dried
(MgSO.sub.4) and evaporated in vacuo to yield a clear colourless
liquid. Purification on a Waters 3000 prep HPLC system (C18,
MeCN/water) yields 3-(4-Methoxycarbonylmethoxy-phenyl)-propionic
acid tert-butyl ester as a pale yellow oil.
Step 3
[0506] To 3-(4-Methoxycarbonylmethoxy-phenyl)-propionic acid
tert-butyl ester (0.097 g, 0.33 mmol) is added a 90% solution of
TFA in DCM (2 ml) and the resulting solution is stirred at room
temperature for 1 hour. The solvents are removed in vacuo to yield
3-(4-Methoxycarbonylmethoxy-phenyl)-propionic acid as an off-white
powder; [M+H-18].sup.+256.0
Intermediate AL
3-[4-(2-Propoxycarbonyl-ethyl)-phenyl]-propionic acid
[0507] To a solution of 3,3'-(1,4-phenylene)dipropanoic acid (250
mg, 1.125 mmol) DCM (15 ml) is added 4-dimethylaminopyridine (137
mg, 1.125 mmol) and propanol (3 ml, 40.1 mmol). The solution is
cooled to 0.degree. C. and dicyclohexylcarbodiimide (232 mg, 1.125
mmol) is added and the resulting solution is stirred at 0.degree.
C. for 30 minutes and 2 hours at room temperature. Concentration in
vacuo affords a white solid which is suspended in Et.sub.2O (50 ml)
and filtered to remove any insoluble material. The filtrate is
concentrated in vacuo and purification by chromatography
(SiO.sub.2, EtOAc/iso-hexane) affords the title compound.
Intermediate AM
3-[4-(2-Ethoxycarbonyl-ethyl)-phenyl]-propionic acid
[0508] This compound is prepared analogously to Intermediate AL
replacing propanol with ethanol.
Intermediate AN
3-[4-(2-Methoxycarbonyl-ethyl)-phenyl]-propionic acid
[0509] This compound is prepared analogously to Intermediate AL
replacing propanol with methanol.
Intermediate AO
1-(2-Phenoxy-ethyl)-1H-indole-4-carboxylic acid
Step 1
[0510] NaH (60% dispersion in mineral oil, 68.5 mg, 1.71 mmol) is
added to solution of methyl indole-4-carboxylate (200 mg, 1.142
mmol) in DMF (5 ml) and the resulting suspension is stirred at room
temperature for 20 minutes. After this time (2-bromoethoxy)benzene
(298 mg, 1.484 mmol) is added and the reaction is stirred at room
temperature for 18 hours. Dilution with EtOAc (50 ml) and washing
with water (25 ml.times.2), saturated NaHCO.sub.3 (25 ml) and brine
(25 ml), drying over MgSO.sub.4, concentration in vacuo and
purification by chromatography (SiO.sub.2, EtOAc/iso-hexane)
affords 1-(2-Phenoxy-ethyl)-1H-indole-4-carboxylic acid methyl
ester; [M+H].sup.+ 296
Step 2
[0511] 1-(2-Phenoxy-ethyl)-1H-indole-4-carboxylic acid methyl ester
(185 mg, 0.626 mmol) is suspended in a mixture of MeOH (3 ml) and 2
M NaOH (2 ml). The suspension is stirred at room temperature for 2
hours, THF (1 ml) is added and the reaction is heated at 60.degree.
C. for 1 hour. The reaction is allowed to cool to room temperature
and diluted with sat. NH.sub.4Cl solution (10 ml), extracted with
EtOAc (10 ml.times.3), dried over MgSO.sub.4, and concentrated in
vacuo to give the title compound; [M+H].sup.+ 282
Intermediate AP
1-(2-p-Tolyl-ethyl)-1H-indole-4-carboxylic acid
[0512] This compound is prepared analogously to Intermediate AO
replacing (2-bromoethoxy)benzene with 4-methylphenethyl bromide;
[M+H].sup.+ 280
Intermediate AQ
1-[2-(Tetrahydro-pyran-2-yloxy)-ethyl]-1H-indole-4-carboxylic
acid
[0513] This compound is prepared analogously to Intermediate AO
replacing (2-bromoethoxy)benzene with
2-(2-bromoethoxy)tetrahydro-2H-pyran; [M+H].sup.+ 290
Intermediate AR
1-[2-(4-Methoxy-phenoxy)-ethyl]-1H-indole-4-carboxylic acid
[0514] This compound is prepared analogously to Intermediate AO
replacing (2-bromoethoxy)benzene with
1-(2-bromoethoxy)-4-methoxybenzene; [M+H].sup.+ 312
Intermediate AS
1-[2-(4-tert-Butyl-phenoxy)-ethyl]-1H-indole-4-carboxylic acid
[0515] This compound is prepared analogously to Intermediate AO
replacing (2-bromoethoxy)benzene with
1-(2-bromoethoxy)-4-tert-butylbenzene; [M+H].sup.+ 338
Intermediate AT
1-(2-[1,3]-Dioxan-2-yl-ethyl)-1H-indole-4-carboxylic acid
[0516] This compound is prepared analogously to Intermediate AO
replacing (2-bromoethoxy)benzene with (2-bromethyl)1,3-dioxane;
[M+H].sup.+ 276
Intermediate AU
2,3-Dimethyl-1-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1H-indole-5-carboxylic
acid
[0517] This compound is prepared analogously to Intermediate AO
replacing (2-bromoethoxy)benzene with
(2-(2-bromoethoxy)tetrahydro-2H-pyran and replacing Methyl
indole-4-carboxylate with 2,3-dimethyl-1H-indole-5-carboxylate;
[M+H].sup.+ 318
Intermediate AV
1-(4,4,4-Trimethoxy-butyl)-1H-indole-4-carboxylic acid
[0518] This compound is prepared analogously to Intermediate AO
1-(2-Phenoxy-ethyl)-1H-indole-4-carboxylic acid replacing
(2-bromoethoxy)benzene with trimethyl 4-bromoorthobutyrate.
Intermediate AW
1-[2-(2-Methoxy-ethoxymethoxy)-ethyl]-1H-indole-4-carboxylic
acid
Step 1
[0519] NaH (60% dispersion in mineral oil, 86 mg, 2.14 mmol) is
added to a solution of methyl indole-4-carboxylate (250 mg, 1.427
mmol) in DMF (20 ml) and the resulting suspension is stirred at
room temperature for 30 minutes. After this time
(2-(2-bromoethoxy)tetrahydro-2H-pyran (388 mg, 1.86 mmol) is added
and the reaction is stirred at room temperature for 22 hours.
Dilution with EtOAc (50 ml), washing with water (25 ml.times.3),
saturated NaHCO.sub.3 (25 ml.times.2) and brine (25 ml), drying
over MgSO.sub.4, concentration in vacuo and purification by
chromatography (SiO.sub.2, DCM/MeOH) affords
1-[2-(Tetrahydro-pyran-2-yloxy)-ethyl]-1H-indole-4-carboxylic acid
methyl ester; [M+H].sup.+ 304
Step 2
[0520] To a solution of
1-[2-(Tetrahydro-pyran-2-yloxy)-ethyl]-1H-indole-4-carboxylic acid
methyl ester (120 mg, 0.396 mmol) in MeOH (10 ml) is added
p-toluenesulfonic acid monohydrate (7.25 mg, 0.04 mmol). The
reaction is stirred at room temperature for 16 hours and the
solvent is removed in vacuo. The residue is dissolved in MeOH (3
ml) and loaded onto a 1 g PEAX cartridge washed with MeOH (20 ml).
The filtrate is concentrated in vacuo to give
1-(2-Hydroxy-ethyl)-1H-indole-4-carboxylic acid methyl ester;
[M+H].sup.+ 220
Step 3
[0521] To a solution of 1-(2-Hydroxy-ethyl)-1H-indole-4-carboxylic
acid methyl ester in DCM (3 ml) is added DIPEA (0.129 ml, 0.739
mmol) and 1-Chloromethoxy-2-methoxy-ethane (0.084 ml, 0.739 mmol).
The solution is stirred at room temperature for 72 hours. The
reaction is diluted with DCM (50 ml) and washed with 0.5 M HCl (20
ml), 1 M NaOH (20 ml) and 0.5 M HCl (20 ml). The organic layer is
dried over MgSO.sub.4 and the solvent is removed in vacuo.
Purification by chromatography (SiO.sub.2, DCM/MeOH) affords
1-[2-(2-Methoxy-ethoxymethoxy)-ethyl]-1H-indole-4-carboxylic acid
methyl ester; [M+H].sup.+ 308
Step 4
[0522] To a solution of
1-[2-(2-Methoxy-ethoxymethoxy)-ethyl]-1H-indole-4-carboxylic acid
methyl ester (69 mg, 0.225 mmol) in MeOH (2 ml) is added 2 M NaOH
(1 ml) and the reaction is stirred at room temperature for 19.5
hours, then for 2 hours at 50.degree. C. The reaction is allowed to
cool to room temperature and the solvent removed in vacuo. To the
residue is added sat. NH.sub.4Cl (10 ml), and the product is
extracted with EtOAc (5.times.25 ml), washed with brine (10 ml),
dried over Na.sub.2SO.sub.4, and the solvent is removed in vacuo,
to give the title compound
1-[2-(2-Methoxy-ethoxymethoxy)-ethyl]-1H-indole-4-carboxylic acid;
[M+H].sup.+ 294
Intermediate AX
1-Diethylcarbamoylmethyl-1H-indole-4-carboxylic acid
Step 1
[0523] Methyl indole-4-carboxylate (50 mg, 2.85 mmol) and
2-chloro-N,N-diethylacetamide (854 mg, 5.71 mmol) are dissolved in
DMF (10 ml) and to the solution is added potassium carbonate (986
mg, 7.14 mmol). The reaction is heated using microwave radiation at
100.degree. C. for 2 hours, then diluted with DCM (60 ml) and
washed with water (5.times.10 ml). Drying over MgSO.sub.4,
concentration in vacuo, and trituration with Et.sub.2O affords
1-Diethylcarbamoylmethyl-1H-indole-4-carboxylic acid methyl ester;
[M+H].sup.+ 289.
Step 2
[0524] To a solution of
Diethylcarbamoylmethyl-1H-indole-4-carboxylic acid methyl ester
(480 mg, 1.665 mmol) in MeOH (5 ml) is added 2 M NaOH (5 ml). The
reaction is heated at 50.degree. C. for 20 hours and then allowed
to cool to room temperature. The solvent is removed in vacuo and
the residue dissolved in water (10 ml). The pH of the solution is
adjusted to 5 using 1 M HCl and the resulting solid is collected by
filtration to give the title compound
1-Diethylcarbamoylmethyl-1H-indole-4-carboxylic acid; [M+H].sup.+
275
Intermediate AY
4-[6-((R)-2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-naphthalen-2-ylmethoxy]--
benzoic acid
Step 1
[0525] To a solution of methyl 6-hydroxy-2-naphthoate (4.55 g, 22.5
mmol) in anhydrous acetone (60 ml) are added S-(-)-glycidol (2.0 g,
27.0 mmol) and K.sub.2CO.sub.3 (9.3 g, 67.3 mmol). The reaction
mixture is heated to reflux for 3 days. The reaction mixture is
filtered through Celite.TM. (filter material) and the filtrate is
concentrated in vacuo to afford
6-((S)-2,3-Dihydroxy-propoxy)-naphthalene-2-carboxylic acid methyl
ester as a white solid; .sup.1H NMR (DMSO-d.sub.6): 3.49 (2H, t,
J=6.0 Hz), 3.85-3.88 (1H, m), 3.89 (3H, s), 4.02 (1H, dd, J=9.9,
6.0 Hz), 4.16 (1H, dd, J=9.9, 4.0 Hz), 4.73 (1H, t, J=6.0 Hz), 5.04
(1H, d, J=5.2 Hz), 7.26 (1H, dd, J=9.0, 2.0 Hz), 7.41 (1H, d, J=2.0
Hz), 7.88-7.94 (2H, m), 8.04 (1H, d, J=9.0 Hz), 8.55 (1H, s).
Step 2
[0526] To 6-((S)-2,3-dihydroxy-propoxy)-naphthalene-2-carboxylic
acid methyl ester (0.9 g, 3.26 mmol) in anhydrous DMF (10 ml) is
added 2,2-dimethoxypropane (2.0 ml, 16.3 mmol) and pyridinium
p-toluenesulfonate (0.08 g, 0.32 mmol) and the reaction mixture is
stirred at room temperature for 16 hours. The reaction mixture is
concentrated in vacuo and the residue is dissolved in EtOAc. The
EtOAc layer is washed with 10% NaHCO.sub.3, water, and brine, dried
over anhydrous Na.sub.2SO.sub.4 and the solvent is evaporated in
vacuo to obtain
6-((R)-2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-naphthalene-2-carbo-
xylic acid methyl ester as solid; .sup.1H NMR (DMSO-d6): 1.32 (3H,
s), 1.37 (3H, s), 3.78-3.82 (1H, m), 3.88 (3H, s), 4.11-4.20 (3H,
m), 4.45-4.50 (1H, m), 7.26 (1H, dd, J=9.0, 2.0 Hz), 7.45 (1H, d,
J=2.0 Hz), 7.88 (1H, d, J=9.0 Hz), 7.93 (1H, d, J=9.0 Hz), 8.04
(1H, d, J=9.0 Hz), 8.55 (1H, s).
Step 3
[0527] To a solution of
6-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-naphthalene-2-carboxylic
acid methyl ester (1.0 g, 3.16 mmol) in anhydrous THF (20 ml) at
0.degree. C. is added LiAlH4 (1.9 ml of a 2M solution in THF, 3.8
mmol). The reaction mixture is stirred at room temperature
overnight. The reaction mixture is concentrated in vacuo and the
residue is purified by column chromatography (SiO2, DCM) to afford
[6-((R)-2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-naphthalen-2-yl]-MeOH
as a colourless viscous oil which solidified on standing; 1H NMR
(d6-DMSO): 1.32 (3H, s), 1.37 (3H, s), 3.78 (1H, dd, J=8.3, 6.0
Hz), 4.01-4.15 (3H, m), 4.45-4.48 (1H, m), 4.60 (2H, d, J=6.0 Hz),
5.24 (1H, t, J=6.0 Hz), 7.14 (1H, dd, J=8.5, 2.5 Hz), 7.32 (1H, d,
J=2.5 Hz), 7.41 (1H, dd, J=8.5, 1.5 Hz), 7.33-7.80 (3H, m).
Step 4
[0528] A mixture of methyl 4-hydroxybenzoate (0.5 g, 3.28 mmol),
[6-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-naphthalen-2-yl]-methanol
(0.9 g, 3.12 mmol) and triphenylphosphine (0.83 g, 3.16 mmol) in
DCM (20 ml) is cooled to 0.degree. C. Diethyl azodicarboxylate (0.5
ml, 3.17 mmol) is added dropwise. The reaction mixture is stirred
at room temperature overnight. The reaction mixture is concentrated
in vacuo and purified by column chromatography (SiO.sub.2,
EtOAc/iso-hexane) to obtain white solid. The product obtained is
once again purified by column chromatography (neutral alumina,
EtOAc/petroleum ether) to obtain
4-[6-((R)-2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-naphthalen-2-ylmethoxy]-
-benzoic acid methyl ester as white solid; .sup.1H NMR
(d.sub.6-DMSO): 1.32 (3H, s), 1.38 (3H, s), 3.77-3.82 (4H, m),
4.08-4.16 (3H, m), 4.46-4.49 (1H, m), 5.30 (2H, s), 7.15-7.21 (3H,
m), 7.37 (1H, d, J=2.0 Hz), 7.53 (1H, dd, J=8.50, 1.5 Hz), 7.83
(2H, dd, J=9.0, 6.0 Hz), 7.92 (3H, m).
Step 5
[0529] To a solution of
4-[6-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-naphthalen-2-ylmethoxy]-
-benzoic acid methyl ester (0.46, 1.09 mmol) in THF/water (10 ml of
a 1:1 mixture) is added lithium hydroxide (0.15 g, 3.57 mmol). The
reaction mixture is stirred at room temperature overnight, then at
70.degree. C. for 24 h. The reaction mixture is cooled to room
temperature, neutralized with 1.5 M HCl and the white solid
obtained is collected by vacuum filtration, washed with water and
dried under vacuum to afford
4-[6-((R)-2,2-Dimethyl-[1,3]dioxolan-4-ylmethoxy)-naphthalen-2-ylmethoxy]-
-benzoic acid. [M].sup.- 407.
Intermediate AZ
4-{3-[4-((R)-2,2-Dimethyl-[1,3]-dioxolan-4-ylmethoxy)-phenyl]-propoxy}-ben-
zoic acid
[0530] This compound is prepared analogously to Intermediate AY by
replacing
[6-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-naphthalen-2-yl-
]-methanol in Step 4 with
3-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-phenyl]-propan-1-ol;
.sup.1H NMR (DMSO-d6): 1.30 (3H, s), 1.35 (3H, s), 1.97-2.01 (2H,
m), 2.68 (2H, t, J=7.5 Hz), 3.72-3.75 (1H, m), 3.93-4.00 (4H, m),
4.06-4.10 (1H, m), 4.38 (1H, dd, J=6.0, 5.0), 6.87 (2H, d, J=9.0
Hz), 6.92 (2H, d, J=9.0 Hz), 7.14 (2H, d, J=, 9.0 Hz), 7.84 (2H, d,
J=9.0 Hz).
Intermediate BA
4-{2-[(E)-3,5-Diamino-6-chloro-pyrazine-2-carbonylimino]-1,3,8-triaza-spir-
o[4.5]decane-8-carbonyl}-piperidine-1-carboxylic acid tert-butyl
ester
[0531] This compound is prepared analogously to Example 97 by
replacing 4-benzyloxyphenylacetic acid with
1-Boc-piperidine-4-carboxylic acid; [M+H].sup.+ 536.
Intermediate BB
4-[(Naphthalene-1-sulfonylamino)-methyl]-benzoic acid
[0532] 4 N NaOH solution (30 ml) is added to a suspension of
4-(aminomethyl)benzoic acid (5.01 g, 31.82 mmol) in acetone (100
ml). Toluene (100 ml) is added and the reaction is heated at
40.degree. C. to obtain dissolution. The solution is cooled to
0.degree. C. and treated with 1-naphthalene sulfonyl chloride (12
g, 51.35 mmol) in acetone (100 ml) and the resulting reaction
mixture is stirred for 3 hours. The reaction is acidified using
citric acid and concentrated in vacuo. The residue is taken up in
EtOAc and washed with water. The aqueous layer is back extracted
with EtOAc and the combined organic layers are washed with water,
brine, dried (Na.sub.2SO.sub.4) and the solvent removed in vacuo to
yield a light brown solid. Trituration with Et.sub.2O yields the
title compound.
Intermediate BC
3-(Cyclohexyl-methyl-sulfamoyl)-4-methoxy-benzoic acid
Step 1
[0533] A solution of methyl 3-(chlorosulfonyl)-4-methoxybenzoate
(2.0 g, 7.56 mmol) and diisopropylethylamine (1.94 ml, 11.34 mmol)
in DCM (50 ml) is treated with N-methyl cyclohexylamine (0.70 ml,
9.07 mmol) at 0.degree. C. The solution is stirred at room
temperature for 3 hours and N-methyl cyclohexylamine (0.70 ml, 9.07
mmol) is added. The solution is partitioned between DCM (250 ml)
and 0.5 N HCl (100 ml). The organic layer is washed with 0.5 N HCl
(2.times.100 ml), sat. aq. NaHCO.sub.3 (2.times.100 ml) and water
(100 ml), dried over MgSO.sub.4, and the solvent removed in vacuo
to yield a yellow oil. Crystallisation (iPr.sub.2O/EtOAc) yields
3-(Cyclohexyl-methyl-sulfamoyl)-4-methoxy-benzoic acid methyl ester
as yellow crystals; [M+H].sup.+ 342.
Step 2
[0534] A solution of
3-(Cyclohexyl-methyl-sulfamoyl)-4-methoxy-benzoic acid methyl ester
(1.50 g, 4.39 mmol) in 1,4 dioxane (40 ml) is treated with 2 N NaOH
(10 ml) and the resulting solution is stirred at room temperature
for 21 hours. The solvent is removed in vacuo and ice cold 2 N HCl
(25 ml) is added and the white solid which forms is extracted into
DCM (150 ml). The organic layer is washed with water, dried
(MgSO.sub.4) and the solvent removed in vacuo to yield the title
compound as a white solid; [M-1].sup.- 326.
Intermediate BD
3-Chloro-5-methoxy-4-[2-(4-methyl-piperazin-1-yl)-ethoxy]-benzoic
acid
Step 1
[0535] A mixture of 5-chlorovanillic acid (5.0 g, 24.6 mmol) and
conc. HCl (5 ml) in MeOH (100 ml) is heated at reflux for 48 hours.
The solvent is removed in vacuo and water is added to the residue
to yield a white precipitate, which is collected by filtration,
washed with water, and then dissolved in Et.sub.2O. The solution is
dried (Na.sub.2SO.sub.4) and the solvent removed in vacuo to yield
3-Chloro-4-hydroxy-5-methoxy-benzoic acid methyl ester as a white
solid.
Step 2
[0536] Triphenylphosphine (6.4 g, 24.4 mmol) and DIAD (4.8 ml,
202.2 mmol) are added to a solution of
3-Chloro-4-hydroxy-5-methoxy-benzoic acid methyl ester (2.5 g, 11.5
mmol) in THF (40 ml) at 0.degree. C. and the resulting solution is
stirred for 2 hours at 0.degree. C. and 16 hours at room
temperature. The solvent is removed in vacuo, and water is added to
the residue. The product is extracted in EtOAc, dried
(Na.sub.2SO.sub.4) and the solvent removed in vacuo to afford a
yellow oil. Flash chromatography (SiO.sub.2, EtOAc/MeOH) yields
3-Chloro-5-methoxy-4-[2-(4-methyl-piperazin-1-yl)-ethoxy]-benzoic
acid methyl ester as an orange solid.
Step 3
[0537] A solution of
3-Chloro-5-methoxy-4-[2-(4-methyl-piperazin-1-yl)-ethoxy]-benzoic
acid methyl ester (3.7 g, 10.7 mmol) in 2 N NaOH (20 ml) and THF
(40 ml) is heated at reflux for 1 hour. The reaction mixture is
washed with Et.sub.2O. The aqueous phase is concentrated in vacuo,
and water (50 ml) is added. The pH is adjusted to 3-4 using 2 N
HCl. To this solution is added DOWEX 50WX4 (previously washed with
MeOH, 2 N HCl and water), and the resulting mixture is stirred at
room temperature for 1 hour. The resin is filtered, washed with
water, and the product is released from the resin by washing with
MeOH/NH.sub.4OH. The solution is concentrated in vacuo, diluted
with DCM and MeOH, dried (Na.sub.2SO.sub.4) and the solvent removed
in vacuo to yield the title compound as a light cream solid.
Intermediate BE
##STR00310##
[0539] To a stirred solution of diethyl amine (500 ml, 4.8 mol) in
Et.sub.2O (1200 ml) is added sulfuryl chloride (177.3 ml, 2.19 mol)
over 80 minutes at -15.degree. C. The reaction is stirred at room
temperature for 2.5 hours. Et.sub.2O (1000 ml) is added and the
white solid present is removed by filtration, and washed with
Et.sub.2O (2000 ml). The combined filtrates are concentrated under
reduced pressure to yield as a colourless oil.
##STR00311##
[0540] To a stirred solution of trans-4-(aminomethyl)-cyclohexane
carboxylic acid (10 g, 63.6 mmol) in 1 N NaOH (153 ml) is added
(10.91 g, 63.6 mmol) and the resulting mixture is stirred at room
temperature for 15 hours. The reaction is cooled to 10.degree. C.
and conc. HCl solution (15 ml) is added and the mixture stirred for
10 minutes at this temperature. White crystals form which are
isolated by filtration and washed with Et.sub.2O (40 ml) to yield
the title compound.
Intermediate BF
3-(3-Phenyl-isoxazol-5-yl)-propionic acid
[0541] This compound is prepared as described by G. S. d'Alcontres;
C Caristi; A Ferlazzo; M Gattuso, J. Chem. Soc. Perkin 1, (1976)
16, 1694.
Intermediate BG
3-(4-Chloro-phenoxymethyl)-benzylamine
[0542] This compound is prepared as described in US 2008200523.
Intermediate BH
2-{4-[2-(4-Fluoro-phenyl)-ethoxy]-phenyl}-ethylamine
Step 1
[0543] A suspension of 4-Hydroxybenzyl cyanide (7.9 g, 59.57 mmol),
1-(2-Bromo-ethyl)-4-fluoro-benzene (17.4 g, 71.48 mmol), potassium
carbonate (19.8 g, 143 mmol) and sodium iodide (2.68 g, 17.87 mmol)
in acetonitrile (120 ml) is heated at reflux for 44 hours. The
reaction mixture is cooled and filtered and the solvent removed in
vacuo to yield a dark brown oil. Flash chromatography (SiO.sub.2,
EtOAc/iso-hexane) yields
{4-[2-(4-Fluoro-phenyl)-ethoxy]-phenyl}-acetonitrile as a yellow
oil.
Step 2
[0544] 2 N NaOH solution (45.2 ml, 90.3 mmol) is added to a
solution of {4-[2-(4-Fluoro-phenyl)-ethoxy]-phenyl}-acetonitrile
(3.29 g, 12.9 mmol) in EtOH (45.2 mol) followed by Al--Ni Alloy
(2.5 g) and the resulting reaction mixture is stirred for 1 hour at
room temperature. The reaction mixture is filtered and the EtOH
removed in vacuo. The product is extracted into DCM (2.times.80
ml), dried (MgSO.sub.4) and the solvent removed in vacuo to yield
the title compound as a yellow oil.
Intermediate BI
2-(4,6-Dimethyl-1H-indol-3-yl)-ethylamine
[0545] This compound is prepared as described in EP 620222
Intermediate BJ
2-[4-(4-Phenyl-butoxy)-phenyl]-ethylamine
[0546] This compound is prepared as described in WOP 2004016601
Intermediate BK
4-(5-Methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonyl
chloride
[0547] This compound is prepared as described in WO 2005026134
Intermediate BL
2-Phenyl-3H-benzoimidazole-5-sulfonyl chloride
[0548] This compound is prepared as described in EP 1205475
Intermediate BM
4-Aminomethyl-1-(1-phenyl-ethyl)-piperidin-4-ylamine
Step 1
[0549] 1-(1-Phenyl-ethyl)-piperidin-4-one is prepared according to
the procedure described on page 525 of J. Org. Chem. 1991, 56(2),
513-528.
[0550] To a mixture of 1-(1-phenyl-ethyl)-piperidin-4-one (10.9 g,
53.6 mmol), ammonium chloride (4.3 g, 80.4 mmol) and 30% aqueous
ammonia solution (30 ml) in water (30 ml) at room temperature is
added sodium cyanide (4.0 g, 81.6 mmol) portion wise. The reaction
mixture is stirred at room temperature for 18 hours, then diluted
with water and extracted with DCM. The organic phase is washed with
brine, dried over Na.sub.2SO.sub.4, filtered and concentrated in
vacuo to obtain
4-Amino-1-(1-phenyl-ethyl)-piperidine-4-carbonitrile as a brown
oil; [M+H].sup.+ 230.
Step 2
[0551] 4-Aminomethyl-1-(1-phenyl-ethyl)-piperidin-4-ylamine is
prepared analogously to Intermediate U by replacing
4-amino-4-cyano-piperidine-1-carboxylic acid tert-butyl ester in
Step 1 with 4-amino-1-(1-phenyl-ethyl)-piperidine-4-carbonitrile;
[M+H].sup.+ 234.
Intermediate BN
4-Aminomethyl-1-(4-methoxy-benzyl)-piperidin-4-ylamine
[0552] This compound is prepared analogously to Intermediate BM by
replacing 1-(1-phenyl-ethyl)-piperidin-4-one with
1-(4-methoxybenzyl)piperidin-4-one in step 2; .sup.1H NMR
(DMSO-d6): 1.46-1.64 (4H, m), 2.38-2.55 (4H, m), 2.67 (2H, s), 3.26
(2H, s), 4.08 (3H, s), 6.87 (2H, d, J=8.2 Hz), 7.18 (2H, d, J=8.2
Hz).
Intermediate BO
4-Aminomethyl-1-pyridin-4-ylmethyl-piperidin-4-ylamine
Step 1
[0553] To a solution of
4-aminomethyl-4-(2,2,2-trifluoro-acetylamino)-piperidine-1-carboxylic
acid tert-butyl ester (Intermediate U, Step 2) (5.0 g, 15.4 mmol)
in DCM (50 ml) at 0.degree. C. is added pyridine (10 ml) followed
by trifluoroacetic anhydride (3.5 ml, 25.3 mmol) and the reaction
mixture is stirred at room temperature for 16 hours. The reaction
mixture is diluted with DCM, washed with brine, dried over
Na.sub.2SO.sub.4 and concentrated in vacuo. The residue obtained is
dissolved in diethyl ether and re-precipitated by adding petroleum
ether. The solvent mixture is decanted and the solid dried under
vacuum to afford
4-(2,2,2-Trifluoro-acetylamino)-4-[(2,2,2-trifluoro-acetylamino)-methyl]--
piperidine-1-carboxylic acid tert-butyl ester; [M+H].sup.+ 420.
Step 2
[0554] To a solution of
4-(2,2,2-trifluoro-acetylamino)-4-[(2,2,2-trifluoro-acetylamino)-methyl]--
piperidine-1-carboxylic acid tert-butyl ester (5.25 g, 12.5
mmol)
[0555] in dioxane (50 ml) is added 4 M HCl in dioxane (15 ml) and
the reaction mixture is stirred at room temperature for 3 hours.
The reaction mixture is concentrated in vacuo and the off-white
solid obtained dissolved in the minimum amount of MeOH and
re-precipitated by adding diethyl ether. The supernatant solvent
mixture is decanted and the product is washed again with diethyl
ether and dried under vacuum to afford
2,2,2-Trifluoro-N-{4-[(2,2,2-trifluoro-acetylamino)-methyl]-piperi-
din-4-yl}-acetamide hydrochloride; [M+H].sup.+ 322.
Step 3
[0556] To a suspension of NaH (170 mg of a 60% dispersion in
mineral oil, 4.25 mmol) in anhydrous DMF (20 ml) is added
2,2,2-trifluoro-N-{4-[(2,2,2-trifluoro-acetylamino)-methyl]-piperidin-4-y-
l}-acetamide hydrochloride) (500 mg, 1.4 mmol) followed by
4-bromomethylpyridine hydrobromide (350 mg, 1.4 mmol). The reaction
mixture is stirred at room temperature for 3 hours. The reaction
mixture is quenched with sat. NH.sub.4Cl solution and is
concentrated in vacuo. The residue is purified by column
chromatography (basic alumina, MeOH/DCM) to obtain
2,2,2-Trifluoro-N-[1-pyridin-4-ylmethyl-4-(2,2,2-trifluoro-acetylamino)-p-
iperidin-4-ylmethyl]-acetamide as off-white solid; [M+H].sup.+
413
Step 4
[0557] To a solution of
2,2,2-trifluoro-N-[1-pyridin-4-ylmethyl-4-(2,2,2-trifluoro-acetylamino)-p-
iperidin-4-ylmethyl]-acetamide (200 mg, 0.49 mmol) in MeOH (10 ml)
is added 30% aqueous ammonia solution (10 ml) and the reaction
mixture is stirred at 60.degree. C. for 3 h. The reaction mixture
is concentrated in vacuo to obtain
4-Aminomethyl-1-pyridin-4-ylmethyl-piperidin-4-ylamine as a
colourless gummy oil that is used without further purification;
.sup.1H NMR (DMSO-d6): 1.63-1.77 (4H, m), 2.45-2.54 (4H, m), 2.49
(2H, s), 3.57 (3H, s), 7.30 (2H, d, J=5.5 Hz), 8.68 (2H, d, J=5.5
Hz).
Intermediate BP
4-Aminomethyl-1-(3-phenyl-propyl)-piperidin-4-ylamine
[0558] This compound is prepared analogously to Intermediate BO by
replacing -bromomethylpyridine hydrobromide (Step 3) with
1-bromo-3-phenylpropane; [M+H].sup.+ 248
Intermediate BQ
4-Aminomethyl-1-cyclohexylmethyl-piperidin-4-ylamine
[0559] This compound is prepared analogously to Intermediate BO by
replacing -bromomethylpyridine hydrobromide (Step 3) with
cyclohexylmethylbromide. This intermediate is used crude in the
preparation of Example 250.
Intermediate BR
3-Amino-3-aminomethyl-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid
tert-butyl ester
[0560] This compound is prepared analogously to Intermediate BM by
replacing 1-(1-phenyl-ethyl)-piperidin-4-one (Step 1) with
N-Boc-nortropinone; .sup.1H NMR (DMSO-d6): 1.40 (9H, s), 1.63-1.85
(8H, m), 2.79 (2H, s), 4.06 (2H, s).
* * * * *